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SUMMARY
Levels of anti-(AChR) antibodies were determined in s e r ia l  
serum samples frcm 14 myasthenic p a tien ts  over a period of several 
months, using de te rgen t-so lub ilized  muscle e x trac ts  of junctional 
r a t  AChR, ex tra -junc tiona l r a t  AChR and human a d u lt AChR as 
an tigens. Anti-(AChR) antibody t i t r e s  obtained using human a d u lt 
A(ZhR were always higher than those obtained using ex tra -ju n c tio n a l 
r a t  AChR, which were, in tu rn , a lm ys higher than those obtained 
using junctional r a t  AChR. The ra t io s  of antibody t i t r e s  obtained by 
using the d if fe re n t antigens varied between p a tie n ts , but were 
constant fo r an indiv idual over the period of study. Complementary 
evidence fo r the same phenomenon was obtained by o ther experiments 
in which an excess of each serum was used to  p re c ip ita te  lim ited  
amounts of AChR frcm muscle e x tra c ts . The re su lts  obtained by 
combining myasthenic sera argue again st the suggestion th a t  
incomplete p rec ip ita tio n  of receptor by ce rta in  sera  i s  caused by 
the absence of p a rtic u la r  antibody sub-populations. An a lte rn a tiv e  
explanation, th a t sera p rec ip ita tin g  low amounts of AChR contain 
tox in -re leasing  an tibodies, i s  supported by d ire c t  measurements of 
antibody-mediated toxin lo ss .
The hypothesis th a t embryonic AChR may co n stitu te  the 
autoimmunogen in M3 was investigated  by comparing the in te rac tio n  of 
human fo e ta l AChR with and anti-(AChR) antibodies ag a in st th a t
estab lished  fo r ad u lt human AChR. Tissue sections and teased muscle 
f ib re s  from human ad u lt and fo e ta l muscle were compared 
immunohistochemically. Detergent ex trac ts  of ad u lt and fo e ta l AChRs 
were compared in th e ir  in te rac tio n  with rad io labe lled  o(-BGT by
k in e tic  measurements involving determ ination of assoc ia tion , 
d isso c ia tio n  and equilibrium  binding constan ts. AChR was iso la ted  
and p a r t ia l ly  p u rif ied  frcm human a d u lt and fo e ta l muscle, and th e ir  
binding to  anti-(AChR) antibodies in myasthenic sera  and IgG were 
compared. No s ig n if ic a n t d ifference  vtas observed between the binding 
c h a ra c te r is tic s  of the  two receptor types, ind icating  the absence 
(a t le a s t  in  14 -  22 week old foetuses) o f ligand binding or 
an tigen ic  s i te s  unique to  fo e ta l AChR.
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INTRODUCTION
"Nevertheless, those labouring with a  want of s p i r i t s ,  w ill  
use these s p i r i t s  fo r lo ca l motions as well they can; in  the morning 
they are  ab le  to  m lk  firm ly , to  f lin g  th e ir  arms about h ith e r  and 
th ith e r  o r to  take up any heavy th ing; before noon the stock of 
s p i r i t s  being spent, v^ich has flowed in to  the  muscles, they a re  
scarcely  ab le  to  move hand nor fo o t. At th is  time I  have under my 
charge a prudent and honest wonan vho fo r many years has been 
subject to  th is  form of spurious palsy , not only in her members, but 
a lso  in  her tongue. She can fo r  seme time speak h a s tily  o r eagerly , 
she is  not ab le  to  speak a word, but beccmes suddenly as mute as a 
f is h , nor can she recover the use of her voice fo r  an hour o r two."
Ihcmas W illis , 1672
The human d isease myasthenia gravis (MG), the syirptcms of 
vhich are  v iv id ly  described above, was f i r s t  documented over th ree  
hundred years ago. Since then, and esp ec ia lly  over the l a s t  twenty 
years, a  g rea t volume of information has been recorded concerning 
the aetio logy , pathogenesis and treatm ent of the d isease (fo r 
comprehensive reviews see Lindstrcm, 1979; Vincent, 1980; Vincent & 
Newscm-Davis, 1982a). C lin ic a lly , MG i s  characterized  by weakness 
and rapid fa t ig u a b il i ty  of sk e le ta l muscle. The d iso rder may be 
se lec tiv e  fo r a p a rtic u la r  muscle group (eg. ocu lar, bulbar, limb, 
resp ira to ry  e tc .)  o r generalized. I t  i s  now generally  accepted th a t 
the basic de fec t in  MG is  a decrease in  the number of functional 
acety lcholine receptors (AChRs) a t  the post-synaptic  membrane of the 
neuromuscular junction , re su ltin g  from an antibody-mediated
response. E lucidation of the  mechanisms involved in  the pathogenesis 
of MS has in  many ways p a ra lle led  the understanding of muscle and 
nerve physiology; the l a t t e r  w ill  th erefo re  be d e a lt  with f i r s t ,  
before progressing to  a d e ta ile d  discussion  of the pathology of the 
d isease .
The organization of the  neuromuscular junction
I h t i l  the l a t t e r  p a r t  of the nineteenth  century the 
s tru c tu ra l organization  of the nervous system was supposed to  be a 
continuous network, vhereby ccmmunication between c e lls  was a 
continuation of the process by vhich nerve inpulses were conducted 
w ithin the boundaries of each indiv idual c e l l .  Ramon y Cajal (1888) 
challenged th is  theory, suggesting instead  th a t nerve c e l ls ,  
although in c lose  contact w ith each o th er, a re  d isc re te  u n its , each 
enclosing i t s  own cytoplasmic conten ts. Sherrington (1925) confirmed 
th is  hypothesis by e lectrophysio log ical s tu d ies , and coined the term 
'synapse' to  describe the specia lized  contacts ex is tin g  between 
c e l ls .
The d isco n tin u ity  of the nervous systom implied the presence 
of an add itional communication system between c e l ls ;  th is  led  to  the 
idea th a t a chemical messenger might be p resen t a t  the synapse 
(E lio tt , 1904; Dixon, 1906). The f i r s t  convincing demonstration th a t  
th is  vtas so came from Loewi (1921) Wiose experiments on the  vagal 
stim ulation of iso la ted  frog h eart muscle led  to  the form ulation of 
the neurotransm itter theory of synaptic transm ission. I n i t i a l  
attem pts to  show th a t th is  chemical messenger, Wiich, in the  case of 
frog h ea rt, Loewi l a te r  id e n tif ie d  as ace ty lcho line  (ACh), was 
released  as a re s u l t  of nerve stim ulation  were hindered by i t s  rap id  
hydrolysis; but the inclusion  of eserin e  (an acety lcholine  e s te rase
(AChE) in h ib ito r)  in the perfusion f lu id  (Loewi & N avratil, 1926; 
Dale e t  a l . ,  1936) then f a c i l i ta te d  i t s  de tec tion . A dditional 
experiments using curare a lso  allowed the demonstration th a t  ACh was 
released  by stim ula tion  of the  motor nerve and not by the ac tion  of 
the muscle. Iharm acological s tu d ies  led  Langley (1907) to  propose 
th a t the muscle contains a ' recep tive  substance* vhich receives the  
"special substance secreted  by the  end of the nerve". The 
nerve-muscle junction is  now one of the best understood systems w ith 
respect to  the organization of the elements of neurotransm ission.
I t s  function i s  to  tra n s fe r  the propagated nerve inpulse frcm the 
motor nerve ending to  the muscle f ib re ,  resu ltin g  u ltim ate ly  in 
muscle con trac tion . In the m ajority  of verteb ra te  muscles, each 
muscle f ib re  i s  innervated one nerve, and the area  of contact 
between the two i s  termed the neurcmuscular junction (see Figure 1 ) .
Ehrly s tu d ies  of ace ty lcho line  receptors were dependant on 
the a b i l i ty  of the  receptor to  depolarize the membrane of the 
post-synaptic  muscle c e l l ,  the  la rg e  s ize  of vhich f a c i l i t a te s  
in tra c e l lu la r  recording. Neurcmuscular transm ission i s  in i t ia te d  
vhen a nerve impulse invades the  nerve term inal, vÆiich can be 
achieved experim entally 1:̂  e le c t r ic a l  stim ulation  of the nerve. This 
increases membrane perm eability  to  calcium ions and th e i r  in flux  
in to  the nerve term inal tr ig g e rs  re lease  of ACh vhich d iffu ses  in to  
and across the synaptic c le f t .  The binding of ACh to  AChR in  the 
post-synaptic  membrane re s u lts  in  a conformational change which i s  
associated  w ith the opening of an ion channel. The channel remains 
open fo r approximately 1 m illisecond allowing sodium and potassium 
ions to  flow through i t  down th e i r  electrochem ical g rad ien ts . More 
sodium ions move in  than potassium ions move ou t, re su ltin g  in a n e t 
in flux  of p o sitiv e  charge and depo larization  of the muscle membrane
Figure 1. Schematic representation of the neuranuscular junction
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Acetylcholine (ACh ) in te ra c ts  with the recep tor (R ). The 
in te rac tio n  re s u lts  in the opening of the ionophore (I ) and Na^ ions 
en ter the c e l l  generating mini end-plate  p o ten tia ls  (MEPPs). The 
summated MEPPs change the manbrane p o ten tia l (Ay) and promote an 
aggregation of the in tr in s ic  gate  p ro te ins with the s e le c tiv i ty  f i l t e r  
(SF), thereby forming a functional sodium channel. The system can be 
blocked a t  3 d is t in c t  s i te s  by tox ins; cc-toxin (<xtx); h is tr io n ic a to x in  
(Htx) and tetrodotoxin  (T tx ).
producing an 'en d -p la te  p o te n t ia l ' (EPP). I f  the sunitation of EPPs 
causes depo larization  to  the threshold value, the muscle membrane 
generates an ac tio n  p o ten tia l which i s  propagated along the muscle 
f ib re  and u ltim ate ly  produces i t s  con traction . Smaller, spontaneous 
depo la riza tions, known as 'm iniature end-plate p o te n tia ls ' (MEPPs), 
occur in  re s tin g  muscle, a t  a frequency of about one per second; 
these r e s u l t  from the loca lized  re lease  of small q u a n titie s  of ACh. 
Their presence has led  to  the fom ula tion  of the "quantal" theory of 
chemical transm ission according to  vhich ACh i s  released  in  d isc re te
4
quanta. In huirans, each quantum probably contains le s s  than 10 ACh 
molecules, and 50 -  200 quanta a re  released  frcm one nerve ending 
following nerve stim u la tion . The ac tion  of A(Zh is  term inated by i t s  
hydrolysis by AChE, and by d iffu sion  out of the synaptic c le f t  (see 
Figures 1 & 2 ).
S tru c tu ra l analysis  of the "receptive substance" vhich binds 
ACh and in i t i a te s  such contraction  had to  await the development of 
su itab le  techniques. Two fac to rs  vhich s ig n if ic a n tly  and ra d ic a lly  
advanced the ch arac te riza tio n  of the AChR were, f i r s t l y ,  the 
discovery of an abundant source of the receptor in  the e le c t r ic  
organ of the e le c t r ic  f ish e s , and, secondly, the a v a i la b i l i ty  o f the  
o(-neurotoxins from snake venons vhich bind with high a f f in i ty  and 
sp e c if ic ity  to  the  AChR.
E le c tr ic  organs of e le c t r ic  f ish
The e le c t r ic  organ frcm e le c t r ic  f ish  consists  of a regu lar 
array  of stacks of la rg e , f l a t  sy n c itia  ca lled  e lectrop laques, each 
of which is  sub jec t to  dense cholinerg ic  innervation and produces a 
change in p o te n tia l in  response to  A(Zh released  frcm the nerve 
term inals. Because the c e l ls  a re  arranged in s e r ie s , summation of
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the evoked p o te n tia ls  gives r is e  to  a discharge. The organ is  
onbryologically s im ila r to  th a t of sk e le ta l muscle, but has no 
c o n tra c ti le  elem ents, the non-innerva ted  face being specia lized  fo r 
ac tiv e  tra n sp o rt. The two most studied e le c tr ic  organs are  those of 
the freshw ater e e l ,  Electrophorus e le c tr ic u s  and various species of 
the Torpedo genus -  the e le c tr ic  ray -  which frequents temperate 
marine v a te rs . The area  of synaptic contact in  these species i s  2% 
and 50% resp ec tiv e ly , and the fa c t  th a t  a l l  synapses respond to  ACh 
means th a t  the  e le c t r ic  organ i s  a r ich  and homogenous source of 
AChR vhich has been used extensively  fo r biochemical 
ch a rac te riza tio n s . AChRs iso la ted  frcm both e le c tr ic  f ish  and 
v e rteb ra te  s k e le ta l  muscle show c h a ra c te r is tic  n ico tin ic  
pharmacology.
The oC-neurotoxins
The discovery th a t  the AChR is  the ta rg e t of the 
o4-neurotoxins from elap id  and hydrojhobid snake venoms has 
undoubtedly been one of the major con tribu tions not only to  the 
s tru c tu ra l ch arac te riza tio n  of the recep to r, but a lso  (as w ill  be 
described la te r )  to  the  c la r if ic a tio n  of the ro le  of the recep to r in 
M3. These oc-neurotoxins were f i r s t  p u rif ied  by Chang & Lee (1962), 
vho demonstrated th a t  they produce an an ti-depo lariz ing  block of the  
AChR a t  the neuromuscular junction (Lee, 1972) in a manner s im ila r 
to  th a t  of the  cho linerg ic  an tagonist d-tubocurarine. The X -toxins 
are  small compact peptides comprising 61 -  74 amino-acid residues, 4 
-  5 d i-su lph ide  bridges and a ne t p o sitiv e  charge. They have been 
divided in to  two c la sses  (Type 1 and Type 11) on the basis o f th e i r  
behaviour a t  the  neuromuscular junction .
Type 1 cK.-toxins have 60 -  62 amino-acid residues, produce a
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rev e rs ib le  neuranuscular block and therefore  have been explo ited  as 
ligands fo r a f f in i ty  p u rif ic a tio n  of AChR (eg. the oC-toxin frcm 
Naja naja  siam ensis).
Type 11 o(rtoxins have 7 1 - 7 4  amino-acid residues and bind 
almost ir re v e rs ib ly  to  the  AChR. Their usefulness as probes fo r the 
AChR has re lie d  upon the finding  th a t they may be rad io labe lled  to  
high sp e c if ic  a c t iv i ty  w ith re ten tion  of b io log ica l a c t iv i ty  (eg. 
oC-bungarotoxin (oC-BGT) frcm Bungarus m ulticinctus ).
Iso la tio n  and ch arac te riza tio n  of AChR frcm e le c tr ic  f ish
AChR has been found to  be an in te g ra l membrane p ro te in , and 
d isso lu tio n  of the membrane is  accordingly a p re -re q u is ite  to  any 
p u rif ic a tio n  procedures. Extraction of AChR with non-ionic detergen t 
(eg. T riton X-100) re s u lts  in a soluble form of receptor vhich 
re ta in s  i t s  a b i l i ty  to  bind o^-toxins and cholinerg ic ligands 
(Changeux e t  a l . ,  1970; Miledi e t  a l . ,  1971). P u rifica tio n  by 
a f f in i ty  chrcmatography, b io spec ific  e lu tion  and concentration on 
DEAE-cellulose y ie ld s  preparations with sp e c if ic  a c t iv i t ie s  of 5 -  
10 pmol oC-BGT binding s i te s  per gram p ro te in . The AChR has by now 
been extensively  characterized , and i t s  p roperties  have been 
described in reviews by many groups of workers (K arlin, 1980; 
Changeux, 1981; Conti-Tronconi & R aftery, 1982; 1983; Barrantes, 
1983; Changeux e t  a l . ,  1984). The receptor i s  a glycoprotein 
containing 4 - 7 %  carbohydrate. I t  comprises four subunits, 
designated o(‘,ç>,y,S in the r a t io  2 :1:1:1 with apparant molecular 
weights (from polyacrylamide gel e lectrophoresis) o f 40000, 50000, 
60000 and 65000 respec tive ly . The subunit contains the binding 
s i t e  fo r ACh, the ro le  of the o ther th ree  subunits i s ,  as y e t, 
uncertain . The primary s tru c tu re s  of a l l  four polypeptide chains
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have been recen tly  e lucidated following the ex trac tion  of the 
corresponding messenger RNA (mRNA) and i t s  tra n s la tio n  in c e l l- f r e e  
systems (Mendez e t  a l . ,  1980; Anderson & Blobel, 1981; Sumikawa e t  
a l . , 1981) and in Xenopus oocytes (Sumikawa e t  a l . ,  1981; Mishina e t  
a l . , 1984). Id e n tif ic a tio n  of the mE?NA fo r AChR has allowed the 
cloning of the complementary DNA (cDNA) which has, in tu rn , enabled 
nucleotide sequencing of the o( subunit from Torpedo marmorata 
(Sumikam e t  a l . ,  1982a; D ev illers-Ih ie ry  e t  a l . ,  1983) and a l l  four 
subunits from Torpedo c a lifo m ic a  (B a lliv e t e t  a l . ,  1982; Noda e t  
a l . ,  1982; 1983a,b ). R econstitution of the receptor in to  model 
membranes leads to  res to ra tio n  of ligand and ion perm eability 
p roperties (Anholt, 1981; McNamee & Ochoa, 1982). The function of 
AChR in reconstitu ted  membranes can be a lte re d  by changing the l ip id  
composition in the membrane; l ip id s  displaying the h ighest a f f in i ty  
fo r the AChR are  those having the la rg e s t e ffe c ts  on the in flux  
properties of the receptor (Ellena e t  a l . ,  1983). Such stud ies may 
shed l ig h t  on the p roperties  of the ion channel and the functional 
contribution  of the various subunits.
The p u rified  receptor consists  of ro se tte s  9 nm in diam eter, 
each with a c en tra l p i t  of 2 nm as revealed by e lec tron  microscope 
(EM) stud ies ; th is  agrees well with freez e -fra c tu re  images vhich 
show p a rtic le s  on the synaptic face of the electroplaque membrane 
(Cartaud e t  a l . ,  1978). EM stud ies of anti-(AChR) antibody binding 
to  the post-synaptic  membrane show th a t  the AChR is  a transmembrane 
pro tein  exposed on both the cytoplasmic and e x tra c e llu la r  surfaces 
(Tarrab-Hazdai e t  a l . ,  1978; S trader e t  a l . ,  1979). I n i t i a l  stud ies 
used to  determine the ex ten t of exposure of indiv idual chains to  the 
cytoplasmic face were con troversia l because of the d isru p tiv e  
treatm ents used (Strader & Raftery, 1980; Wennogle & Changeux,
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1980). Recent s tud ies involving monoclonal antibody binding have 
shown th a t  a l l  four subunits are  exposed on the cytoplasmic face 
(Sargent e t  a l . ,  1984), while stud ies using lactoperoxidase 
catalysed iod ination  (Hartig & R aftery, 1977), peptide c ro ss-link ing  
(Witzmann & R aftery , 1978; K arlin , 1980) and p ro teo ly tic  degradation 
(Strader & R aftery , 1980; Anderson & Blobel, 1981) ind ica te  th a t  a l l  
four subunits a re  a lso  exposed on the e x tra c e llu la r  surface (see 
Figure 3 ). The im plications of th is  in the pathogenesis of MG w ill be 
discussed l a t e r .
Iso la tio n  and ch arac te riza tio n  of AChR from sk e le ta l muscle
The iso la tio n  and charac te riza tion  of AChR from verteb ra te  
sk e le ta l muscle has proved considerably more d i f f ic u l t  than th a t  fo r  
electroplaque AChR, mainly because of the very low content of AChR 
in the muscle membrane (W allis e t  a l . ,  1980) and a lso  as a r e s u l t  of 
p ro teo ly sis  during p u rific a tio n  (Lindstrcm e t  a l . ,  1980). In normal 
ad u lt innervated muscle the receptor comprises 0.002% of the to ta l  
pro tein  p resen t (Nathanson & H all, 1980). A fter denervation, 
however, AChRs increase 5 - 4 4  fo ld  (Dolly, 1979), providing a 
u se fu l, enriched source of receptors which has enabled th e ir  
p u rif ic a tio n  and p a r t ia l  charac te riza tion  from a v a rie ty  of sources 
(see Tables 20 & 22). Care must be taken in drawing conclusions from 
such s tu d ie s , as although the receptors which appear in the muscle 
membrane a f te r  denervation are  in  many ways sim ila r to  those found 
a t  the muscle end-p la te , some d ifferences between these two recep tor 
types are  apparent (see p. 13).
I n i t i a l  f^ysicochemical s tud ies on p u rified  AChRs led  to  some 
controversy regarding the subunit s tru c tu re  of v e rteb ra te  muscle 
AChRs, with repo rts  of between one and fiv e  subunits (reviewed by
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Figure 3. Schematic rep resen ta tion  of the receptor peptides 
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Conti-Tronconi & R aftery, 1982), v^ich may o r may not correspond to  
the pu tative  and S subunits of Torpedo AChR. These
discrepancies have to  sane degree been c la r if ie d  by the production 
of an tise ra  and moioclonal antibodies ag a in st ind iv idual Torpedo 
AChR subunits Wiich have been found to  cross reac t with maimalian 
muscle AChR (Lindstron e t  a l . ,  1978b; 1979t; 1980; Tzartos &
Lindstran, 1980). Furthermore, the induction of an immune response 
in ra ts  to  th e ir  own AChR by immunization with any of the Torpedo 
AChR subunits (Lindstron e t  a l . , 1978a) suggests th a t  mammalian 
muscle AChR may contain an tigen ic  s i te s  vhich a re  s im ila r to  those 
of the Torpedo AChR. Noda and co-workers (1983c) have cloned 
conplementary DMAs fo r the oC subunit precursor of c a lf  sk e le ta l 
muscle AChR and fo r a human genonic DMA containing the corresponding 
gene. The nucleotide sequences obtained fran  these stud ies show a 
large  degree of sequence honology with the corresponding Torpedo 
cDNAs, suggesting a conservation of the AChR pro tein  between 
species.
The d is tr ib u tio n  of AChR in  the  muscle membrane
The d is tr ib u tio n  of AChRs on muscle c e l ls  has been analysed 
both by recording the membrane p o ten tia l during loca lized  
iontophoretic app lica tion  of ACh to  the c e l l  su rface , and by mapping 
the binding of rad io labe lled  oC-BGT by using au to rad iogra j^ ic  and 
histochemical methods (Famborough, 1979). These investiga tions have 
revealed th a t two c la sses  of AChR e x is t  in the muscle membrane;-  
junctional (J) and e x tra junetio n a l (EJ) recep to rs. Adult innervated 
muscle f ib re s  contain junctional AChRs which a re  found a t  high 
density  in the post-synaptic  fo lds of the muscle membrane (see 
Figure 1 ), a t  a concentration of 2 -  6 x 10^ recep tors per junction
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(Famborough, 1979). The enzyme A(ZhE, which causes hydrolysis of A(Zh, 
i s  located along the folded membrane (Kamovsky & Roots, 1964).
Extra junctional recep to rs, which a re  barely  de tectab le  in normal 
ad u lt innervated muscle, appear, following denervation, a t  high 
density  over the e n tire  surface of the muscle f ib re  (Axelsson & 
T hesleff, 1959; M iledi, 1960a; Miledi & P o tte r, 1971; Berg e t  a l . ,  
1972; H artze ll & Famborough, 1972), re su ltin g  from de novo synthesis 
and d ire c t  incorporation in to  the ex tra  junctional membrane (Chang & 
Tung, 1974). I f  denervated muscle i s  reinnervated, then a reversa l 
of th is  process occurs with a reduction in the number of receptors 
outside the endplate u n t i l  a normal a d u lt p a tte rn  i s  achieved 
(M iledi, 1960b). E xtra-synaptic receptors are  a lso  present in 
developing iryotubes of embryonic species (Bevan & Steinbach, 1977), 
and, although they are  s im ila r in many respects to  the 
ex tra junc tiona l receptors of a d u lt denervated muscle, i t  i s  not 
c le a r whether they represen t d is t in c t  molecular forms.
(jcmparison of junctional and ex tra -ju n c tio n a l AChRs
Extrajunctional recep tors d if f e r  in  several respects from 
junctional receptors (see Famborough 1979 fo r review). In 
p a r tic u la r , junctional receptors are  re la tiv e ly  iirmdDile, have a 
slower m etabolic turnover time and a sh o rte r channel open time (Katz 
& M iledi, 1972). Biochemical s tud ies  on a f f in i ty  p u rified  receptors 
have shown few jiiysicochemical d ifferences between the two recep tor 
types. The r a t  AChRs have s im ila r subunit canpositions, as revealed 
by 1-dimensional peptide maps of the major (dC and/3) subunits 
(Nathanson & H all, 1979), and a re  ind is tingu ishab le  by gel 
f i l t r a t io n  and sucrose density  cen trifuga tion  (Brockes & H all,
1975b; Froehner e t  a l . ,  1977). Studies by Sumikam and co-workers
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(1982b) on AChR frcm chick embryonic, denervated and innervated 
muscle suggest th a t they a re  c lo sely  re la te d  s tru c tu ra lly . However, 
sane d ifferences between junctional and ex tra junc tiona l receptors 
have been observed:- junctional r a t  AChR has a lower iso e le c tr ic  
point than ex tra  junctional AChR (Brockes & H all, 1975b), although 
th is  was not noted fo r chick AChRs (Sumikava e t  a l . , 1982b). The 
s e n s it iv i ty  of the receptors to  d-tubocurarine d i f f e r s : -  junctional 
r a t  AChR has an apparent d isso c ia tio n  constant of 4.5 x 10 ^ M, 
canpared with 5.5 x 10 fo r ex tra  junctional receptors (Brockes & 
H all, 1975b). E xtrajunctional receptors re a c t p re fe re n tia lly , 
canpared to  junctional recep to rs, with anti-(AChR) antibodies frcm 
MG sera (Almon & Appel, 1975; Lindstrcm e t  a l . ,  1979a;
Savage-Marengo e t  a l . , 1980; Dwyer e t  a l . , 1981a; Reiness & H all,
1981), and with anti-(AChR) antibodies ra ised  ag a in st p u rified  
receptor frcm denervated c a t and chick muscle (Dolly e t  a l . ,  1983). 
I t  has been suggested th a t the observed d ifferences between the two 
receptor types may be due in p a rt to  carbohydrate residues (Dwyer e t  
a l . ,  1981b; Dwyer e t  a l . , 1981a; Hall e t  a l . , 1983; Turnbull e t  a l . , 
1984). Studies on the phosphorylation of d if fe re n t ACZhR fonns have 
a lso  revealed d ifferences between junctional and ex tra junc tiona l 
receptors (Saitoh & Changeux, 1981). There i s  no evidence th a t  
separate genes e x is t  fo r the coding of the  e x tra -  and sub-synaptic 
forms of the recep tor; observations concerning g lycosylation and 
phosphorylation suggest th a t the  d ifferences may re s u l t  frcm 
p o s t- tran s la tio n a l m odifications to  the recep tor p ro tein  (Barnstable 
e t  a l . ,  1983). P rotein  s t a b i l i ty  may be a consequence of i t s  
3-dimensional s tru c tu re  (Goldberg & S t. John, 1976), in which 
glycosyl residues have been proposed to  have a s ta b iliz in g  function 
(Olden e t  a l . ,  1978). Enzymes e ffec tin g  rev e rs ib le  j^osphorylation
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reactions in Torpedo e le c tr ic  organ have been demonstrated 
(Teichberg & Changeux, 1976; Saitoh & Changeux, 1980). I t  i s  
therefo re  possib le th a t  such p o s t- tra n s la tio n a l m odifications may 
occur before the recep tor i s  in serted  in the membrane (Changeux & 
Danchin, 1976).
Synaptogenesi s
During the development of the neuromuscular junction the AChR 
undergoes a se r ie s  of complex changes, both in i t s  d is tr ib u tio n  and 
in  a number of i t s  p ro p e rtie s . In myotubes, AChRs i n i t i a l l y  occur 
over the e n tire  muscle c e l l  surface (Axelrod e t  a l . , 1976; Bevan & 
Steinbach, 1977). Functional contact of the myotube with nerves 
(Dennis e t  a l . , 1981) re su lts  in  the appearance of c lu s te rs  of 
receptors packed a t  high density  a t  the s i te s  of neuromuscular 
contact (Bevan & Steinbach, 1977; Braithw aite & H arris, 1979; (Zhow & 
Cohen, 1983); th is  coincides with a re -d is tr ib u tio n  of AChE a c t iv i ty  
(Bevan & Steinbach, 1977). During fu rth e r development the number of 
AChRs a t  the end p la te  (junctional AChRs) increases, while the 
density  of receptors in  the ex tra  junctional membrane gradually 
decreases (Diamond & M iledi, 1962; Bevan & Steinbach, 1977), u n t i l  
in the ad u lt, AChRs a re  found almost exclusively  a t  the muscle 
end-plate (Axelsson & T hesleff, 1959; M iledi, 1960b; H artze ll & 
Famborough, 1972). For example, in the embryonic r a t ,
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ex tra  junctional AChRs are  d is tr ib u te d  with a  density  of 160/pm (a t
2
embryonic day 15 ) ; th is  decreases to  10/pm by embryonic day 19 and 
stays s ta b le  a t  th is  lev e l a f te r  b ir th  (Bevan & Steinbach, 1977).
The maintenance of AChR c lu s te rs  a t  the neuranusular junction i s  
thought to  depend upon specia lized  p ro teins Wiich cause anchorage in 
the membrane (Bloch & (Zeiger, 1980; H all, 1981; Prives e t  a l . ,
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1982), the calcium ion concentration (Bimbaum e t  a l . ,  1980; 
Bursztajn e t  a l . , 1984), the membrane f lu id i ty  (Bridgman &
N akajinia, 1981) and the ra te s  of synthesis and degradation of the 
receptor (Bursztajn e t  a l . ,  1983). The c lu s te rin g  of AChR molecules 
i s  thought not to  e f fe c t  the tra n s itio n  of the ion channel 
c h a ra c te r is tic  frcm long to  sho rt opening time (Berg & H all, 1975; 
Burden, 1977b; Sakmann & Brenner, 1978).
The development of monoclonal and polyclonal AChR 
subun it-specific  an tibodies has recen tly  allowed the c la r if ic a t io n  
of d isc re te  molecular events in the biosynthesis of A(ZhR and i t s  
incorporation in to  the post-synaptic  membrane (Anderson, 1983;
Merlie e t  a l . ,  1984). These stud ies have previously been lim ited  
because of the in a b il i ty  of the developing AChR to  bind oC-BGT. A(ZhR 
subunits are  tran s la te d  independently frcm separate  mRNAs, on 
manbrane-bound riboscmes of the rough endoplasmic reticulum . This 
has been demonstrated by c e l l- f r e e  p ro te in  synthesis of Torpedo AChR 
subunits (Anderson & Blobel, 1981) in BC3H-1 mouse myoblast c e l l  
l in e s  (Merlie e t  a l . ,  1981) and confirmed by experiments using 
ccmplementary DNA (cDNA) probes (B a llive t e t  a l . , 1982; Noda e t  a l . , 
1982). The independant synthesis of the four su b m its  implies th a t 
they a re , lik e  o ther membrane and secre to ry  p ro te in s, synthesized 
with a signal peptide extension a t  th e ir  amino terminus (Blobel,
1980), and th is  has been shown in G su b m its  (Noda e t  a l . ,
1982; B a lliv e t e t  a l . ,  1982; Anderson e t  a l . ,  1982). Asymmetrical 
in se rtio n  of these su b m its  in to  the membrane i s  a c o -tra n s la tio n a l 
process d irec ted  by signal recognition p a r t ic le  (Walter & Blobel,
1982), vhich forms a high a f f in i ty  'b rid g e ' between the nascent 
polypeptide chains and an in te g ra l membrane pro tein  receptor in  the 
rough endoplasmic reticulum  (Gilmore e t  a l . , 1982; Meyer e t  a l . .
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1982), and decodes the information contained in  the signa l sequence. 
The complex then in i t i t a t e s  translocation  of the amino term inal 
portion of nascent polypeptide across the l ip id  b ila y e r . The signa l 
pro tein  is  p ro te o ly tic a lly  removed following in se rtio n  in to  the 
membrane. During in teg ra tio n  in to  the rough endoplasmic reticulum  
membrane, a l l  four subunits receive asparagine-linked 'c o re ' 
o ligosaccharides side  chains (Anderson & Blobel, 1981; Anderson e t  
a l . ,  1982; M erlie e t  a l . ,  1981). The function of carbohydrate 
residues in the mature AChR is  unknown, but i t  has been suggested 
th a t th e ir  presence may be re la te d  to  the con tro l o f the ra te  of 
degradation of the molecules (Prives & Bar-Sagi, 1982). Assembly of 
the four subunits in to  a functional ccmplex does not happen 
immediately a f te r  in se rtio n  in to  the rough endoplasmic reticulum  
mambrane. Transport to  the c e l l  surface takes 2 - 3  hours, and i s  a 
temperature and energy dependant process (Devreotes e t  a l . ,  1977), 
however, the exact s i t e  of heterologous AChR subunit assembly i s  
unknown. Electron microscope autoradiography suggests th a t newly 
synthesized AChR i s  present in  the CZolgi apparatus v^ere i t  res id es  
fo r approximately 2 hours (Famborough & Devreotes, 1978; Bursztajn & 
Fischbach, 1984), demonstrating th a t in te g ra l membrane pro te ins 
follow the same in tra c e llu la r  tran spo rt pathway as secretory  
pro teins (Palade, 1975). P o s t-tra n s la tio n a l events in AChR assanbly 
have been studied by pulse-chase experiments using [^^S] methionine 
lab e llin g  of BC3H-1 c e lls  in tis su e  cu ltu re , and have shown th a t  
conformational m aturation occurs during the f i r s t  th i r ty  minutes 
a f te r  syn thesis, where c< subunits acquire the a b i l i ty  to  bind Û/-BGT 
and be immunoprecipitated by monoclonal an tibod ies. Further 
p o s t- tra n s la tio n a l m odifications of glycosylation and/or 
phosphorylation of subunits may occur a t  th is  s tage . Discrepancies
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between the molecular weights of subunits obtained by SDS-EAGE of 
a f f in i ty  p u rified  AChR and those obtained as tra n s la tio n  products of 
mRNA may suggest th a t the pro tein  does undergo sane form of 
processing (Marx, 1983).
S truc tu ra l s tud ies of membrane AChR by scanning transm ission 
e lectron  microscopy have indicated  th a t  each subunit borders the 
cen tra l channel (Wise e t  a l . , 1981), which in p lie s  th a t each subunit 
has a hydrophilic surface which must be maintained in  the 
hydrocarbon in te r io r  of the monbrane p r io r  to  oligcm eric assembly. 
Evidence frcm experiments using c e l l- f r e e  systems suggests th a t  AChR 
subunits may se lf-a sso c ia te  p r io r  to  ccmplex formation, such 
associations would serve to  s ta b il iz e  hydrophilic surfaces of the 
subunits (Anderson & Blobel, 1983). No evidence fo r th is  in  v i tro  
has been documented. The re su lts  obtained by Mishina e t  a l .  (1984) 
show th a t assembly of a l l  four subunits is  required to  e l i c i t  a 
normal n ico tin ic  response to  ACh; only the ^(subunit i s  indispensable 
fo r oC-BGT binding a c t iv i ty .
The change in  immunological p roperties of r a t  muscle AChR 
frcm the embryonic to  the ad u lt form takes place during the f i r s t  
two p o st-n a ta l weeks, concurrently with developmental changes in the 
mean channel open time (Reiness & H all, 1981). At th is  stage the 
changes in AChR c lu s te rin g  and metabolic turnover time have already 
taken place.
The development of the human neuromuscular junction has not 
been so well documented. S tru c tu ra l s tu d ies  of developing human 
muscle (fo e ta l age 9 weeks to  9 months) have revealed th a t 
development i s  in two main s tag es: -
1. Up to  18 weeks, where two types of muscle c e l ls  -  myoblasts and 
myotubes -  a re  observed
19
2. A fter 18 weeks, where muscle f ib re s  a re  sim ila r to  those 
observed in ad u lt muscle (Minguetti & Mair, 1981).
The con tribu tion  of junctional and ex tra  junctional AChR types 
in th is  developmental scheme has not been documented.
B rief h is to ry  of myasthenia gravis
Jo lly  (1895) coined the name 'myasthenia g ra v is ' fo r  p a tie n ts  
su ffering  from "grave muscle weakness" and showed th a t in  these 
pa tien ts  muscle streng th  was normal in i t i a l l y ,  but declined rap id ly  
following exerc ise . By the end of the n ineteenth  century, about 70 
cases of MG had been documented, most of them a re  described in 
summary form by Campbell & Bramwell (1900), who a lso  proposed th a t 
the muscle weakness observed in MG p a tien ts  might r e s u l t  from the 
presence of a c irc u la tin g  fac to r , possibly  a  toxin of m icrobial 
o rig in . The s im ila r ity  of myasthenic syirptons to  those of curare 
poisoning led  Mary Walker (1934) to  t ry  the e ffe c ts  of 
phytostigmine, the anti-AChE an tido te  to  curare poisoning. This 
provided the f i r s t  evidence d ire c tly  im plicating an abnormality a t  
the neuromuscular junction (see Figure 4) in  M3 p a tien ts ; such a 
d e fec t could be p re-synap tic , in tra -sy n ap tic  or post-synaptic  and 
various hypotheses were proposed as to  the p rec ise  s i t e  and nature 
of the de fec t. Possible fac to rs  considered by various authors 
include the follow ing:-  
Pre-synaptic s i t e : -  fa i lu re  in  impulse propagation along the axon; 
impaired synthesis o f ACh; fau lty  packaging of ACh in synaptic 
v e s ic les ; impaired re lease  of ACh; re lease  of "fa lse" 
neurotransmi t t e r
In tra -synap tic  s i t e : -  increased d iffu sio n  of ACh am y from the 
synaptic c le f t ;  prevention of ACh trav e rsin g  the  synaptic c le f t
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MG junction shows normal p re-synaptic  term inal, but 
s iiip lif ie d  post-synaptic  membrane with reduced numbers of AChRs, 
sparse shallow synaptic fo lds where carplonent-mediated focal ly s is  
re s u lts  in shedding of membrane fragments (containing AChR and C3) 
in to  the synaptic c le f t ,  and antigen ic  modulation, involving antibody 
cross-link ing  of AChR, in te rn a liza tio n  and p ro teo ly sis . The synaptic 
space is  widened as a re s u lt  of the lo ss  of membrane.
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Post-synaptic s i t e : -  canbination of c irc u la tin g  blocking agent 
with ACh ' receptive substance' ;  depletion of ACh ' receptive 
substance ' ; increased AChE a c t iv i ty .
I t  was Siiipson (1960) and Nastuk e t  a l .  (1959) v^o proposed 
th a t the ACh ' receptive substance' (then merely a  hypothetical 
construct) vas involved and postulated th a t i t  was blocked by an 
autoantibody. The e lucidation  of the p rec ise  s i t e  of the defec t 
followed e lectrog^ysio log ica l s tu d ies . Measurement of the response 
of v^ole muscle to  re p e tit iv e  supra-maximal stim ulation  of the nerve 
shows a s ig n if ic a n t decronental response in  MG p a tien ts  (Desmedt, 
1966), which i s  consis ten t with the  observed physical fa t ig u a b il i ty  
of the myasthenic. D etailed stud ies revealed th a t  the  action  
p o ten tia l generated ky the nerve was normal, but th a t  m iniature 
end-plate p o ten tia ls  were reduced in MG p a tien ts  (Elmquist e t  a l . ,  
1964; Santa e t  a l . , 1972; Albuquerque e t  a l . , 1976). Myasthenic motor 
end-plates a lso  show reduced se n s it iv i ty  to  ion tophore tically  
applied ACh in  v i tro  (Rash e t  a l . , 1976). Furthermore, 
m u lti-e lec trode  recordings frcm two or more muscle f ib re s  frcm the 
same motor u n it during a voluntary contraction  showed a g rea te r time 
delay between the two impulses in MG muscle f ib re s  than in  normal 
contro ls (Ekstedt & S talberg , 1967). This re s u lts  frcm the delay in 
onset of end-plate p o ten tia ls  vAiich in turn  re s u lts  frcm the 
diminished s ize  of m iniature end-plate p o te n tia ls . The loca tion  of 
the defec t a t  the post-synaptic  membrane vas f in a l ly  s e t t le d  
following the a v a i l ib i l i ty  of the post-synaptic  &C--neurotoxins (see 
"Introduction" p. 7 ) v^ich bind with high sp e c if ic i ty  and a f f in i ty  
a t  the n-AChR in  the post-synaptic  membrane. Neurcmuscular junctions 
of myasthenic p a tien ts  show morphological a lte ra t io n s  of f la tte n in g  
and s im p lifica tion  of post-synaptic  fo lds (Engel & Santa, 1971) and
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a lso  bind fa r  le s s  iodinated oĈBGT than normal con tro ls (Famborough 
e t  a l . ,  1973), ind icating  a reduced number of av a ilab le  AChR s i te s ,  
which may be reduced to  30% of normal (see Figure 4 ). The area of 
the post-synaptic  membrane th a t  can bind o^BGT is  a3so reduced (Engel 
e t  a l . ,  1979), vhich re f le c ts  a decrease in  the content of AChR 
ra th e r than blocking of o(-BGT binding to  the recep tor by seme other 
fac to r (Lindstrcm & Lambert, 1978). These physiological changes 
re s u lt  in decreased e ffic ien cy  of neurcmuscular synaptic 
transm ission, vhich, i f  reduced below threshold lev e ls  w ill  r e s u l t  
in  fa ilu re  to  tr ig g e r  ac tion  p o ten tia ls . This w ill  u ltim ately  lead 
to  reduction of muscle power and hence to  the weakness and 
su sc e p tib il ity  to  fa tigue  which a re  c h a ra c te r is tic  of the d isease .
In c o n tra s t, the s tru c tu re  of the axon term inal has been 
shown to  be re ta ined , with the normal number of synaptic v esic les  
p resent and twice the normal concentration of ACh (I to  e t  a l . ,  1976; 
Chll-Candy e t  a l . ,  1978; 1980).
The autoimmune nature of MG was f i r s t  suspected (Simpson, 
1960; Nastuk e t  a l . ,  1960) because of i t s  assoc iation  with o ther 
presumed autoimmune d isorders (eg. Hashimoto's th y ro id i t is ,  systan ic  
lupus erythrem atosus, rheumatoid a r th r i t i s  e t c . ) ,  as well as because 
of s tru c tu ra l abnorm alities of the thymus found in  approximately 75% 
myasthenic p a tien ts  (Castleman, 1966). The serendipitous production 
of an experimental animal model fo r MG (Patrick & Lindstrcm, 1973; 
Sugiyama, e t  a l . ,  1973; Heilbronn & Mattson, 1974), obtained by 
immunization of rabb its  with p u rified  e le c tr ic  e e l AChR, 
substan tia ted  th is  hypothesis, providing evidence th a t  an autoimmune 
response d irec ted  ag a in st AChR can produce many of the fea tu res 
c h a ra c te r is tic  of MG. This suggested th a t antibody d irec ted  against 
AChR might be found in MG p a tie n ts , but early  attem pts to
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danonstrate such a ' c irc u la tin g  fac to r ' ,  vhich in te rfe re d  with 
neurcmuscular transm ission, were unsuccessful and gave r i s e  to  
co n flic tin g  re su lts  (Wilson & Stoner, 1944; Lairmers & Van Spijk , 
1954; Nastuk, e t  a l . ,  1959; McFarlin e t  a l . , 1966; Barkes & McKinna, 
1967; Namba & Grob, 1969). I t  was not u n t i l  1974 th a t Almon e t  a l .  
were ab le  to  show th a t approximately 50% of MG sera  te s te d  could 
in h ib it  t<-BGT binding to  r a t  denervated AChR p reparations. The 
fac to r responsible fo r th is  observation was la te r  id e n tif ie d  as 
Immunoglobulin G (IgG) (Almon & Appel, 1975). Shortly  a f te r  th is .  
Bender e t  a l .  (1975) showed th a t peroxidase-labelled  myasthenic IgG 
in h ib ited  the binding of <-BGT to  normal human muscle, and Aharonov 
e t  a l .  (1975) showed th a t in 80% of MG p a tie n ts , ccmplement f ix a tio n  
could be e ffec ted  in the presence of small q u a n titie s  of Torpedo 
AChR.
Hie question as to  whether c irc u la tin g  antibodies are  
pathogenic, o r merely represen t a secondary response to  AChR damage 
caused by seme o ther agent, i s  c r i t i c a l  in understanding the 
pathogenesis of MG, and a number of observations a re  re levan t to  
th is .  Toyka e t  a l .  (1977) showed th a t passive tra n s fe r  of myasthenic 
IgG in to  mice induces c h a ra c te r is tic  fea tu res of MG. Plasma exchange 
of MG p a tien ts  causes temporary improvements in  th e ir  muscle 
s treng th , vhich p a ra lle ls  the decrease in the concentration of serum 
antibodies (Pinching e t  a l . , 1976; Dau e t  a l . ,  1977). P lacental 
tra n s fe r  of anti-(AChR) antibodies frcm a myasthenic mother to  the 
foetus causes tra n s ie n t neonatal MG, with an antibody lev e l a t  b ir th  
sim ilar to  th a t  of the mother (Keesey e t  a l . ,  1977). The antibody 
leve l declines with a of 8 days; f u l l  recovery i s  noticed a f te r  3 
weeks. These observations c le a rly  demonstrate the involvement of a 
c irc u la tin g  fac to r as a primary agent in  the d isease  process.
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Mechanisms fo r the pathogenesis of anti-(AChR) an tibodies
In order to  cause synaptic dysfunction, an tibodies need to  
leave the vascular system, d iffu se  in to  the e x tra -c e llu la r  space, 
en ter the synaptic c le f t  and reach AChR on the post-synaptic  fo ld s . 
Zum & Fulpius (1976) used complexes of oC-BGT covalently  coupled to  
IgG to  show th a t molecules the s ize  of an tibodies can reach the AChR 
in  s i tu  in mouse diaphragm. Localization of IgG a t  end-plates has 
a lso  been reported by Engel e t  a l .  (1977a) using peroxidase-labelled  
Staphylococcal p ro tein  A (which binds to  the Fc portion  of human IgG 
subclasses 1 ,2  and 4) and by Sahashi e t  a l .  (1980). Although these 
re su lts  alone do not necessarily  im plicate an tibodies in  a  primary 
pathogenic ro le  in  MG, there  i s  evidence th a t c irc u la tin g  
anti-(AChR) antibodies may be pathogenic in one o r more of th ree  
d if fe re n t ways;-
( i)  ky a lte r in g  the ra te  of turnover of A(3iR
( i i )  by blocking the ac tiv e  s i t e  of ACkiR
( i i i )  ky ccmplement-mediated membrane destruction  
These w ill iDe discussed in  tu rn .
Increased degradation of ACItR
IgG from myasthenic sera  kias keen shown to  acce le ra te  the 
degradation of A(3iRs in r a t  (Anwyl e t  a l . , 1977; Kao & Drachman,
1977b) and human (Bevan e t  a l ,  1977; Drachman e t  a l . , 1981) muscle
tis su e  cu ltu re  systems; the ra te  increasing 2 - 3  fo ld  above tkiat of 
nonnal contro ls (Kao & Drachman, 1977b). S ig n ifican t acce le ra tion  of 
AChR degradation in th is  system was observed in 66% (Conti-Tronconi 
e t  a l . , 1981) and 90% (Drachman e t  a l . ,  1982) of myasthenic p a tien ts  
stud ied . (jonti-Tronconi e t  a l .  (1981) found, in  add ition , th a t
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increased degradation was proportional to  the  sev e rity  of the 
d isease s ta te  (see a lso  Drachman e t  a l . ,  1981), and was re la te d  to  
the antibody t i t r e  ( i f  the t i t r e  vas le s s  than 10 nM) (see a lso  
Appel & ELias, 1979). Increased degradation i s  dependent on the 
a b i l i ty  of IgG to  cross lin k  receptors (Drachman e t  a l . ,  1978; 
(jonti-Tronconi e t  a l . ,  1981), vhich i s  possib le  because of th e ir  
d iv a len t nature (see Figure 5 ). Monovalent Fab fragments a re  
in ac tiv e , except when they are  thanselves cross-bridged by a second 
antibody (Prives e t  a l . ,  1979; Drachman e t  a l . ,  1978; Lindstrcm & 
Einarson, 1979). Morphological s tud ies ind ica te  th a t  such 
c ross-link ing  causes re -d is tr ib u tio n  of AChR in the membrane, 
followed by enhanced endocytosis. Aggregation of AChRs in muscle 
cu ltu res  following the add ition  of myasthenic serum has a lso  been 
observed hy fluorescence microscopy, autoradiography (Lennon, 1978; 
Icirrab-Hazdai e t  a l . ,  1979) and by freeze -frac tu re  e lec tron  
microscope stud ies (Puirplin & Drachman, 1983). Antibody-induced 
accelera tion  of AChR degradation has been described in  sections of 
nonnal ad u lt sk e le ta l muscle (Merlie e t  a l . ,  1979; Reiness e t  a l . , 
1978; Stanley & Drachman, 1978) ind ica ting  th a t  th is  i s  not purely a 
fea tu re  of ex tra -ju n c tio n a l recep to rs. More recen t re s u lts  frcm 
Wilson e t  a l .  (1983a,b) have shown th a t synthesis of diaphragm 
end-plate AChRs is  increased in  vivo, suggesting the ex istance of a 
compensatory mechanism serving to  s ta b il iz e  the number of A(ZhRs.
Blockade of AChR
Anti-(AChR) antibodies frcm MG sera  may in h ib i t  neurcmuscular 
transm ission by pharmacologica1 blockade of AChRs; however, the 
ex ten t of such a contribu tion  to  the pathogenesis of MG is  s t i l l  a 
con troversia l m atter. E lectrophysiological s tud ies  have shown th a t
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Figure 5. Diagram showing in te r -  and in tra^no lecu lar cross-link ing  
of AChR by anti-(AChR) antibodies





iiïmunoglobulins frcm sera with MG (Anwyl e t  a l . ,  1977; Bevan e t  a l . , 
1977) and animais with EAMG (Patrick  e t  a l . , 1973) cause reduced 
s e n s i t iv i ty  of muscle c e l ls  in cu ltu re  to  applied AQi. Such
125inmunoglobulins have a lso  long been known to  block binding of [ I]
d(rBGT to  detergen t so lub ilized  AChR; an e ffe c t th a t  has served as a
method of iden tify ing  antibodies d irec ted  a t  (or near) the
cholinerg ic  binding s i t e  (Almon e t  a l . , 1974a; Shibuya e t  a l . , 1978;
I to  e t  a l . ,  1978; Vincent & Na^cm-Davis, 1979; M ittag e t  a l . ,
1981). Reports concerning the incidence of an tibodies with th is
s p e c if ic ity  vary g rea tly  -  the proportion of MG p a tien ts  Wio have
anti-(ACh binding s i te )  an tibodies has been reported as ranging frcm
7 -  90% (Almon e t  a l . ,  1974a; Vincent & Na^cm-Davis, 1979; Drachman
e t  a l . , 1980; Drachman e t  a l . ,  1982); while the proportion of such
antibodies in an individual p a tie n t has been quoted as varying frcm
0 -  100% of the to ta l  anti-(AChR) antibodies (Whiting e t  a l . , 1983;
Dv^er e t  a l . ,  1979). Attempts to  re la te  anti-(ACh binding s i te )
antibodies to  the c l in ic a l  sev erity  of MG symtcms have proved
unsuccessful so fa r  (Lindstrcm e t  a l . ,  1976a; L efvert e t  a l . ,  1978;
Vincent & Newsom-Davis, 1979), although these an tibodies have been
im plicated in the pathogenesis of EAMG (Zum & Fulpius, 1977; Gcroez
& Richman, 1983).
Care must be taken in  drawing conclusions frcm these da ta , as
the a b i l i ty  of a p a rtic u la r  serum to  block ligand binding to  the
receptor in  s i tu  and to  the so lub ilized  receptor may d i f f e r  (Sanders
125e t  a l . , 1976; K arlin e t  a l . ,  1978). Furthermore, blockade of [
-BGT binding does not necessa rily  p a ra lle l  the blockade of ACh 
binding in v ivo , as the small molecular weight of A(Zh (182 ccmpared 
to  8000 fo r o(-BGT) may allow g rea te r a c c e s s ib il i ty  to  the ACh 
binding s i t e ,  even in the presence of antibody.
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Ganplement-mediated destruction  of muscle manbrane
Uie sim plified  post-synaptic  s tru c tu re  observed in myasthenic 
p a tien ts  has been a ttr ib u te d  to  the ccmplement-mediated destru c tiv e  
e ffe c ts  of anti-(AChR) antibodies (Engel e t  a l . ,  1979; Toyka e t  a l . ,  
1977). Published evidence fo r muscle c e l l  ly s is  i s  la rg e ly  in d ire c t, 
re ly ing  mainly on the demonstration of IgG and C3 binding to  the 
post-synaptic  membrane (Engel e t  a l . ,  1977a; Sahashi e t  a l . , 1978; 
1980). The f in a l  ly t ic  ccmponent, C9, i s  found both on the 
post-synaptic  membrane and a lso  on degenerated membrane in  the 
synaptic space (Engel e t  a l . ,  1979; Engel & Pum igalli, 1982). D irect 
measurement of antibody-mediated ly s is  of muscle c e lls  has been more 
d i f f i c u l t  to  demonstrate because of the lack , u n t i l  recen tly , of a 
s u f f ic ie n tly  se n s itiv e  and sp e c if ic  method fo r q u an tita tin g  such 
ly s is .  (Cambridge & Stem  (1981) reported a procedure fo r measurement 
of iryotube-specific to x ic ity , dependent on the se lec tiv e  uptake of 
[^H ]-cam itine  which is  subsequently re leased  following c e l l  ly s is .  
Using th is  method, Childs e t  a l .  (1984) have shown th a t  e igh t out of 
th ir te e n  myasthenic sera  (and zero out of nine con tro ls) showed 
myolytic a c t iv i ty  in  monolayer r a t  muscle cu ltu res , ind icating  th a t 
ccmplement-mediated mechanisms could be responsib le, a t  le a s t  in 
seme myasthenic p a tie n ts , fo r the known post-synaptic  membrane 
damage. A lte ra tions of membranes by such means would be expected to  
reduce the e ffic ien cy  of transm ission and could con tribu te  to  the 
o ther fac to rs  v^ich reduce neurcmuscular transm ission in MG.
Present evidence suggests th a t  each of the immune mechanisms 
mentioned above i s  involved to  seme ex ten t in  indiv idual p a tie n ts , 
but th e ir  re la tiv e  ro les  in  the pathogenesis of the d isease  i s  s t i l l
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a con troversia l m atter.
C irculating  anti-(AChR) an tibodies could a lso  be pathogenic 
as immune complexes; th e ir  deposition would lead to  widespread 
generalized damage. Methods fo r th e ir  detection  a re , however, 
la rg e ly  non-specific , and fu rth er information concerning th e ir  ro le , 
i f  any, in MG must await the developnent of sp e c if ic  assay methods.
Q uantitation of anti-(AChR) antibodies
Following the discovery of the presence of anti-(AChR)
antibodies in  the sera  of myasthenic p a tien ts  (Almon e t  a l . , 1974a),
a radioimmunoassay fo r th e ir  q u an tita tio n  soon became a standard
diagnostic  procedure (Lindstrcm e t  a l . , 1976; Lindstrcm, 1977;
Monnier & Fulpius, 1977; Newscm-Davis e t  a l . ,  1978; Dwyer e t  a l . ,
1979; T indall e t  a l . ,  1981; C arter e t  a l . ,  1981). This method is
based on a d ire c t  immunoassay developed by P a trick  e t  a l .  (1973) fo r
the q u an tita tio n  of anti-(AChR) antibodies induced 1:̂  in jec tio n  of
e le c tr ic  e e l A(ZhR in to  ra b b its . I t  uses, as an tigen , crude detergen t
ex trac ts  of amputated human limb muscle in v^ich the AChR is  
12Slab e lled  with [ I]oC-BGT. The lab e lled  e x tra c t i s  incubated with MG 
serum, followed by goat anti-(human IgG) antiserum  and fu rth er 
incubation. The re su ltin g  p re c ip ita te  i s  p e lle te d , washed, counted 
and the amount of sp e c if ic  antibody binding expressed as nmoles/1 
sp e c ific  o(-BGT binding s i te s  (see Figure 6 ). 70 -  95% of c l in ic a lly  
diagnosed MG p a tien t have de tec tab le  anti-(AChR) antibodies (Appel 
e t  a l . , 1975; Lindstrcm e t  a l . , 1976a; M ittag e t  a l . , 1981; 1984; 
Monnier & Fulpius, 1977; I to  e t  a l . , 1978; L efvert e t  a l . ,  1978; 
Bradley e t  a l . , 1978), showing values ranging frcm G -  844 nM. 
(jontrol values, including normals, p a tien ts  with o ther neurological 
d isorders (eg. d iab e tic  neuropathy, F rie d re ic h 's  a ta x ia , nyotonic
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Figure 6. Diagrammatic represen tation  of the radioimmunoassay 










dystrophies, Lambert-Ehton myasthenic syndrane, G uillain-B arre 
syndrome e tc .)  and p a tien ts  with o ther autoimmune d iseases (eg. 
polym yositosis, S jogren 's syndrome, systemic lupus erythrematosus 
e t c . ) ,  were in  the range 0 - 6  nM.
Anti-(AChR) antibodies have been detected  in  MG associated  
with D-penicillamine treatm ent fo r rheumatoid a r t h r i t i s  or W ilson's 
d isease  (Masters e t  a l . , 1977; R ussell & Lindstrcm, 1978). Most 
cases improve rap id ly  a f te r  cessation  of penicillam ine treatm ent, 
and th is  i s  accompanied by a decrease in  the antibody leve l (Vincent 
e t  a l . , 1978a). Penicillam ine may d is tu rb  the maintenance of 
to lerance in  seme way; attem pts to  t e s t  th is  in experimental animals 
have so fa r  proved unsuccessful (Russell & Lindstrcm, 1978).
The anti-(AChR) antibody assay described above i s  sp e c if ic  
fo r IgG, but o ther immunoglobulins can be detected  with d if fe re n t 
a n ti- Ig  p rec ip ita tin g  sera  (T indall, 1981), although only 
concurrently with IgG and in low concentrations. There i s  no d ire c t  
evidence fo r d if fe re n t pathogenic ro les  fo r the d if fe re n t Ig types, 
desp ite  the fa c t th a t IgM is  known to  appear in  the ea rly  phase of 
an immunization procedure. Lefvert e t  a l .  (1978) observed th a t in  
th ree  p a tien ts  with sho rt duration of myasthenic symptoms, IgM 
antibodies were present in i t i a l l y ,  but not IgG an tibod ies. This 
s itu a tio n  vas, however, reversed during the course of the d isease , 
when IgM antibodies disappeared as IgG antibodies appeared. This 
finding was not confim ed by T indall (1981).
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Heterogeneity of anti-(AChR) antibodies
The AChR e x is ts  in  detergent so lu tion  as a  large  
nacronolecule with several an tigen ic  domains. The v ariab le  s izes  of 
AChR -  anti-(AChR) antibody complexes observed by gel f i l t r a t io n  
(Vincent & Newscm-Davis, 1979; Dwyer e t  a l . , 1979) and the broad 
peaks of anti-(AChR) a c t iv i ty  obtained on is o e le c tr ic  focussing of 
myasthenic IgG (Lefvert & Bergstrom, 1978) suggest th a t  d if fe re n t  
sera contain an tibodies of d if fe r in g  s p e c i f ic i t ie s .  Such experiments 
ind ica te  th a t anti-(AChR) antibody i s  polyclonal in  most p a tie n ts . 
A dditional evidence fo r th is  comes from the use of IgG subclass 
sp e c ific  a n tise ra  in  the assay fo r anti-(AChR) an tibod ies, vhere 
Vincent & Newscm-Davis (1980) show th a t most p a tien ts  have 
anti-(AChR) antibodies in  subclasses 1 ,2  and 4, and th a t 
occasionally  IgG3 predominates. This i s  in  agreement with the 
observations of T indall (1981) who found the same anti-(AChR) 
antibody t i t r e  using e ith e r  Staphylococcal p ro te in  A or anti-(human 
IgG) antiserum  to  p re c ip ita te  AChR-antibody complexes; but con trasts  
with the findings of L efvert & Bergstrom (1978) vho suggested th a t 
IgG3 is  the dominant form of anti-(AChR) antibody.
The d iv e rs ity  of anti-(AChR) antibodies i s  a lso  suggested by 
the v a ria tio n  seen between individual sera  in th e i r  c ro ss -re a c tiv ity  
with AChR preparations from d if fe re n t  species (Lindstrcm e t  a l . , 
1978a; McAdams & Roses, 1980; Savage-Marengo e t  a l . ,  1979; 1980; 
Harrison e t  a l . ,  1981; Z ie linsk i e t  a l . ,  1982) and a lso  from 
d if fe re n t  muscles of the same species (Vincent & Navsom-Davis, 1979; 
Compston e t  a l . , 1980; Almon & Appel, 1975; Weinberg & H all, 1979). 
The a b i l i t i e s  of MG sera to  in h ib it  binding of [^^^I]oo-BGT to
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detergent so lub ilized  AChR a lso  show sim ila r variab le  
c h a ra c te r is tic s  (see "Introduction" p. 2 5 ). Anti-(ACh binding s i te )  
antibodies a re  found in 7 -  90% p a tie n ts , and the proportion of 
antibodies in h ib itin g  oc-BGT binding as a percentage of those v^ich 
do not in te r fe re  with the oC-BGT binding s i t e  v a rie s  frcm 0 -  100% 
(Whiting e t  a l . ,  1983; Dwyer e t  a l . ,  1979).
The nature of the an tigen ic  domains on AChR responsible fo r 
variab le  re a c tiv ity  with anti-(AChR) antibodies i s  not known. 
However, the recen t advances in  monoclonal antibody technology have 
enabled the production of monoclonal an tibodies (Kohler & M ills te in , 
1975) to  p u rif ied  AChR. These a re  being used to  probe the s tru c tu re  
and function of AChR, and, in d ire c tly , to  define  the binding s i te s  
of anti-(A(3hR) antibodies to  the recep tor (Tzartos & Lindstrcm,
1980; Vincent, 1983). The m ajority  of an tibodies (60 -  70%) bind to  
a main iiimunogenic region on the c<. subunit, although a proportion 
of an tibodies may be d irec ted  towards the  /2> and S subunits v^ich l i e  
next to  the subunit (Tzartos & Lindstrcm, 1980; Tzartos e t  a l . , 
1981; 1982; 1983).
R elationship between anti-(AChR) antibody t i t r e  and d isease  sev erity
The discovery of c irc u la tin g  anti-(A(ZhR) antibodies was 
exciting  from a c l in ic ia n 's  po in t of view, as a p o sitiv e  co rre la tio n  
between the lev e l of antibody and the c l in ic a l  s ta tu s  of the MG 
p a tie n t would permit assessment of the progression of the d isease , 
p red ic t the occurrence of relapses and enable monitoring of the 
e ffec tiveness and benefits  of a p a r tic u la r  treatm ent regime. S e ria l 
assays performed on serum samples from a given MG p a tie n t show 
t i t r e s  vhich r e f le c t  the c l in ic a l  s ta te  of the  p a tie n t; th is  has 
been most convincingly demonstrated in p a tien ts  tre a te d  by plasma
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exchange combined with immunosuppressive therapy (Newsom-Davis e t  
a l . ,  1978; 1979; C arter e t  a l . ,  1980). Continued post-exchange 
a lle v ia tio n  of MG symptoms was p a ra lle led  by lowered anti-(AChR) 
antibody t i t r e s  and, i f  relapse did occur, was associated  with a 
sharp r i s e  in antibody t i t r e  (Carter e t  a l . , 1980).
Between p a tie n ts , however, the lev e l of antibody does not 
co rre la te  well with the c lin ic a l  s ta tu s  of the p a tie n t (I to  e t  a l . ,  
1978; L efvert e t  a l . , 1978; Lindstrcm e t  a l . , 1976a). A high 
percentage of po sitiv e  a n t i - (AChR) antibody t i t r e s  a re  found in 
p a tien ts  with generalized MG, but many p a tien ts  in  c l in ic a l  
remission a lso  have antibody t i t r e s  w ell w ithin the range of those 
w ith ac tiv e  d isease  (Vincent & N^fsom-Davis, 1979). A fu rth er number 
of iryasthenic p a tien ts  have no de tec tab le  antibody (Lindstrcm,
1977), but have severe generalized MG. Many p a tien ts  with low t i t r e s  
have predominantly ocular symptoms (I to  e t  a l . ,  1978; Lindstrcm e t  
a l . ,  1976a; Comps ton e t  a l . , 1980) and a proportion of these are  
w ithin the s t a t i s t i c a l  lim its  of con tro l values. The a b i l i ty  to  
d e te c t low t i t r e s  re lia b ly , and hence d iscrim inate  between MG and 
normal se ra , depends on the lower cu to ff value used. The v a ria tio n  
seen in the percentage of MG p a tien ts  reported to  have s ig n if ic a n t 
anti-(AChR) antibody t i t r e s  may w ell be a re f le c tio n  of the 
d if fe re n t  lower cu to ff values used by d if fe re n t  workers (Mittag e t  
a l . ,  1984).
The lack of co rre la tio n  between antibody t i t r e  and d isease  
sev erity  can be explained in  a number of ways, including the 
follow ing; -
-  the immunoprecipitiation assay used does not d e tec t a l l  
an tibodies present (eg. anti-(ACh binding s i te )  an tibodies)
-  the antibodies detected may not n ecessa rily  be pathogenic in
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the d isease
-  the lev e ls  of c irc u la tin g  antibodies may not r e f le c t  lev e ls  a t  
the neurcmuscular junction
-  an tibodies c irc u la tin g  as immune complexes escape detection
-  the h a l f - l i f e  of IgG varies between subclasses
Comparisons of re su lts  obtained are  fu rth e r  complicated by 
the d if fe re n t sources of antigen used in the assay. M odifications to  
the assay include the use of denervated r a t  muscle AChR as antigen 
(Mittag e t  a l . ,  1978; 1981; 1984), the advantage of denervation 
being th a t a f te r  8 - 1 0  days a 10 -  50 fo ld  increase in the amount 
of AChR is  found re su ltin g  from the development of ex tra  junctional 
AChRs over the surface of the muscle membrane (Dolly, 1979; see a lso  
"In troduction" p. lo  ) . Although sera from many MG p a tien ts  rea c t 
with r a t  AChR, the antibody t i t r e s  obtained a re  lower and the 
percentage of negative re s u lts  increases when th is  antigen is  used 
(Savage-Marengo e t  a l . ,  1979). I t  i s  now generally  accepted th a t 
human muscle AChR is  the preferred  antigen fo r use in the RIA, 
although th is  presents a problen in  obtaining a regular and 
co n sis ten t source, and there  i s  some controversy in  the l i te r a tu r e  
concerning the nature of human muscle used fo r such s tu d ies . Further 
thought i s  given to  th is  problem in the "Discussion" sec tion . 
Although the use of r a t  antigens i s  not recommended fo r use in the 
RIA, the re su lts  obtained from such experiments may be usefu l fo r 
giving information about an tigen ic  s i te s  v^ich m y  be conserved and 
therefo re  represent functionally  important domains on the AChR.
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Thymic involvenent in MG
The high incidence of thymcma, thymic hyperplasia (Castleman, 
1966) and germinal cen tres in MG has drawn a tte n tio n  to  the ro le  of 
the thymus in MG, and i t  has been suggested th a t the thymus may be 
the source of the autoiirmune response (L indstran, 1979). I t  i s  now 
well e stab lished  th a t the thymus i s  responsible fo r the developnent 
of immunocompetent T c e l ls ,  vhich are  involved in  both regulatory  
and e ffe c to r  functions. Ncai-specific and antigen sp e c if ic  T c e l l  
mediated help and suppression of Ig synthesis in hunan peripheral 
blood lymphocytes has been reported; and i t  considered th a t th is  
regulation  i s  important in  normal immune mechanisms. Breakdown of 
regulation  m y play a ro le  in the aetio logy of immune d iso rders , 
e spec ia lly  those of an autoimmune natu re . The production of 
autoantibodies in MG suggests th a t the normal immunoregulatory 
mechanisms m y be a lte re d  in seme vay. Thymectomy i s  one of the 
e ffe c tiv e  therap ies in the management of myasthenia (although i t s  
value i s  con tinually  debated (McQuillen & Leone, 1977; Vincent & 
Nesvscm-Davis, 1982a)), and m y  (Lefvert e t  a l . ,  1978; Scadding e t  
a l . ,  1977) o r m y  not (Roses e t  a l . ,  1981; Olanow & Roses, 1981a; 
Olanow e t  a l . ,  1982) be accompanied by a decrease in  the leve l of 
c irc u la tin g  serum anti-(AChR) an tibod ies. Although i t  has been 
suggested (Olanow & Roses, 1981b) th a t a 'thymic f a c to r ' i s  c r i t i c a l  
to  the development of c l in ic a l  weakness in MG, the ro le  of the 
thymus in the pathogenesis of the d isease  i s  not understood. The 
thymus is  known to  be a s i t e  of AChR antigen in ra ts  (Lindstram e t  
a l . ,  1976b) and humans (Henry, 1972); thymic e p ith e l ia l  c e l ls  bear 
AChR (Engel e t  a l . ,  1977b); so too do thymic lymphocytes (Fuchs e t  
a l . ,  1980). Furthermore myoid c e l ls  in t is su e  cu ltu re  from r a t  and 
human thymus a lso  express AChR (Kao & Drachman, 1977a). There i s
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evidence th a t the thymus i s  a s i t e  of antibody production (Mittag e t  
a l . ,  1976). Germinal centres contain c e l ls  exh ib iting  B c e l l  markers 
(Abdou e t  a l . ,  1974; Staber e t  a l . ,  1975); thymic c e l ls  from MG 
p a tien ts  can spontaneously synthesis anti-(AChR) antibody in  cu ltu re  
(Vincent e t  a l . ,  1978b; Navsom-Davis e t  a l . ,  1981a,b) and can 
enhance anti-(AChR) antibody production by autologous peripheral 
blood lymphocytes (Newson-Davis e t  a l . ,  1981a,b; Willcox e t  a l . ,  
1984). However, the ra te s  of anti-(AChR) antibody synthesis in 
cu ltu re  do not suggest th a t  the thymus i s  a major s i t e  of antibody 
production.
Cell-mediated immunity
While i t  i s  well estab lished  th a t the humoral immune system, 
via  anti-(AChR) an tibod ies, plays a cen tra l ro le  in the pathogenesis 
of MG (Vincent, 1980), the re la tiv e  ro le  of the c e llu la r  immune 
response i s  much le s s  c le a rly  defined. Peripheral blood lymphocytes 
from MG p a tien ts  can be stim ulated to  undergo b la s t  transform ation 
in the presence of muscle AChR frcm e le c tr ic  e e l (Abramsky e t  a l . ,  
1975; Richman e t  a l . ,  1976), e le c tr ic  ray (Conti-Tronconi e t  a l . ,  
1977; Hohlfeld e t  a l . ,  1984) and fo e ta l c a lf  (S in igag lia  e t  a l . ,  
1984); but the corresponding experiments using human AChR have not 
been convincing (McQuillen e t  a l . ,  1983), possib ly  because of the 
d if f ic u l ty  in obtaining su f f ic ie n t  quantity  of AChR. Stim ulation of 
lymphocytes in response to  a sp ec ific  antigen ind ica tes th a t  the 
c e l ls  have been previously sen sitized  to  th a t  an tigen . Lymphocytic 
se n s itiz a tio n  to  AChR in  v i tro  could ind ica te  two d if fe re n t 
functions th a t might be ca rried  out in  p a tien ts  by sp e c if ic a lly  
primed T c e l l s : -  ( i)  regu lation  of synthesis of anti-(AChR) 
an tibodies ( i i )  d ire c t  ac tion  of sp e c if ic  cy to toxic  lymphocytes in
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the d estruc tion  of the neuronuscular junction . A ltered regulation  of 
immunosuppressive function is  associated  w ith a lte re d  suppressor 
c e l l  a c t iv i ty  in  various diseases and espec ia lly  in  autoimmune and 
immunodeficient s ta te s  (Waldeman e t  a l . ,  1976; Abdou e t  a l . ,  1976), 
and a decrease in  suppressor a c tiv i ty  has been suggested in M3 
(Kelley e t  a l . ,  1981; Mishak & Dau, 1981). However, as with humoral 
immunity, there  has been found no co rre la tio n  between cell^ned iated  
e ffe c ts  and the c l in ic a l  s ta tu s  of MG p a tie n ts .
Origin of the autoimmune response in  M3
While the pathogenesis of MG is  well documented and becoming 
increasingly  understood, the reasons fo r i t s  in i t ia t io n  a re  s t i l l  
specu la tive . In MG, as in  o ther autoimune d iso rd e rs , the immune 
system responds to  s e lf  components in an inappropriate  way. This may 
re s u lt  frcm
1. An a lte ra t io n  in the antigen causing i t  to  be perceived as
' n o n -se lf ' eg. shedding of receptor from the muscle surface; 
v i r a l  in fec tion  causing m odification of surface p ro te in ; 
exposure of normally sequestered antigens
2. Defective con tro l of the immune system, allowing i t  to  respond 
to  normal antigen eg. fa i lu re  to  elim inate an tig en -sen sitiv e  
c e l ls  during development, monoclonal p ro life ra tio n  of 
an tig en -sen sitiv e  c e l ls  or non-specific stim ulation  of the 
immune system by v ir a l  or m icrobial in fec tio n  leading to  
imbalance of con tro l mechanisms.
3. A combination of 1 and 2.
4. The presence of an ti-iod io type  an tibodies ag a in st a n t i -v ir a l  
an tibodies vhich have the inciden ta l p roperties of being 
antibodies to  host s tru c tu re s .
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Ccmpston e t  a l .  (1980) have d istinguished  th ree  d is t in c t  
groups of MG p a tie n ts , based on thymic pathology and age of onset 
Group A -  thymoma
Group B -  non-thymoma; age of onset le s s  than 40 years 
Group C -  non-thymoma; age of onset g rea te r than 40 years 
Between these groups there  were highly s ig n if ic a n t 
d ifferences in mean anti-(ACZhR) antibody lev e ls  -  the h ighest leve l 
being in Group A and the lowest in  Group C. HIA-Al, B8 and/or DRw3 
h is tocom patib ility  antigens were strongly  associated  with Group B; 
A3, B7 and/or DRw2 with Group C, but none in p a rtic u la r  with Group 
A. Other d ifferences between the th ree  groups were v is ib le  in  the 
sex incidence; in  the proportions with a n t i - (s t r ia te d  muscle) 
antibody and o ther autoantibodies ; in  the incidence of o ther 
autoimmune d iso rders and in  th e ir  response to  thymectomy and 
immunosuppressive drugs. One fu rth er sub-group may comprise those 
p a tien ts  with r e s tr ic te d  ocular d isease -  a la rg e  proportion of th is  
group do not have de tec tab le  anti-(AChR) antibody and the r a t io  of 
a n ti- (o c u la r  AChR) antibody to  an ti-(lim b  AChR) antibody i s  higher 
than in  those with generalized MG (Vincent & Navsom-Davis, 1979). 
This d isease  heterogeneity  implies d iverse  o rig in s  fo r the d isease , 
which may re s u l t  from a genetic  p re-d isposition  to  an a lte re d  
autoimmune response.
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AIMS OF THE PROJECT
In view of the lim ited  co rre la tio n  observed between 
anti-(AChR) antibody t i t r e  and disease sev erity  in  MS p a tien ts  
(Lindstrcm e t  a l . ,  1976), and the re s u lts  of prelim inary 
investiga tions in the laboratory  vdiich had revealed a p a tie n t-  
sp e c if ic  antibody p a tte rn  in a group of MG p a tie n ts , the nature of 
the heterogeneity  of anti-(AChR) antibodies in the  sera  of 
p a tien ts  m s  investigated  with the aim of e luc ida ting  possib le  
co rre la tio n s  between lev e ls  of sp ec ific  antibody sub-populations in 
the d isease , both in indiv idual p a tien ts  and between p a tie n ts . I f  
such co rre la tio n s  a re  p resent they may help c la r ify  the ro le  of 
humoral an tibodies in MG.
The ro le  of anti-(ACh binding s i te )  an tibodies in the d isease  
remains unclear (Vincent, 1980), the antibody-induced re lease  of 
bound [ ̂ ^^I ]o(-BGT frcm [^^^I]ot-BGT lab e lled  AChR complexes was 
theisfore examined. This m y  help to  id en tify  a pa tho log ically  
re levan t antibody sub-population in MG se ra .
F in a lly , s tud ies were m de to  compare the in te rac tio n  of 
o(.-BGT and anti-(AChR) antibodies with fo e ta l and ad u lt AChR, as 
d if f e r e n t ia l  reactions between the two receptor types m y  help 




125C arrie r-free  Na[ I]  in d ilu te  NaOH (100 mCi/ml) was frcm Amer sham
In te rn a tio n a l (Amersham, Bucks, U.K.) and was sto red  a t  ambient
temperature fo r not longer than th ree  weeks a f te r  i t s  a c t iv i ty
reference date .
125[ I]oc-BGT in 0.05 M phosphate buffer containing BSA (5 mg/ml) a t  
sp e c if ic  a c t iv i ty  g rea ter than 200 Ci/mmol was frcm Amer sham 
In te rn a tio n a l (Amersham, Bucks, U.K.), or m s  prepared in our 
laboratory  (see "Methods" section  1 .1 ) , and m s  sto red  a t  ambient 
temperature fo r not longer than th ree  weeks a f te r  i t s  a c t iv i ty  
reference d a te .
N- [ propionyl-^H ] -propionylated- oC-BGT ( [ ̂  ] ©< -BGT ) in aqueous 
so lu tion  containing 0.02% (w/v) BSA a t  40 -  70 Ci/mmol m s  frcm 
Amersham In te rn a tio n a l (Amersham, Bucks, U.K.) and m s  sto red  a t  
-20°C.
Ligands
oC-BGT from Bungarus m ulticinctus m s  purchased frcm Boehringer 
Corps., Mannheim, W. (Germany, or frcm Sigma Chanical Co.,
Kingston-upon-Ihames, U.K., as a lyoph ilised  powder.
Naja naja siamensis vencm m s  obtained frcm the Miami Serpentarium, 
F lo rida, U.S.A.
Benzoquinonium chloride m s  a generous g i f t  frcm S tir l in g  Winthrop 
In c ., Rensselaer, N.Y., U.S.A.
FITC-c(-BGT m s  frcm Sigma Chanical Co., Kingston-upon Thames, U.K.
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Sources of AChR
Human ad u lt muscle was supplied by the Royal United H ospital, Bath; 
S t. Martins H ospital, Bath and the B ris to l Royal Infirm ary, and was 
obtained frcm lower limb amputations re su ltin g  frcm severe vascular 
d iso rders or frcm road t r a f f i c  acciden ts. Within f if te e n  minutes of 
anputation, c a lf  muscle was crudely d issec ted  free  frcm f a t ,  tendon 
and sk in , transported  in ic e , so lid  carbon dioxide or liq u id  
nitrogen and stored  a t  -80°C fo r up to  s ix  months.
Human foetuses (fo e ta l age 9 - 2 2  weeks) were supplied by the Royal 
United H ospital, Bath; the B ris to l Royal Infirm ary; the  General 
H ospital, B ris to l and the B ris to l Public Health Laboratory, and were 
obtained by suction on a vacuum lin e  or frcm prostaglandin-induced 
term inations. Foetuses were frozen as soon as possib le . Limb, back 
and in te rc o s ta l muscles were d issec ted  p rio r to  use.
Torpedo marmorata e lectrop lax  were purchased from I n s t i tu t  de 
Biologie Marine, Arcachon, France and sto red  a t  -80°C.
Three-month old female W istar r a ts  were used as a source of muscle 
fo r both junctional and ex tra -ju n c tio n a l receptor preparations (see 
"Methods" section  4 .2 ).
Immunoreagents
Sera frcm normal volunteers were obtained frcm colleagues in the 
department. Myasthenic serum samples were obtained frcm several 
h osp ita ls  in  the U.K. as samples received fo r the rou tine  assay of 
anti-(AChR) an tibod ies. Sera were frozen and sto red  a t  -20°C.
Goat anti-(human IgG) antiserum  was prepared by repeated 
intram uscular in jec tions of p u rified  human IgG in to  goat, as
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described in the "Methods" section  (6).
A lkaline phosphatase conjugated to  anti-(human IgG) antibodies 
( rab b it, lyoph ilised) was obtained frcm Sigma Chemical Co.,
Kingston-upon-Ihames, U.K.
Rabbit anti-(K-BGT) antiserum vas a generous g i f t  frcm Jean Whyte. 
Normal sheep serum vas a generous g i f t  frcm Ahmed Jeh an li, to  whcm I 
am a lso  g ra te fu l fo r helpfu l discussion concerning the methodology 
of the immunohistochanical s tu d ies .
Sheep a n ti- ( ra b b it  IgG) an tibod ies, and Horseradish Peroxidase 
anti-Iteroxidase (PAP) ccmplex (rabb it) were frcm Miles Labs., Stoke 
Poges, Slough, England.
Freunds complete and inccmplete adjuvants were frcm Miles L abs., 
Stoke Poges, Slough, England.
Chemicals
Standard Laboratory Reagents were frcm Sigma Chemical Co., 
Kingston-upon-Ihames, U.K. or B.D.H. Chemicals, Poole, Dorset, U.K. 
Gel f i l t r a t io n  reagents were supplied by Pharmacia L td ., Hounslow, 
U.K.
Ion-exchange re s in s , DEAE-cellulose f i l t e r  d iscs and GFC g lass f ib re  
f i l t e r  d iscs were frcm Whatman Lab. Sales L td ., Maidstone, Kent,
U.K.
Soluene-350 tis su e  so lu b iliz e r  was frcm Packard, Reading, Berks. 
Tissue Tek embedding medium fo r frozen tis su e  sections vas obtained 




125[ I]  was counted in an LKB 1280 Ultrogairma counter.
Tritium  was counted in a tr it iu m -sp e c if ic  channel in  a Packard 
Tri-Carb S c in ti l la t io n  counter (model 3255) fo r a two-minute 
counting period. Correction fo r quenching was made using the 
channels r a t io  method.
45
METHODS
1. lod ination  and charac te riza tion  of oC-BGT.
1 oc;
1.1 Preparation of [ I ] - la b e lle d  o(-bGT
125o(.-BGT was labelled with [ I] by the chloramine-T method
(Hunter, 1967) as modified by Urbaniak et al. (1973). Carrier-free 
1 25Na[ I ] (100 mCi/ml) in d ilu te  sodium hydroxide (10 p i) was added to
c(rBGT (10 pg) in 0.05 M potassium phosj^ate bu ffer, pH7.5 (20 p i ) ,
followed by 0.5% (w/v) chloramine-T in 0.05 M potassium jhosphate
b u ffer, gH7.5 (10 p i) .  The mixture was s t i r r e d  a t  roan temperature
fo r 1 min a t  23°C, a f te r  vhich the reaction  was term inated by the
addition  of 0.016% (w/v) sodium m etabisulphite in  0.05 M potassium
(iiosphate bu ffer, pH7.5 (750 p i ) ,  followed by 1% (w/v) c a r r ie r
potassium iodide in 0.05 M potassium phosphate bu ffer, pH7.5 (200
125p i ) .  The lab e lled  p ro tein  was separated frcm unreacted [ I]  by 
passage through a column of Sephadex G-25 (25 x 1 cm) previously 
eq u ilib ra ted  in 10 mM potassium jhosphate b u ffer, pH7.5, containing 
1% (w/v) BSA. F ractions (1 ml) were co llec ted  and a liquo ts (5 pi) 
frcm these frac tio n s  were counted for ra d io a c tiv ity . The peak
frac tio n s  containing [^^^I]eC-BGT were pooled and sto red  a t  4°C fo r
125not longer than 3 weeks. The sp e c ific  ra d io a c tiv ity  of the [ I]  
ô BGT was calcu lated  assuming 100% recovery of p ro te in . The 
b io log ica l a c t iv i ty  of the toxin and the amount of iodinated pro tein  
p rec ip ita te d  by tr ic h lo ro a c e tic  acid were a lso  determined, as 
described below.
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1 251.2 Fractionation of [ I]-labelled oc-BGT species
The mono- and d i-iod ina ted  o(-BGT species were separated by 
ion-exchange chromatography by using a method adapted from those of 
Vogel e t  a l .  (1972) and James e t  a l .  (1980). oCrBGT was iodinated in 
the usual way (see "Methods" section  1 .1 ) , except th a t chloramine-T, 
sodium m etabisulphite and potassium iodide were made up in 3.3 mM 
potassium j^osphate bu ffer, pH7.5. The iod ination  products were 
d ilu te d  2-fo ld  in  e lu tio n  buffer (3.3 mM potassium jiiosphate bu ffer, 
pH7.5 containing 0.1% (w/v) BSA and 0.01% (w/v) sodium az id e), and 
applied to  a column (1 ml) of CM-Sephadex C-50 vhich had been 
pre-equi l ib ra  ted  in e lu tio n  bu ffer. The column was washed 
extensively  with e lu tio n  buffer alone, then with e lu tio n  buffer 
containing 10 irM sodium chloride and f in a lly  w ith e lu tio n  buffer 
containing 100 mM sodium ch lo ride . The flow ra te  throughout was 15 
ml/h and frac tio n s  of 1 ml were co llec ted . Samples (5 pi) from each 
frac tio n  were taken and counted fo r ra d io a c tiv ity . The iodinated 
toxins of the 2 peaks were pooled separately  and sto red  a t  4°C.
1.3 Determination of the concentration of iodinated otrBGT species by 
d ilu tio n  assay
The concentrations of iodinated oc-BGT species obtained from 
125frac tio n a tio n  of [ I]o(-BGT on CM-Sej^adex C-50 (see "Methods" 
section  1.2) were determined by a d ilu tio n  assay sim ila r to  th a t 
described by James e t  a l .  (1980). A constant volume (5 p i) of each 
iodinated oC-BGT species was d ilu ted  with various known 
concentrations of oir-BGV (0, 4, 8, 12 pmol per t e s t  sample, d ilu te d  
from 0.125 pM sto ck ), and the binding to  so lu b ilized  Torpedo AChR 
(0.1, 0 .2 , 0 .3 , 0.4 pmol per t e s t  sample, d ilu ted  from 25 mM stock) 
was measured. The to ta l  oC-BGT concentration was always a t  le a s t
47
10-fold in  excess of the receptor concentration, and the to ta l  
volume of each sample was 150 p i, a l l  d ilu tio n s  being made in toxin 
binding assay buffer (see "Methods" section  7 .2 ) . A fter incubation 
fo r 90 min a t  23°C (or overnight a t  4°C), each sample was applied  to  
2 DEAE-81 ce llu lo se  f i l t e r  d iscs (diamter 24 nm; pre-moistened w ith 
toxin binding assay b u ffe r) , l e f t  to  stand fo r 2 min, followed by 
vacuum f i l t r a t i o n  in  a M illipore f i l t e r  u n it. The f i l t e r s  were 
washed (3 x 1 ml) with toxin  binding assay buffer and counted fo r 
ra d io a c tiv ity . Non-specific binding was measured as described fo r 
the toxin  binding assay (see "Methods" section  7 .2 ).
1.4 Determination of the b io log ica l a c t iv i ty  of rad io labe lled  «C-BGT 
species.
The b io log ica l a c t iv i t ie s  of rad io labe lled  oC-BGT species were 
determined by 2 d if fe re n t methods, each involving the measurement of 
the proportion of rad io labe lled  *<.-BGT th a t can be bound by a la rge  
molar excess of p u rif ied  AChR frcm Torpedo marmorata. Duplicate 
samples of Torpedo AChR (20 pmol, 100 pi) were incubated with the 
te s t  rad io labe lled  «(-BGT species (0.2 pmol, 50 p i) fo r 90 min a t  23°C 
in the presence and absence of LmM benzoquinonium ch lo ride . The 
f i r s t  assay method involves separation of bound and free  species by 
ion-exchange chromatography in a DEAE c e llu lo se  f i l t r a t io n  assay, as 
described in the "Methods" section  7 .2 . The second method fo r 
separation of bound and free  species was by gel f i l t r a t i o n  on 
Sephadex G-50. Torpedo AChR was incubated w ith the rad io labe lled  
ô BGT species as described above, a f te r  which each sample was then 
applied to  a column (25 x 1 cm) of Sephadex G-50 p re-eq u ilib ra ted  in 
toxin binding assay buffer (see "Methods" section  7 .2 . Fractions (1 
ml) were co llec ted  and counted fo r ra d io a c tiv ity . When using [^H]
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û(-BGT, the methods of assay were as described above, except th a t 
DEAE-81 f i l t e r  d iscs were d ried , then added to  s c in t i l la n t  (10ml) 
which contained 10% (v/v) Soluene-350, 0.45% (w/v) PPO, 27% (v/v) 
Triton X-100 and 63% (v/v) toluene. Aqueous samples were counted in
0.5% (w/v) PPO, 30% (v/v) T riton X-100 and 70% (v/v) toluene. The 
b io log ical a c t iv i t ie s  of the rad io labe lled  c(-BGT species were 
expressed as a percentage of the to ta l  counts added.
1.5 Determination of the rad io labe lled  pro tein  by p re c ip ita tio n  with 
tr ic h lo ro a c e tic  ac id .
The rad io labe lled  o(-BC?r species were d ilu te d  1 in  100 with 10 
mM potassium phosphate bu ffer, pH7.4, containing 1% (w/v) BSA. 
T rip lica te  samples of the d ilu ted  toxin (100 pi) were placed on ice  
and 12% (w/v) cold tr ic h lo ro a c e tic  acid (100 pi) added. A fter 30 min, 
the p re c ip ita te s  were co llec ted  by vacuum f i l t r a t i o n  on a Whatman 
GFC glass f ib re  f i l t e r  d isc s , washed with 6% (w/v) cold 
tr ic h lo ro a c e tic  acid  (5 ml) and counted fo r ra d io a c tiv ity . Discs 
containing [̂ HleC-BCTT were trea te d  as described in the previous 
section . Acid p rec ip itab le  counts were expressed as a percentage of 
the to ta l  counts added.
2. P u rifica tio n  of the oc-toxin from vencm of Naja naja  siam ensis.
oC-Toxin was p u rif ied  frcm the crude vencm of Naja naja 
siamensis by m odification of the method of Cooper and Reich (1972). 
Crude vencm (1 g) was dissolved in d i s t i l l e d  water (10 ml) and 
loaded onto a phosj^ocellulose column (30 x 2.5 cm) pre-equi l ib ra te d  
in 10 mM potassium f±iosphate buffer, pH6.0. The column was washed 
with the same buffer (300 m l), to  remove non-bound m ate ria l, u n t i l  
the o p tica l density  a t  280 nm returned to  base le v e l. The p ro te ins
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were then e lu ted  frcm the column with a l in e a r  g rad ien t frcm 10 rtM
potassium ghosghate b u ffer, pH6.0 (600 ml) to  500 mM potassium
phosjiiate bu ffer, jH6.0 (600 ml) a t  a ra te  of 70 m l/h. F ractions (14
ml) were co llec ted  and the o p tic a l density  a t  280 nm measured. Solid
ammonium sulphate was slowly added to  the major peaks to  give
sa tu ra ted  so lu tio n s , which were then s t i r r e d  fo r 16 h a t  4°C. The
p re c ip ita te s  were co llec ted  by cen trifuga tion  (30,000 g, 10 min,
4°C), d issolved in  d i s t i l l e d  water and d ialysed  fo r 16 h a t  4°C
ag ain st d i s t i l l e d  water (3 x 4 L ). The non-dialysable m ateria l was
lyophilized  and sto red  a t  4°C. The pro tein  content of each peak was
determined by the method of Lowry e t  a l .  (1951). The a c t iv i ty  of the
125oC-toxin in each peak was assayed by competition w ith [ I]o(-BGT 
fo r binding to  AChR as follows : -  P u rified  Torpedo AChR (100 p i, 0.3 
pmol) in toxin binding assay buffer was pre-incubated fo r 30 min a t  
23°C with the t e s t  sample (20 p i ) .  [^^^I]o(-BGT (50 p i ,  0.3 pmol) in 
toxin  binding assay buffer was added and the mixture incubated fo r a 
fu rth e r 60 min a t  23°C. The amount of [̂ ^ Î]o<c-BGT bound was 
determined by the DEAE-cellulose f i l t r a t io n  assay (see "Methods" 
section  7 .2 ) . The samples assayed fo r <><:-toxin a c t iv i ty  were s e r ia l ly  
d ilu te d  u n ti l  le s s  than 50% in h ib itio n  of [^^^Ilod-BGT binding was 
observed.
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3. Preparation of the «(-toxin affinity resin.
The oC-toxin p u rif ie d  from Naja naja siamensis crude vencm was 
coupled to  ac tiv a ted  Sepharose 4B (March e t  a l .  1974) following the 
method of Lindstrcm e t  a l .  (1981). Sepharose 4B (50 ml packed beads) 
was washed with 0.1 M sodium chloride ( I D ,  followed by d i s t i l l e d  
water (500 m l). The beads were re-suspended in  cold d i s t i l l e d  water 
(100 ml) and 2 M sodium carbonate (100 ml) added and s t i r r e d  over 
ice-w ater to  4°C. Cyanogen brcmide (2.5 g) dissolved in a c e to n itr i le  
(2.2 ml) was added to  the Sejharose 4B so lu tion  and s t i r r e d  fo r 2 
minutes a t  4°C. The mixture was rap id ly  f i l te r e d  and washed with 
ice-co ld  d i s t i l l e d  water (500 m l). Purified  o(-toxin (25 mg) was 
dissolved in 0.2 M sodium hydrogen carbonate, gH9.4 (100 m l), and 
the o p tica l density  a t  280 nm was measured. The Sepharose beads were 
then added to  the «-toxin so lu tion  vhich was then s t i r r e d  overnight 
a t  4°C. The a f f in i ty  beads were co llec ted  by f i l t r a t io n  and the 
e luan t re ta ined  fo r o p tic a l density  measurement a t  280 nm. The beads 
were then washed with d i s t i l l e d  water (400 ml) resuspended in 2 M 
glycine, gH9.0 (200 ml) and s t i r r e d  overnight a t  4°C to  block 
unreacted groups. The a f f in i ty  beads were again f i l te r e d  and washed, 
sequen tia lly , with 0.1 M ace ta te  bu ffer, pH4.0, containing 1 M 
sodium chloride (150 ml) and 0.1 M borate b u ffer, pH8.0 containing 1 
M sodium chloride ( 150 ml ) . This washing process was repeated 3 
tim es, a f te r  vhich the beads were eq u ilib ra ted  in 10 mM potassium 
phosphate bu ffer, 017.4, containing 0.1% (v/v) T riton  X-100, and 
stored  a t  4°C in the presence of 0.02% (w/v) sodium azide. A fter 
use, the a f f in i ty  column was washed with 10 nM potassium fhosphate 
bu ffer, 0 Î7 .4 , containing 1 M sodium chloride (300 ml) followed by 
10 mM potassium phosphate bu ffer, pH7.4 (500 m l).
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4. Purification of AChR
4.1 Human ad u lt o r fo e ta l AChR
AChR frcm human adu lt or fo e ta l sk e le ta l muscle was p u rified  
e s se n tia lly  by the method of Stephenson e t  a l .  (1981). A ll 
manipulations were performed a t  4°C, and the buffers were fresh ly  
prepared in double d i s t i l l e d  w ater. Muscle (300 g) was coarsely 
chopped and homogenized in a Waring blender a t  maximum speed fo r 1 
min in 4 volumes of buffer 'A' comprising 0.02 M potassium phosphate 
b u ffer, pH7.4, 1 mM EDTA, 0.1 irM FMSF, 0.1 irM benzethonium ch lo ride , 
2 mM benzamidine hydrochloride, bac itrac in  (500 pg/ml) and 0.01% 
(w/v) sodium azide. The hcmogenate vas centrifuged (20,000 g, 60 
min, 4°C) and the re su ltin g  supernatant was decanted and discarded. 
The p e lle t  was re-suspended and homogenized as before in 1 volume of 
buffer 'A' containing ad d itio n a lly  2.5% (v/v) T riton X-100 
(ex traction  b u ffe r) , s t i r r e d  fo r 3 h a t  23°C, and centrifuged 
(100,000 g, 60 min, 4°C). The re su ltin g  supernatant was f i l te r e d  
through g lass wool. Varying amounts of th is  'c rude ' muscle e x tra c t 
were re ta ined  fo r use in la te r  assays. The remainder was s t i r r e d  fo r 
4 h a t  23°C with Sepharose 4B (25 ml) coupled to  Naja naja siamensis 
oC-toxin. The Sepharose beads were then washed th ree  times 
a lte rn a te ly  on a sc in te red  g lass funnel with buffer 'B' (3 x 250 ml) 
containing 0.5 M sodium chloride and buffer 'B' alone (3 x 250 ml); 
where buffer 'B' ccmprised 10 mM potassium phosphate b u ffer, pH7.4, 
containing 1 mM EDTA, 0.1 mM benzethonium ch lo ride , 0.1 mM FMSF,
0.02% (w/v) sodium azide and 0.1% (v/v) T riton X-100. The receptor 
p ro tein  was e lu ted  frcm the Sepharose beads by s t i r r in g  with 0.5 M 
carbachol in buffer 'B' (50 ml) fo r 16 h a t  4°C, followed hy washing 
with buffer 'B' alone (50 m l). The e lu a te  v^s dialyzed against
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buffer 'B' (5 L) fo r 3 h a t  4°C, and residual carbachol was removed
by passage through a column (5 x 1 cm) of DEAE-cellulose,
pre-equi lib ra te d  in buffer 'B '. The column was washed, a t  4°C, with
buffer 'B' (2 L) and the receptor pro tein  e lu ted  with 0.5 M sodium
chloride in buffer 'B' (20 m l). 20 x 1 ml frac tio n s  were co llec ted ,
125and a liquo ts  of these frac tio n s assayed fo r [ I]&-BGT binding 
a c t iv i ty  (see "Methods" section  7 .2 ). The peak frac tio n s  containing 
the receptor pro tein  were pooled, dialyzed aga in st buffer 'B' and 
sto red  a t  4°C.
4.2 Junctional and ex tra -ju n c tio n a l r a t  AChR.
Diaphragms frcm 3-month old female W istar r a ts  were 
u n ila te ra lly  denervated under d ie thy l e ther anaesthesia  by section  
of the l e f t  phrenic nerve w ithin the p leura l cav ity . A fter 18 days 
the r a ts  were k ille d  by cerv ica l d isloca tion  and th e ir  diaphragms 
ronoved. The diaphragms were d issec ted  in to  denervated and 
innervated halves. The denervated honi-diaphragms were fin e ly  
chopp)ed and hcmogenized in 4 volumes of hcmogenization buffer (vhich 
ccmprised 0.02 M potassium phosphate bu ffer, pH7.4, 1 mM EDTA, 0.1 
mM FMSF and 0.01% (w/v) sodium azide) in a Sorvall Qmnimix fo r 1 min 
a t  f u l l  speed. The hcmogenate was centrifuged (20,000 g, 45 min,
4°C) and the re su ltin g  supernatant decanted and discarded. The 
p e lle t  was re-hcmogenized as before in 1 volume of homogenization 
buffer containing ad d itio n a lly  2.5% (v/v) T riton X-100 (ex traction  
b u ffe r) , s t i r r e d  for 2 h a t  23°C and centrifuged (100,000 g, 60 min, 
4°C ). The re su ltin g  supernatant gave a ' crude ' detergen t e x tra c t of 
ex tra -ju n c tio n a l AChR. The end-plate regions frcm innervated r a t  
diaphragms were d issec ted  out and trea te d  as above, giving a 'crude ' 
e x tra c t of junctional AChR.
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4.3 Torpedo marmorata AChR
AChR was p u rified  frcm Torpedo marmorata as described by 
Wonnacott e t  a l .  (1980).
5. P u rifica tio n  of human immunoglobulin G (IgG)
IgG vas prepared frcm normal and myasthenic sera  by the 
method of Stevenson and Dorrington (1970). A so lu tion  of sa tu ra ted  
ammonium sulphate (6 ml, sa tu rated  in 0.2 M TRIS-HCl, pH8.0) vas 
added dropwise to  normal or iryasthenic serum (10 ml) with s t i r r in g  
a t  4°C. The so lu tion  was s t i r r e d  fo r a fu rth e r 30 min a t  4°C and the 
p re c ip ita te  sedimented by cen trifuga tion  (500 g, 15 min). The 
p re c ip ita te  was dissolved in 0.03 M potassium phosphate bu ffer,
0Î7.3 (10 ml) and d ialysed  overnight a t  4°C ag a in st the same buffer 
( I D .  The non-dialysable m aterial was applied to  a column (13.2 x 
2.9 cm) of DE-52 ce llu lo se  p re-equ ilib ra ted  with 0.03 M potassium 
phosphate b u ffer, pH7.3. The column was e lu ted  with the same buffer 
and the absorbance a t  280nm of the e luan t containing IgG was 
monitored. P u rified  IgGs so obtained were sto red  a t  -20°C in the 
presence of 0.02% (w/v) sodium azide.
6. Preparation of goat anti-(human IgG) antiserum.
Normal human IgG (3.0 ml, 1.5 mg/ml) was em ulsified with 
Freund's ccmplete adjuvant (3.0 ml) and in jec ted  in tra-m uscularly  a t  
one s i t e  in each hind leg  of a goat. Repeated in jec tio n s  of IgG in 
Freund's inccmplete adjuvant were performed a t  3 ^ eek ly  in te rv a ls . A 
blood sample (10 ml) was taken from the goat before each in je c tio n  
to  allow the determ ination of anti-(human IgG) an tibod ies. When an 
adequate t i t r e  was reached, the goat was bled ou t. The blood was 
allowed to  c lo t  a t  4°C overnight, and then cen trifuged (5000 g, 20
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min, 4°C). The serum was co llec ted  and sto red  a t  -20°C in the
presence of sodium azide. An adequate goat anti-(human IgG) antibody
t i t r e  was one vhere le ss  than 100 \xl of antiserum  was needed to
e ffe c t  to ta l  p rec ip ita tio n  of [ I  ]K-BGT-labelled-AChR-antibody
ccmplex obtained by incubation of a fixed volume (5 pi) of myasthenic
125serum with a constant amount of [ I]«.-BGT lab e lled  ad u lt human
AChR in  the presence and absence of benzoquinonium ch lo ride . The 
d e ta ils  of the assay method are  given in "Methods" section  8.
1257. Measurement of [ I]«-BGT binding
7.1 Ammonium sulphate p rec ip ita tio n  method
AChR in 'crude ' detergen t ex trac ts  of muscle was determined
a method adapted frcm th a t  of Meunier e t  a l .  (1972). T rip lica te
samples of the receptor e x tra c t (100 pi) were incubated with 10 -  15
nM [^^^I]«-BGT in ex trac tion  buffer (50 p i) fo r 45 min a t  23°C before
the addition  of sa tu rated  ammonium sulphate to  give 40% sa tu ra tion
o v e ra ll, and fu rth er incubation fo r 16 h a t  4°C. The re su ltin g
p re c ip ita te s  were co llec ted  on Whatman GFC g lass f ib re  f i l t e r  d isc s ,
washed with 40% satu rated  aumonium sulphate so lu tion  ( 3 x 1  ml) by
vacuum f i l t r a t io n  on a M illipore f i l t e r  u n it, and counted fo r
125ra d io a c tiv ity . S u ffic ien t excess of [ I]«-BGT was ensured by
re p e titio n  of the assay using s e r ia l  2-fold  d ilu tio n s  of the
receptor e x tra c t in ex trac tion  buffer, vÆien a lin e a r  re la tio n sh ip
between d ilu tio n  number and p rec ip ita ted  rad io a c tiv ity  should be
125obtained. Specific  binding of [ IIK-BGT was blocked in p a ra lle l  
incubations performed as above, but containing ad d itio n a lly  1 mM 
benzoquinonium ch lo ride . Subtraction of the counts so obtained gave 
sp e c if ic a lly  bound rad io a c tiv ity  in  the t e s t  sample. One piccmole of
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AChR is defined as the amount of receptor that binds one piccmole of 
125[ I]«-BGT under saturating conditions. This allows the calculation
of the amount of receptor present as:-
AChR cpm(sample) - cpii(blank) pmol sample
 ------------------------------------ X toxin X X 10
(pnol/ml) cpm( total) input dilution
7.2 DEAE-cellulose f i l t r a t io n  method
Purified  AChR was measured using a DEAE-cellulose f i l t r a t io n  
assay sim ila r to  th a t described by Schmidt and R aftery (1973). 
Duplicate s e r ia l  d ilu tio n s  of receptor sample ( f in a l  volume 100 pi) 
in toxin  binding assay buffer (vdiich ccmprised 10 irM potassium 
phos0iate bu ffer, pH7.4, containing 0.1% (w/v) BSA, 1% (v/v) T riton
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X-100 and 0.01% (w/v) sodium azide) were incubated with [ I]«-BGT
(50 p i , 0.2 pnol) fo r 90 min a t  23°C (or overnight a t  4°C). Each
sample was then applied to  2 DEAE-81 ce llu lo se  f i l t e r  d iscs
(diameter 24 nm), pre-moistened with toxin  binding assay bu ffer,
l e f t  to  stand fo r 2 min, followed by vacuum f i l t r a t i o n  in  a
M illipore f i l t e r  u n it. The f i l t e r s  were washed ( 3 x 1  ml) w ith toxin
binding assay buffer and counted fo r ra d io a c tiv ity . Specific  binding
was blocked in p a ra lle l  incubations performed as above, but
containing ad d itio n a lly  1 mM benzoquinonium ch lo ride . Determination
125of sp e c if ic a lly  bound [ I]«-BGT allows the ca lcu la tio n  of pnol 
AChR/ml as described in the previous section .
7.3 Immunoprécipitation method
P urified  AChR and detergen t e x trac ts  of AChR were a lso
determined by an immunoprécipitation method involving the addition
125of a large  molar excess of iryasthenic serum (5 p i) to  [ I]  
o^BGT-labelled AChR (100 p i ) ,  followed by p rec ip ita tio n  with goat
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anti-(human IgG) antiserum . The conditions of incubation and
re levan t contro ls fo r the non-specific p rec ip ita tio n  of
radioactivity are the same as those for the radioimmunoassay
procedure described below. Sera from MG p a tie n ts , v^en used in
125excess, vary in  th e ir  a b i l i ty  to  p re c ip ita te  a l l  ava ilab le  [ I]
«-BGT lab e lled  AChR ccmplex (see "Results" sections 4.2 & 4 .3 ),
therefo re  care must be taken to  use serum frcm a se lec ted  individual
i f  values are  to  be consisten t and ccmparable with those of o ther
methods. The g rea te s t p rec ip ita tio n  of ccmplex was consis ten tly
obtained by serum from one p a rtic u la r  p a tie n t and represented 95 -
100% of th a t p rec ip ita ted  by ammonium sulphate, and i t  was therefo re
th is  serum th a t  was rou tine ly  used. The AChR concentration was
calcu lated  from the sp e c if ic a lly  p rec ip ita te d  rad io a c tiv ity  and
125expressed as pmoles [ I]oC-BGT binding sites/ml of extract.
8. Radioimmunoassay of anti-(AChR) antibodies not d irec ted  a t  the
cC-BGT binding s i t e .
A radioimmunoassay procedure sim ila r to  th a t  previously
described (Lindstrcm a t  e l . , 1976a; C arter e t  a l . , 1981) and used in
the c l in ic a l  assay of sera frcm myasthenic p a tien ts  was used to
examine the binding of anti-(AChR) antibodies to  crude and p u rified
human a d u lt and fo e ta l an tigens. A f in a l concentration of crude or
p u rified  human ad u lt or fo e ta l AChR of g rea te r than 0.5 nM of
sp e c ific  toxin binding s i te s  was lab e lled  by incubation with a
10-fold molar excess of [^^^I]ot-BGT fo r 45 min a t  22°C. The sp ec ific  
125binding of [ I]«-BGT was blocked in p a ra lle l  incubations vhich 
contained ad d itio n a lly  1 irM benzoquinonium ch lo ride . Duplicate 
samples (100 pi) of the re su ltin g  so lu tions were incubated with 
myasthenic serum or IgG (5 p i ) ,  appropria te ly  d ilu te d  with normal
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human serum or IgG, respec tive ly , fo r 2 h a t  22^C (or 16 h a t  4'^C).
The lab e lled  AChR-antibody complex was p rec ip ita te d  by the add ition
of goat anti-(human IgG) antiserum (65 -  100 p i) and incubation fo r
16 h a t  4°C (or 2 h a t  22°C). The re su ltin g  p re c ip ita te s  were
co llec ted  by cen trifuga tion  (3000 g, 10 min, 4°C) and the p e lle ts
washed twice with 10 irM potassium phosphate bu ffer, pH7.4,
containing 0.15 M sodium ch lo ride , 1% (v/v) T riton X-100 and 0.1%
(w/v) sodium azide (radioimmunoassay b u ffe r) , by a lte rn a te
resuspension and cen trifu g a tio n , and counted fo r rad io a c tiv ity .
Subtraction of the counts obtained in the presence of benzoquinonium
chloride from counts obtained in the absence of benzoquinonium
chloride gave sp e c if ic a lly  bound rad io a c tiv ity  in the t e s t  sample,
which can then be re la te d  to  the concentration of «-BGT binding
s i te s  in the AChR e x tra c t, and therefore  the antibody t i t r e  i s
expressed as moles of sp e c ific  «-BGT binding s i te s  p rec ip ita ted  per
125l i t r e  of serum. For each p a tie n t, maximal formation of [ I]  
«-BGT-AChR-antibody complex was ensured by re p e tit io n  of the assay 
using s e r ia l  2-fo ld  d ilu tio n s  of sera or IgG in  order to  obtain a 
l in e a r  re la tio n sh ip  between the volume of undiluted serum or IgG and 
p rec ip ita ted  ra d io a c tiv ity .
9. Radioimmunoassay fo r rab b it anti-(«-BGT) an tibod ies.
Duplicate s e r ia l  2-fo ld  d ilu tio n s  of rab b it anti-(«-BGT)
125a n ti serum (5 p i) in normal rab b it serum were incubated with [ I]
(/(-BGT (0.5 pmol, 50 pi) fo r 2 h a t  23°C. The sp e c if ic  binding of 
125[ I]oC-BGT was blocked in p a ra lle l  incubations which œ ntained  
ad d itio n a lly  a 1000-fold molar excess of unlabelled  «-BGT (25 p i ) .  
Toxin-antibody complexes were p rec ip ita ted  by the add ition  of goat 
a n ti- ( ra b b it  IgG) antiserum (30 pi) and incubation fo r 16 h a t  4°C.
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The re su ltin g  p re c ip ita te s  were co llec ted  by cen trifuga tion  (3000 g,
10 min, 4°C) and the p e lle ts  washed twice with radioimmunoassay
buffer (see "Methods" section 8) by alternate resuspension and
cen trifu g a tio n , and counted fo r ra d io a c tiv ity . Subtraction of counts
obtained in the presence of unlabelled oC-BGT frcm counts obtained in
125the absence of unlabelled û̂-BGT gave sp e c if ic a lly  bound [ I]o6-BGT 
in the t e s t  sample. The antibody t i t r e  was then expressed as moles 
of sp e c ific  «-BGT binding s i te s  p rec ip ita te d  per l i t r e  of serum.
10. P ro te in  measuronents
Protein was determined by the method of Lowry e t  a l .  (1951) 
using BSA as standard. For samples containing T riton X-100, the 
sodium carbonate reagent contained ad d itio n a lly  5% (w/v) sodium 
dodecyl sulphate (Wang & Smith, 1975).
11. Displacement of [^^^I]«-BGT from [^^^IK-BGT lab e lled  AChR
complexes by anti-(AChR) antibodies frcm iryasthenic sera
The time course fo r displacement of [^^^I]«-BGT frcm
oC-BGT lab e lled  AChR complexes by anti-(AChR) an tibodies m s  followed.
AChR (f in a l  concentration 0.25 nM) was incubated in the presence and
absence of a large  molar excess of benzoquinonium chloride ( f in a l
125concentration 2.5 irM) with [ I]ot-BGT (f in a l concentration 0.5 nM)
in ex trac tio n  buffer (see "Jfethods" Section 4.1) fo r 16 h a t  4°C. In
125some cases a 10-fold molar excess of [ I]«-BGT m s  used, in vhich
case incubation m s  fo r 90 min a t  23°C, followed by gel f i l t r a t io n
125on a G-75 Se0iadex column (1.2 x 16 cm) to  remove non-bound [ I]  
«-BGT. The column m s  p re-eq u ilib ra ted  and e lu ted  in ex trac tion  
bu ffer, frac tio n s  (25 x 1 ml) were co llec ted  and a liq u o ts  (50 pi)
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125counted fo r ra d io a c tiv ity . The void volume peak containing [ I] 
ot-BGT lab e lled  AChR was pooled and used as described below.
Duplicate sanples of ]«-BGT-AChR (100 p i) lab e lled  in the
presence and absence of benzoquinonium chloride were incubated with 
b u ffer, unlabelled  o(-BGT, normal human serum o r iryasthenic serum (5 
-  150 p i) fo r various times a t  23°C, a f te r  which the  reaction  m s  
stopped by one of two methods
(i)  ion-exchange f i l t r a t io n  on DfAE-cellulose f i l t e r  d isc s  -  see 
"Methods" section  7.2 .
( i i )  g e l- f i l t r a t io n  on G-75 Sephadex. Samples were applied  to  a 
column (1.2 x 16 cm) of G-75 Sephadex, p re -equ ilib ra ted  in 
ex trac tion  bu ffe r. The column m s  e lu ted  with the same bu ffe r, 
frac tio n s  (0.5 ml) co llec ted  and a liquo ts  (10 p i) counted fo r 
radioac t iv i  t y .
12. Binding p roperties of de te rgen t-so lub ilized  human a d u lt and 
fo e ta l AChRs with [ ^IloC-BGT
125Throughout these experiments unfractionated  [ I]«-BGT m s  
used (see "Methods" section  1 .1 ) , and "crude" detergen t e x tra c ts  of 
ad u lt and fo e ta l muscle AChR (see "Methods" section  4.1)
12.1 Determination of the assoc iation  constant (K ^)  —— on —
The ra te  of assoc ia tion  between de te rgen t-so lub ilized  ad u lt
1 p c
or fo e ta l AChR and [ I]«r-BGT m s  determined frcm the i n i t i a l
125progress curves of the reaction  a t  increasing [ I]«-BGT
concentrations. AChR (0.5 nM, 100 p i) in  toxin  binding assay buffer
125(see "Methods" section  7.2) m s  incubated w ith a range of [ I]  
ô BGT concentrations (2.8 -  16.8 nM, 50 pi) in  the presence and 
absence of unlabelled «-BGT (5 pM, 50 pi) fo r varying times upto 90
60
min a t  23°C. The amount of [^^^I]«-BGT bound was measured by the 
DEAB-cellulose f i l t r a t i o n  assay, as described in  the "Methods" 
section  7 .2 .
12.2 Determination of the d issoc ia tion  constant
125The d isso c ia tio n  of [ I  ]«-BGT-labelled AChR carplexes was
125studied  by allowing the binding of [ I]«-BGT and AChR to  reach
125equilibrium , a f te r  vhich the rebinding of [ I  ]oC-BGT was prevented
125and the amount of [ I]«-BGT-AChR ccmplex determined a t  various
times th e re a f te r . Detergent ex trac ts  of a d u lt o r fo e ta l AChR (0.5
125nM, 100 pi) in toxin binding assay buffer were incubated w ith [ I]
ï/c-BCxT (5 nM, 50 p i) fo r 90 min a t  23°C. A large  molar excess of
unlabelled  «-BGT (5 pM, 10 pi) was then added, and the time course of 
125replacement of [ I]«-BGT ty  unlabelled «-BGT was followed, using 
the DEAE-cellulose f i l t r a t io n  assay (see "Methods" section  7 .2 . 
Samples without the add ition  of cold «-BGT were assayed in p a ra lle l  
to  co rrec t fo r any changes in binding over th is  time period.
12.3 Saturation  experiments
Detergent e x tra c ts  of ad u lt or fo e ta l AChR (0.5 nM, 100 p i)  in 
ex trac tio n  buffer (see "Methods" Section 4.1) were incubated with a
1 pc
range of [ I]«-BGT concentrations (0.085 -  51 nM, 50 p i ;  giving
0.025 -  15 nM f in a l  concentrations) in the presence and absence of 
unlabelled «-BGT (12.75 pM, 20 p i ;  giving 1.5 pM f in a l  concentration) 
fo r 15 min a t  23°C. Saturated ammonium sulphate m s  added to  give a 
f in a l  concentration of 40% sa tu ra tion  o v e ra ll, and saitples were then 
incubated fo r 16 h a t  4°C. The resu ltin g  p re c ip ita te s  were co llec ted  
and counted fo r rad io a c tiv ity  as described in "Methods" section  7 .1 .
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13. Immimohistochemistry
13.1 Gelatin!zation of microscope slides
Microscope s lid e s  were cleaned with 50% (v/v) alcohol.
G elatin so lu tion  was made up fresh ly  by adding 0.5% (w/v) g e la tin  
and 0.05% (w/v) chrane alum to  d i s t i l l e d  w ater, heating to  80°C and 
then f i l t e r in g  through Whatman f i l t e r  paper. S lides were dipped in to  
the g e la tin  so lu tion  and allowed to  drain  and dry a t  room 
tem perature.
13.2 Cryostat sectioning of tissue material
Small pieces of human ad u lt or fo e ta l limb muscle were 
d issec ted  and mounted onto c ryosta t chucks s i t t in g  in dry ice  using 
"Tissue Tek" mounting f lu id , placed in the c ry o s ta t and allowed to  
e q u ilib ra te  to  cu tting  temperature (range -15 -  -25^0  w ithin the 
c ryosta t chamber. S e ria l transverse  sections were taken a t  20 ĵiM, 
co llec ted  onto g e la tin ized  s lid e s  (see "Methods" sec tion  13 .1), 
d ried  a t  room tenperature and then sto red  in sealed boxes a t  -20°C 
u n til  required (less  than 1 month), unless used immediately.
13.3 Immunohistochemical staining using the Peroxidase 
anti-Peroxidase (PAP) technique.
Slides with human a d u lt o r fo e ta l muscle t is su e  were immersed 
and incubated in  one of the following so lu tions , made up in 50 irM 
potassium phosphate bu ffer, pH7.4:-
a) buffer alone (60 min a t  23°C)
b) 0.5 nM o(-BGT alone in  buffer (60 min a t  23°C)
c) 1 mM curare in  buffer (30 min a t  23^C)followed by 0.5 nM
oC-DGT (30 min a t  23°C).
Hie t is su e  sections were then washed in 150 irM potassium
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phosphate bu ffe r, pH7.4 ( 2 x 5  min a t  23°C) and fixed  in  e ith e r  
4% (w/v) paraformaldehyde in 0. 1 M potassium ^ o sp h a te  bu ffer, 
pH7.4 fo r 30 min a t  4°C or in g la c ia l a c e tic  acid :e thanol (5:95 
(v/v) ) mixture fo r 10 min a t  -20°C, washed thoroughly in 0.1 M 
potassium j^osphate bu ffer, pH7.4 (2 x 30 min a t  23°C or PBS 
containing 0.003% (w/v) phenol red as in d ica to r ( 3 x 5  min a t  
23°C) respec tive ly  and incubated w ith non-absorbed or absorbed 
rab b it anti-(oC-BC3T) antiserum (see "Methods" section  13.4) fo r 
60 min a t  23°C or overnight a t  4°C ( f in a l  d ilu tio n  1:200 in 
PBS, 0Î7. 4, containing 0.1% (v/v) T riton X-100; buffer 'A ') ,  
then washed in buffer 'A' alone (2 x 10 min a t  23°C). Hie 
s lid e s  were then incubated with sheep a n ti- ( r a b b it  IgG) 
antiserum  fo r 30 min a t  37°C (f in a l d ilu tio n  1:10 in PBS 
containing 0.1% (v/v) T riton X-100 and 1% (v/v) normal sheep 
serum; buffer 'B ' ) ,  followed by washing in  buffer 'B' alone (2 
X 10 min a t  23°C. Sections were then incubated w ith 'PAP' 
complex (f in a l d ilu tio n  1:50 in buffer 'B' ) fo r  30 min a t  37°C, 
and fu rth e r washed in buffer 'B' alone (2 x 10 min a t  23°C) 
followed by a f in a l  wash in 0.05 M TRIS b u ffe r, pH7.6 (15 min 
a t  23°C). The tis su e  sections were sta ined  w ith 0.0125% (w/v)
3,3 -diaminobenzidine tetrahydrochloride (DAB) in  0.05 M HRIS 
bu ffer, pH7.6 containing 0.0125% (v/v) hydrogen peroxide fo r 2 
-  20 min a t  23°C u n t i l  colour development was complete, a f te r  
v^ich they were m shed in 0.05 M IRIS b u ffe r, pH7.6 ( 3 x 5  min 
a t  23°C) followed by dehydration in a s e r ie s  of a lco h o ls :-  70% 
(v/v) ethanol (2 min a t  23°C), 95% (v/v) ethanol (2 min a t  
23°C), absolute ethanol ( 2 x 2  min a t  23°C) and f in a l ly  xylene 
(16 h a t  23°C). The s lid e s  were embedded and coverslipped in 
DPX mounting medium and l e f t  to  harden fo r 7 days.
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13.4 Absorption of ra b b it anti-ÇoC-BGT) antiserum
13.4 ( i)  Using normal human red blood c e l ls .
Normal human peripheral blood (10 ml) m s  cen trifuged  
(200 g, 10 min, 23°C) and the serum discarded. The red c e l ls  
were m shed 3 times in PBS by a lte rn a te  resuspension and 
cen trifu g a tio n . Packed red c e l ls  were incubated with 
h ea t-in ac tiv a ted  rab b it anti-(ot-BGT) a n ti  serum (1:1 (v/v) ) fo r 
2 X 30 min a t  23°C, followed by cen trifu g a tio n , a f te r  which the 
absorbed antiserum was removed and sto red  a t  4°C in the 
presence of sodium azide.
13.4 ( i i )  Using human a d u lt and fo e ta l muscle honogenate.
Human a d u lt muscle (25 g) and human fo e ta l muscle (25 g) 
were coarsely  chopped and homogenized together in 4 volumes of 
10 irM potassium phosphate bu ffer, pH7.4, containing 1 irM EDTA 
in a Sorvall Omnimix a t  f u l l  speed fo r 1 min. The honogenate 
was centrifuged (20,000 g, 45 min, 4°C) and the re su ltin g  
supernatant decanted and d iscarded. The p e l le t  was 
re-hcmogenized and cen trifuged  as above twice more. A fter the 
f in a l  cen trifu g a tio n , the p e l le t  was re-suspended in  1 volume 
of rab b it anti-(ot-BGT) antiserum  (d ilu ted  1:20 in 10 nM 
potassium phosphate b u ffe r, gH7.4, containing 1 nM EDTA) and 
l e f t  fo r 2 h a t  4°C, followed by cen trifuga tion  (100,000 g, 60 
min, 4°C). The supernatant was assayed fo r anti-(X-BGT) 
a c t iv i ty  (see "Methods" sec tion  9) and sto red  a t  4°C in the 
presence of sodium azide.
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13.5 Fluorescein-œ njugated «<-BGT sta in in g  of teased muscle 
f ib re s
Human ad u lt o r fo e ta l sk e le ta l muscle was teased in to  
f ib re s  under a Sw ift d issec ting  microscope and washed in 0.1 M 
HEPES b u ffer, pH7.4. Bundles of f ib re s  were then d ried  onto 
g e la tin ise d  s l id e s . The s lid e s  were then p re -incuba ted  in  the 
presence and absence of a large  molar excess (10 ^ M) of 
unlabelled  «(-BGT in buffer 'A' (which comprised 0.1 M HEPES 
b u ffer, pH7.4, containing 1% (v/v) heat in ac tiva ted  normal 
human serum) fo r 60 min a t  23°C, washed in buffer 'A' (2 x 10 
min) and incubated w ith fluorescein-conjugated oC-bgt ( 1 - 1 0  
|ig/ml) in  buffer 'A' fo r 90 min a t  23°C. Non-bound m ateria l was 
removed by washing in buffer 'A' (5 x 10 min), a f te r  vdiich the 
sections were fixed  in  4% (w/v) paraformaldehyde in bu ffer *A' 
fo r 30 min a t  4°C, then washed in  buffer 'A' ( 2 x 5  min) 
followed by PBS, pH7.4 (1 x 15 min). The muscle f ib re s  were 
then counterstained in  0.01% (w/v) methyl green in PBS, pH7.4 
fo r 5 min a t  23°C, washed in PBS, pH7.4 ( 3 x 5  min), mounted in 
g lycero l and viewed immediately.
13.6 A cety lcholinesterase sta in in g  of teased muscle f ib re s
Human a d u lt o r fo e ta l sk e le ta l muscle f ib re s  were teased 
and s lid e s  prepared as described in the previous sec tion . Hie 
s lid e s  were incubated fo r 2 h a t  23°C in sta in in g  so lu tion  
(Wiich comprised 15% (w/v) sodium sulphate , 70 irM m aleic ac id , 
20 mM glycine, 4 mM CuS0^.5H20, ad justed  to  pH6.5 ( th is  
so lu tion  i s  s ta b le  fo r up to  2 weeks a t  23°C), followed by the 
add ition  of 0.02% (w/v) acety lth iocho line  iodide ju s t  p r io r  to  
u se ). (jontrol s lid e s  were incubated in the s ta in in g  so lu tion
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which contained a d d itio n a lly  100 pM neostigmine. The s l id e s  were 
then v^shed with PBS, pH7.4 ( 3 x 5  min), a f te r  which the  s ta in  
was developed by incubation in  dithio-cxam ide (prepared by 
naking a sa tu ra ted  so lu tion  and then f i l te r in g  through Whatman 
No. 1 paper). When a dark brown s ta in  had developed 
(approximately 3 min) the s l id e s  were washed extensively  in 




1. lod ination  and charac teriza tion  of oC-BGT
1 os
1.1 Preparation of [ I ] - la b e lle d  ô -BGT
o(-BGT m s  iodinated by the chloramine-T method (see "Methods"
section  1 .1 ) .  A ty p ica l e lu tio n  p ro f ile  from the (3-25 Sephadex
column is  shown in Figure 7, where i t  can be seen th a t  approximately 
12590% of the [ I]  was incorporated in to  the p ro tein  (range 68 -  97%; 
mean + SE (n) = 88 + 1.8% (20)). The sp e c if ic  ra d io a c tiv ity  was in the 
range 590 -  780 Ci/irmol (0.074 -  0.098 ^iCi/^Jig), w ith mean value + SE 
(n) of 710 + 15 (20) Ci/mmol (0.089 + 0.0018 (20) ^iCi/pig).
1 251.2 F ractionation  of [ 13-lab e lled  oirBGT species.
otrBGT contains 2 ty rosine residues vhich may becone
iodinated , giving r is e  to  a mixture of mono- and d i-iod ina ted
species (Vogel e t  a l . ,  1972). These were separated by ion-exchange
chromatography on CM-Seghadex C-50 (see "Methods" section  1 .2 ) .  A
ty p ica l e lu tio n  p ro f ile  i s  shown in Figure 8. The f i r s t  peak, e lu ted
125during loading and washing, m s  free  [ I ] ,  the second peak, e lu ted
with 10 mM NaCl, m s  d i-iod inated  «Xr-BGT, and the th ird  peak, e lu ted  
with 100 mM NaCl m s  mono-iodinated X-BGT (Vogel e t  a l . ,  1972).
1.3 Determination of the concentration of iodinated «C-BGT species by 
d ilu tio n  assay.
The concentration of iodinated o(-BGT species obtained from 
frac tio n a tio n  on CM-Sej^adex C-50 m s  determined d ilu tio n  assay 
(see "Methods" section  1 .3 ) .  The sp e c ific  binding of each iodinated 
oC-BGT species to  Torpedo AChR a t  4 d if fe re n t concentrations of
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unlabelled  oC-BGT was p lo tted  ag a in st the concentration of Torpedo
AChR used. The rec ip rocals of the slopes of the graphs so obtained
were re -p lo tte d  again st the concentrations of unlabelled  oC-BGT used.
The in te rce p t on the x-ax is then gives the amount of iodinated <-BGT
species p resent in  the t e s t  sample used. Typical curves obtained are
125shown in Figure 9. Values obtained fo r unfractionated  [ I]o(-BGT by 
th is  method agreed w ell with those obtained in  section  1 .1 .
1.4 Determination of the b io log ica l a c t iv i ty  of rad io labe lled  «C-BGT 
species.
B iological a c t iv i t ie s  of rad io labe lled  oC-BGT species were
assessed by th e ir  a b i l i ty  to  bind to  a la rge  molar excess of Torpedo
AChR. Tcxin-receptor canplexes were separated from unbound species
by ion-exchange chronatography on DEAE-cellulose f i l t e r  d iscs o r by
gel f i l t r a t io n  on a Septedex G-50 column (see "Methods" section
1251 .4) .  B iological a c t iv i t ie s  of unfractionated  [ I]oC-BGT were 
rou tine ly  assayed by the DEAE-cellulose f i l t r a t io n  method and gave 
mean values + SE of 57 + 5% (n = 6 ). A comparison of the 2 methods was 
undertaken fo r various oC-BGT species, including [^H]«c-BGT, and the 
re su lts  obtained are  shown in Figure 10 and % ble  1. I t  can be seen 
th a t the b io log ica l a c t iv i t ie s  obtained by separation  of bound and 
free  species on a gel f i l t r a t io n  column were in  the order of 90 -  
100%, and were consisten tly  higher than the values obtained by 
ion-exchange chromatography on DEAE-cellulose d isc s , vdiich gave 
values of 40 -  50%. Iftiderestim tion of toxin  binding using 
DEAE-celluose f i l t e r  d iscs was noted during o ther assays, and th is
is  discussed fu rth er in "Results" section  3.2.  The b io log ica l
125a c t iv i ty  of unfractionated [ I]^-BGT was a lso  assessed by i t s
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Figure 9. Determination of the concentration of iodinated 
<-BGT species by d ilu tio n  assay
Ihe concentration of iodinated o(-BGT species obtained 
125from frac tio n a tio n  of [ I]oc-BGT on CM-SepAiadex C-50 was determined 
by d ilu tio n  assay (see "Methods" section  1 .3) .
1. Free [ I ]  (peak 1 1
I from CM-Sephadex
2. D i-iodinated oL-BGT (peak I I
C-50 column
3. Mono-iodinated e<-BGT (peak I I I  ^
1 OR
4. Unfractionated
(a) The sp e c if ic  binding of each iodinated o(-BGT species to  Torpedo 
AChR a t  4 d if fe re n t concentrations of unlabelled o(-BGT ( •  0 
pmoles; A 4 pmoles; A 8 pnoles; o 12 pmoles) was p lo tted  
again st the concentration of AChR used.
(b) The rec ip roca ls of the slopes of the graphs obtained in (a) were 
re -p lo tte d  aga in st the concentrations of unlabelled o(-BGT used. 
Ihe in te rce p t on the x-axis then gives the amount of iodinated
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Figure 10. To compare b io log ical a c t iv i té s  of various rad io labelled  
oCt-BGT species by gel f i l t r a t io n  an Sephadex G-50 with 
DEAE-cellulose d isc  f i l t r a t io n
B iological a c t iv i t ie s  of various rad io labelled  o(-BGT 
species were assessed as described in  the "Methods" section 1 .4 , 
gel f i l t r a t io n  on Sephadex G-50 or by ion-exchange on DEAE-cellulose 
f i l t e r  d isc s .
A 1 ml frac tio n s  from Sephadex G-50 f i l t r a t io n  
A ihe same frac tio n s  f i l te r e d  through 2 DEAE-cellulose f i l t e r  
d iscs and counted fo r rad io a c tiv ity
1251. unfractionated [ I]oC-BGT alone
1252. IM fractionated [ I]o(-BGT incubated with a molar excess of
Torpedo AChR fo r 90 min before f i l t r a t io n
3. Mono-iodinated o(.-BGT incubated with a molar excess of Torpedo 
AChR fo r 90 min before f i l t r a t io n
4. D i-iodinated e(-BGT incubated with a molar excess of Torpedo 
AChR fo r 90 min before f i l t r a t io n
5. [^EU-BGT alone
6. [^H]o(-BGT incubated with a molar excess of Torpedo AChR fo r 90 
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ïüb le  1. A canparison of the b io lo g ica l a c t iv i t ie s  of d if fe re n t
rad io labe lled  o(rBGT species measured by gel f i l t r a t i o n  on 
Sejtodex G-50 and ion-exchange on DEAE-cellulose f i l t e r  




Gel f i l t r a t io n  on Ion exchange on DEAE
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Each value i s  the mean of 2 determ inations.
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a b i l i ty  to  bind to  a la rg e  excess of rab b it anti-(«c-BGT) antiserum, 
the value obtained fo r the b io log ical a c t iv i ty  in  th is  way was 75%.
1.5 Determination of the  rad io labe lled  pro tein  by p re c ip ita tio n  w ith 
tr i-c h lo ro a c e tic  ac id .
Table 2 shows a canparison of the values obtained fo r the 
percentage p rec ip ita tio n  of rad io labelled  «(-BGT species by 6% (w/v) 
TCA. Sim ilar values fo r p ro te in  associated  iodine were derived fo r 
the d if fe re n t  species of In p a rtic u la r , unfractionated  and
mono-iodinated o<-BGT appear very s im ila r.
1.6 Comparison of rad io labe lled  o<r-BGT species in binding assays.
The binding of d if fe re n t  rad io labelled  «<-BGT species with 
AChR was canpared in the DEAE-cellulose f i l t r a t io n  assay, the 
aitmonium sulphate assay and the radioimmunoassay. For the 
DEAE-cellulose and ammonium sulphate assays 0.2 pmol of each 
rad io labelled  oc-BGT species m s  incubated with s e r ia l  2-fold 
d ilu tio n s  of p u rif ied  Torpedo or detergent ex trac ts  of ad u lt human 
AChR, respec tive ly , in the presence and absence of an excess of 
benzoquinonium ch lo ride , and the assays performed as described (see 
"Methods" section  7 ). The radioimmunoassay was performed, using 
detergent e x tra c ts  of a d u lt human muscle, as described (see 
"Methods" section  8 ), using equivalent amounts of each rad io labe lled  
<<-BGT species (5 nM f in a l  concentration). Table 3 (a ,b ,c ) shows the 
re su lts  obtained. In the DEAE-cellulose f i l t r a t io n  and
125immunoprécipitation assays, the behaviour of unf rac tiona  ted  [ I]  
ô BGT, mono-iodinated ô -BGT and [^]oc-BGT were comparable; whereas in 
the ammonium sulphate assay unfractionated  and mono-iodinated oc-BGT
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Thble 3. Canparison of rad io labe lled  o<-BGT species in binding 
assays
(a) DEAE-cellulose f i l t r a t io n  assay
Radiolabelled oC-BGT species 
□ ifrac tionated  mono-iodo d i-iodo  [^H]
1 yc.
[ I]oC-BGT oC-BGT o(-BGT oC-BGT
Torpedo AChR 
(pnol/ml)





(b) Ammonium sulphate assay
Radiolabelled «<-BGT species
Unfractionated mono-iodo d i-iodo  [ H]
o<-BGT o<-BGT125[ I]«C-BGT *(-BGT
Human AChR 
(pnol/ml)





(c) Radioimmunoassay fo r  anti-(AChR) antibodies
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Anti-(AChR) antibody t i t r e  (nM) obtained 
using d if fe re n t  rad io labe lled  ê -BGT species










3 221 (-)* 237 (108) 150 (68) 233 (105)
13 7 (-) 8 (122) 4 (62) 7 (97)
6 31 (-) 35 (115) 19 (63) 32 (102)
10 20 (-) 23 (114) 13 (66) 19 (92)
Normal 0 (-) 0 (0) 0 (0) 0 (0)
Values in parentheses a re  percentage of using
125.unfractionated [ ]Jk-BGT.
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gave similar results, but [̂ H]o<.-bgt gave slightly lower values. In 
all assays di-iodinated «K-BGT gave consistently lower binding.
2. Detergent ex trac tio n  and subsequent p a r t ia l  p u rif ic a tio n  of AChR.
AChR was ex tracted  from d if fe re n t sk e le ta l muscle types using 
the non-ionic detergen t T riton X-100. Some e x trac ts  of human muscle 
were subsequently p a r t ia l ly  p u rified  by a f f in i ty  chranatography on a 
cobra toxin-Sepharose res in  and concentration by ion-exchange 
chromatography on a DEAE-cellulose column. A co ck ta il of protease 
in h ib ito rs  and a n ti-b a c te r ia l  agents vas used throughout the 
procedure in order to  minimize degradation by p ro teo ly sis . The 
p u rif ic a tio n  procedure was performed as quickly as possib le  (within 
2 days), and a t  4°C, fo r the same reason.
2.1 P u rifica tio n  of the «C-toxin frcm vencm of Naja naja siamensis 
and preparation of the oC-toxin a f f in i ty  re s in .
The <-toxin was p u rif ied  frcm Naja naja siamensis crude vencm 
to  provide the ligand fo r the a f f in i ty  p u rif ic a tio n  of AChR (see 
"Methods" section  2 ). The p ro f ile  of absorbance a t  280 ran fo r 
e lu tio n  frcm the phosphocellulose column is  shown in Figure 11. and 
the re s u lts  obtained are  suntnarized in Table 4. The strongest 
- tox in  a c t iv i ty  was e lu ted  frcm the phospocellulose column in  3 
peaks: D,E & F. Recovery of oC-toxin binding a c t iv i ty  was 39%, 
giving an o v e ra ll 3 .4 -fo ld  p u rif ic a tio n . Assuming a MW fo r «(-toxin 
of 8000, i t  was 25% pure.
Peaks D,E and F were pooled, and a sample (25 mg) m s  coupled 
to  cyanogen bromide ac tiva ted  Sepharose 4B (see "Methods" section  
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ïü b le  4. Sunmary of p u rif ic a tio n  of oC-toxin frcm 
ISfeja naja siamensis
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frac tio n  peak
d ilu tio n  
giving 50% 
in h ib ition
of to ta l




sp e c if ic




4.9 X 10-7 1046 1.53 X  10® 1.46 x 10
A 8.0 X 10-4 26.52 2.44 X lo5 9.20 X 10®
B 18.98 — —
column C — 45.50 — —
frac tio n s D 3.0 X 10-G 120.25 9.25 X 10^ 7.69 X lo5
E 1.4 X lO”^ 112.45 3.48 X 10^ 3.09 X lo5
F 6.0 X 10-5 35.20 1.17 X 10^ 3.32 X lo5
G 1.0 X 10-4 798 1.14 X 10^ 1.43 X lo4
freeze-
*
D 2.0 X 10-5 39.40 1.48 X 10^ 3.76 X lo5
dried
*
E 1.5 X 10-5 82.70 4.14 X 10? 5.00 X 105
frac tio n s
*
F 3.5 X 10-5 18.20 3.90 X 10® 2.14 X 10^
* lyophilized  samples a t  1 mg/ml in  d i s t i l l e d  water 
— no in h ib itio n  of toxin binding a c t iv i ty
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œ n te n t of 0.38mg oC-toxin/ml packed Sepharose 4B beads.
2.2 Human a d u lt and fo e ta l AChR
Detergent ex trac tion  of human sk e le ta l muscle gave y ie ld s of 
1250.23 -  2.19 pmoles [ I]«(̂ -BGT binding s i te s  per gram of muscle
(0 .8 9 + 0 .1 1 , 27 determ inations, mean + SE) fo r ad u lt tis su e ; and 0.61 
125-  1.89 pmoles [ I]oC-BGT binding s i te s  per gram of muscle (1.20 +
0.10, 15 determ inations, mean + SE) fo r fo e ta l t is su e . Storage of
tis su e  fo r up to  3 months a t  -80°C did  not cause apparent lo ss  of 
125ex trac tab le  [ I]oC-BGT binding s i t e s .  In most cases no fu rth e r 
p u rif ic a tio n  of the detergent e x tra c t was performed but was used in 
the radioimmunoassay fo r a n t i - (ACZhR) an tibodies (see "Methods" 
section  8).
P u rifica tio n  of AChR by a f f in i ty  chrcmatography on 
immobilized «/-Naja toxin , b io spec ific  e lu tion  with carbachol and 
ion-exchange chromatogragjiy on DEAE-cellulose was performed as 
ou tlined  in the "Methods" section  4 .1 . A flow diagram showing the 
basic  p u rif ic a tio n  scheme i s  shown in  Figure 12. 60 -  90% of the 
av a ilab le  AChR in "crude" detergen t e x trac ts  bound to  the  toxin 
a f f in i ty  column. Determination of AChR in the d iffusa  te  before 
d ia ly s is  v^s not performed, as measurement of AChR a t  th is  stage is  
complicated by the presence of residual carbachol. Yields of 
p u rif ied  AChR were expressed as a percentage of the detergen t 
e x trac tab le  a c t iv i ty ,  and represented 6 -  25% recovery. (The to ta l  
honogenate vas too fibrous to  allow accurate determ ination of AChR. ) 
P u rified  ad u lt AChR preparations showed sp e c if ic  a c t iv i t ie s  of 0.01
-  0.8 nmol/mg pro tein  over 6 preparations; the corresponding values 
fo r fo e ta l AChR (0.01 -  0.1 nmol/mg protein) a re  probably
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Figure 12. Flow diagram showing the method for purification of AChR
MUSCLE ( 2 0 0 g )
Homogenization in buffer A' (4 vol) 
containing anti -  prote a ses 
Centr ifuge at 20  0 0 0  g
2 0  0 0 0  g PELLET
Extract in buffer A' (1 vol) containing anti 
proteases plus 2 * 5 % (v/v) Triton X - 1 0 0  
Centr i fuge at lOOOOOg
lO O O O O g SUPERNATANT (Detergent extract)
Affinity chromatography using immobilized 
oc-toxin from Naia naia siamensis
AChR -o c -  TOXIN-SEPHAROSE
Wash alternately with buffer T O 5 M NaCl 
to remove non -  specifically bound protein  
Biospecific elution with carbachol
AChR - CARBACHOL





125underestimates due to  the rapid lo ss  of [ I]@(.-BGT binding (see 
below). The best preparation of p u rif ied  ad u lt AChR represented a 
20000-fold p u rif ic a tio n  canpared with the detergent e x tra c t. Table 5 
shows a ty p ica l p u rif ic a tio n  tab le  giving y ie ld s and percentage 
recoveries through the p u rif ic a tio n  procedure. Crude detergent 
ex trac ts  of a d u lt AChR were s ta b le  fo r 2 months a t  4°C (Figure 
13(a)) without appreciable lo ss  of toxin binding a b i l i ty ;  v ^ i l s t  
p u rified  preparations of ad u lt AChR were s ta b le  fo r about 1 week a t  
4°C a f te r  vAiich the toxin binding a c t iv i ty  decreased rap id ly . Crude 
detergent e x tra c ts  of fo e ta l AChR stored  a t  4°C lo s t  50% of th e ir  
toxin binding a c t iv i ty  in  the f i r s t  3 weeks a f te r  v^ich they 
renained constant fo r up to  4 months (Figure 13(b)). P u rified  
preparations of fo e ta l AChR were used immediately as the toxin 
binding a c tiv ity  was found to  disappear w ithin 2 days of 
p u rif ic a tio n .
2.3 Junctional and ex tra -ju n c tio n a l r a t  AChR
Detergent ex trac tion  of r a t  junctional and ex tra -ju n c tio n a l 
AChR fron diaphragm muscle gave y ie lds of 0.51 + 0.04 (mean + SE, n =
1 oc
5) and 1.21 + 0.4 pmol (mean + BE, n = 4) [ I]<-BGT binding s i te s  
per gram of muscle respec tive ly . The e x trac ts  were sto red  a t  4°C fo r 
up to  6 months without apparent lo ss  of toxin binding a c t iv i ty .
2.4 Torpedo marmorata AChR
The p u rified  AChR had a sp e c ific  a c t iv i ty  of 2.9 nmol 
sp ec ific  binding sites/m g p ro te in . Other AChR preparations, with 
sp ec ific  a c t iv i t ie s  ranging fron 2 - 7  nmol/mg were a lso  used, and 
were kindly donated by Lindsay Muir.
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Thble 5. P u rifica tio n  tab le  fo r recovery of AChR fron  human ad u lt 
muscle during the p u rif ic a tio n  procedure
S pecific  Recovery
Stage of AChR Protein a c t iv i ty  o(-toxin P u rifica tio n
p u rifica tio n  (pmol) (mg) (pmol/^ig) binding (%) fac to r
Triton X-100 
detergent 
e x tra c t
Non-bound 
to a f f in i ty  
resin
Washes frcm 
a f f in i ty  
beads
Non-bound 


















Figure 13. Loss of binding a c t iv i ty  of detergent ex trac ts  of AChR
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1253. Measurement of [ I ]<-BGT binding
AChR was determined by 3 methods (see "Methods" section  1 ),
depending on the nature of the t e s t  sample. The DEAE-cellulose
f i l t r a t i o n  assay was used mainly fo r p u rif ied  preparations and the
airmonium sulphate p rec ip ita tio n  assay fo r "crude" detergent ex trac ts
v^ich, because of th e ir  high p ro tein  content, gave erroneous re su lts
in the former assay (see Table 6 ). Ihe DEAE-cellulose f i l t r a t io n
125assay was used fo r k in e tic  determ inations of [ I]fi(.-BGT binding to  
AChR in  detergen t ex trac ts  of fo e ta l and ad u lt sk e le ta l muscle, 
where ammonium sulphate was found to  be unsuccessful in  term inating 
the binding reaction  (see Table 7 (a )) . For these purposes, high 
a c t iv i ty  e x tra c ts  were d ilu ted  before use and th is  helped to  reduce 
the non-specific  component of binding.
Ihe immunoprécipitation method was used successfu lly  fo r both 
de te rgen t e x tra c ts  and p u rified  preparations.
3.1 Ammonium sulphate p rec ip ita tio n  method
Ihe f in a l  percentage sa tu ra tio n  of ammonium sulphate required
125to  give maximum p rec ip ita tio n  of [ I]«c-BGT lab e lled  AChR complex
in  "crude" detergen t e x trac ts  was determined by adding increasing
amounts of sa tu ra ted  ammonium sulphate to  a constant amount of 
125[ I]oC-BGT -  AChR complex to  give f in a l  percentage sa tu ra tio n s  of
10 -  70%. The re s u lts  a re  shown in Figure 14 where i t  can be seen
th a t  40% sa tu ra tio n  o vera ll e ffected  maximum p rec ip ita tio n  of
complex. The assay was lin e a r  with p ro te in  concentration i f  excess
[125i ]^_Bgt used. The con tribu tion  of [^^^I]oC-BGT to  the  assay
125blank was assessed by incubating increasing amounts of [ IK-BGT 
(0 -  3.5 pmol, representing 0 -  20 nM in the assay) with 40% f in a l
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Table 6. Comparison of measurement of AChR in  detergen t e x trac ts  by 
DEAE-cellulose f i l t r a t i o n  and ammonium sulgdiate 




f i l t r a t i o n
Ammonium sulphate 















AChR was determined in detergen t e x trac ts  of ad u lt 
and fo e ta l AChR by the DEAE-cellulose f i l t r a t io n  assay and 
airmonium sulphate p re c ip ita tio n  methods, as described in the 
"Methods" section  7.1 & 7 .2 .
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Figure 14. Determination of percentage saturation of ammonium 
sulphate required to give maximal precipitation of 
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sa tu ra tio n  of airmonium su lphate, and performing the assay in  the
125usual m y . Figure 15 shows th a t  non-specific  binding of [ I]<?Cr-BGT
to  the g lass f ib re  d iscs was l in e a r , and represented 9.4% of the 
125to ta l  [ I]«<r-BGT added in i t i a l l y .  The time necessary fo r maximum 
125formation of [ I]oC-BGT -  AChR complex p r io r  to  the add ition  of
ammonium sulphate was determined by incubating constant amounts of 
125[ Ilt-BGT and AChR, adding airmonium sulphate a t  various times
th e re a f te r , followed ty  incubation fo r 16 h a t  4°C, and f i l t r a t io n
on g lass f ib re  d iscs as previously described (see "Methods" section
1257 .1 ). Table 7(a) shows th a t  e ith e r  [ IK-BGT -  AChR complex
formation is  very rapid ie .  v ir tu a lly  immediate, \h ich  did not
appear to  be the case from the DEAE-cellulose f i l t r a t io n  assay (see
"Results" section  5 .3 .1 ) , or th a t the add ition  of ammonium sulphate
does not stop the reaction  immediately, but takes time to  reach
equilibrium . Table 7(b) shows a v a rie ty  of combinations of the order 
125of addition  of [ I]oo-BGT, AChR and ammonium su lphate, and the
resu ltin g  A(ZhR concentration measured a f te r  16 h a t  4°C. Ih is
ind icates th a t whatever the order o f add ition  of the components, the
resu ltin g  measurement of AChR remains the same. Furthermore i t  is
c lea r th a t ammonium sulphate cannot be used to  stop  the reaction  
125between [ IK-BGT and AChR -  th is  i s  important fo r subsequent 
assays (see "Results" section  5 .3 ).
125The optimum time fo r incubation of [ I  ]o(-BGT -  AChR complex 
with ammonium sulphate to  give maximum p re c ip ita tio n  of rad io label 
was determined, and the re s u lts  shown in Table 7 (c ). Incubation fo r 
5 h a t  23°C or 4°C gave maximal p re c ip ita tio n  of complex (although 
other re su lts  (see Table 7(d)) suggested th a t 16 h a t  4°C vas 
b e tte r ) ;  fu rth er incubation upto 16 h did not a f fe c t  the r e s u l t ,  and
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12SFigure 15. Non-specific p rec ip ita tio n  of [ I]cc-BGT and re ten tion  on 
GFC f i l t e r s  in the ammonium sulphate assay
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12SŒ&ble 7. (a) P rec ip ita tio n  of [ I]o(-BGT -  AChR complex 
by airmonium sulphate
Time of incubation of 
125[ I]o(-BGT with AChR 
before addition  of 
airmonium sulphate (min)
AChR measured (pmol/ml) 
a f te r  incubation with 
airmonium sulphate 















I n i t i a l  incubation (incubation




125[ I]*-BGT + AChR 
125[ I]«t-BGT + AChR
















125Tkble 7. (c) Time and temperature of incubation of [ I]oc-BGT 
lab e lled  AChR with ammonium sulphate required fo r 
maximum p rec ip ita tio n  of carplex
AChR measured (pmol/ml) 
Temperature of incubation




T^ble 7. (d) Number of g lass f ib re  f i l t e r  d isc s  fo r maximum
125reten tion  of [ I]ot-BGT -  AChR complex
Time and temperature 
of incubation
AChR measured (pmol/ml)
Number of GFC f i l t e r s  
1 2







incubation fo r 16 h was often  used fo r convenience.
Increasing the number of GFC f i l t e r s  used did not improve the 
125amount of [ I]cC-BGT -  AChR complex measured (see Table 7 (d )) , in
fa c t i t  led  to  le ss  complex being re ta ined .
The combination of using 40% airmonium sulphate to  p re c ip ita te
[^^^I]o(.-BGT -  AChR complex fo r 16 h a t  4°C, and f i l t e r in g  through 1
GFC f i l t e r  d isc , led  to  a r e l ia b le , reproducible method fo r
125determ ination of [ I]o«.-BGT binding in crude detergent ex trac ts  of 
muscle AChR.
3.2 DEAE-cellulose f i l t r a t io n  method
Ihe DEAE-cellulose f i l t r a t io n  assay was used mainly fo r the
125determ ination of AChR in p u rified  p reparations. Binding of [ I]
o(-BGT to  AChR was shown to  be complete a f te r  90 min incubation a t
23°C (see "Results" section  5 .3 .1 ) . Contribution of [^^^I]o(-BGT to
the assay blank was assessed by f i l t e r in g  increasing amounts of 
1 25[ I]o(-BGT ( 0 - 2  pmoles, representing 0 -  20 nM in the assay ), in
the presence of toxin binding assay buffer (see "Methods" section
1257.2) alone. Figure 16 shows th a t the non-specific  binding of [ I]
o(-BGT to  DEAE-cellulose f i l t e r  d iscs was l in e a r  with increasing
amounts of [^^^I]oC-BGT and represented 2.2% of the to ta l  [^^^I]«c-BGT
added. This value is  ra th e r le s s  than the blank value obtained in
the aitmonium sulphate assay, probably due to  some p rec ip ita tio n  of 
125[ I]o(-BGT pro tein  by airmonium sulphate in add ition  to  non-specific
adhesion to  g lass f ib re  d isc s .
Ihere was a suggestion frcm seme experiments (see "Results"
section 1.4) th a t the conditions of the assay were underestim ting  
125the amount of [ I]oc-BGT binding to  DEAE-cellulose f i l t e r  d isc s , as
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Figure 16. Non-specific binding of [ I]cc-BGT to  DEAE-cellulose 
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canpared with gel f i l t r a t i o n  on Seftodex G-50. Ihe e ffe c t  of
increasing the number of DEAE-cellulose f i l t e r  d iscs  used, and
increasing the time of contact o f [ I]oc-BGT -  AChR with the
f i l t e r s  before washing through, both in  the assay fo r measurement of
125AChR and measurement of b io log ica l a c t iv i ty  of [ I ] pc-BGT was
therefo re  investigated . P u rified  Torpedo AChR vias used fo r these
stu d ies , as i t  provided a more abundant source of AChR than human
125muscle. Figure 17(a,b) shows th a t  i f  [ I]et-BGT-AChR i s  f i l te r e d
immediately through the DEAE-cellulose f i l t e r  d isc s , increasing the
number of f i l t e r  d iscs used does increase the re ten tion  of lab e lled
AChR. I f ,  however, the lab e lled  AChR is  allowed to  remain in contact
with the f i l t e r  d isc  fo r 2 or 5 min before washing through, then the
125optimum number of d iscs i s  2 and no fu rth e r [ I]o<-BGT can be 
bound. Therefore, in a l l  fu rth e r experiments, 2 DEAE-cellulose 
f i l t e r  d iscs were used per t e s t ,  and the time of contact of lab e lled  
AChR with the f i l t e r  d iscs was increased to  2 min, instead of 
f i l t e r in g  immediately.
3.3 Inmunoprecipitation method
This method was used fo r determining AChR in both detergen t 
ex trac ts  and p u rified  preparations of human a d u lt and fo e ta l AChR. 
Serum frcm p a tie n t 3 (see "Results" section  4.2) co n sis ten tly  
p rec ip ita ted  95 -  100% of the a c t iv i ty  compared with ammonium 
sulphate or DEAE-cellulose f i l t r a t i o n  methods (see Table 8).
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Figure 17, Optimization of conditions fo r DEAE-cellulose 
f i l t r a t io n  assay
(a ) Determination Torpedo AChR
1 OK
(b) Determination b io log ica l a c t iv i ty  [ I]o(-BGT
The assays fo r Torpedo AChR and b io log ical a c tiv i ty  of
125[ I]o(“BGT were performed as described in "Methods" sections 7.2
and 1.4 respec tive ly , using appropriate amounts of Torpedo AChR and
[^^^I](<-BGT. A fter incubation for 90 min a t  23°C, sanples were 
f i l te r e d  through increasing numbers of DEAE-cellulose f i l t e r  d iscs 
a f te r  increasing times of contact of the samples with the f i l t e r s  
( •  0 min; A 2 min; ■ 5 min) before washing through. Values a re  
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% ble 8 . Comparison of airmonium sulphate p rec ip ita tio n  and 
DfAE-cellulose f i l t r a t io n  assays with the 
inmunoprecipitation method
Result in immunoprécipitation assay as 
a percentage of re s u l t  obtained frcm :-
Detergent ex trac ts  P u rified  preparations 
in ammonium sulphate in DEAE-cellulose
AChR used p rec ip ita tio n  assay f i l t r a t io n  assay
Adult 90 + 4.0 104 + 3.3
Foetal 95 + 5.5 109 + 4.3
Values given represen t mean + SE.
1 0 0
4. Specific  fea tu res of antibody p a tte rn s  in myasthenic p a tie n ts .
4.1 Radioimmunoassay of anti-(AChR) an tibod ies.
The radioimmunoassay fo r the determ ination of anti-(AChR) 
antibodies in  the sera  of ityasthenic p a tien ts  involves sp e c ific  
lab e llin g  of human a d u lt sk e le ta l muscle AChR with rad io labe lled  
snake venon ec-toxin, followed by the use of an excess of the 
lab e lled  AChR to  bind a l l  anti-(AChR) an tibodies p resent in  the 
p a tie n t 's  serum, and p rec ip ita tio n  of the catplex so formed with a 
second antibody (see Figure 6 , "Introduction" p. 3 0 ) .  Assay of 
normal volunteers gave values of 0.024 + 0.007 nM pC-BGT binding s i te s  
(+SE, duplicate  assays on 20 in d iv id u a ls ), v ^ ile  anti-(AChR) antibody 
t i t r e s  in c l in ic a lly  diagnosed myasthenic p a tien ts  ranged frcm 0 -  
600 nM o4-BGT binding s i t e s ,  w ith a mean value of 22 nM s i te s .  
Approximately 90% of myasthenic p a tien ts  show elevated serum lev e ls  
of anti-(A(ZhR) an tibodies (Lindstrcm e t  a l . , 1976a), the assay 
therefore  provides a usefu l a id  in the diagnosis of the d isease .
Ihe assay i s  composed of several s tages, and many aspects of 
published procedures d i f f e r  widely between authors. I  became 
involved in the developnent and evaluation of the f in a l  stages of a 
reproducible RIA procedure vhich i s  su itab le  fo r rou tine  
app lica tion . As th is  work was done in c lose co llabora tion  with o ther 
workers, i t  i s  not d e ta ile d  separa te ly  in the present th e s is , but 
the re su lts  can be seen in  the bound paper "An assessment of RIA 
procedures fo r determ ination of anti-(AChR) an tibodies in the  sera  
of p a tien ts  with myasthenia g rav is ."
Ihe main p a rt of the present section  uses th is  RIA to  
investiga te  sp e c ific  fea tu res of antibody p a tte rn s  in myasthenic 
p a tie n ts . For seme experiments i t  was necessary to  pu rify  IgG frcm
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sera  by airmonium sulphate p rec ip ita tio n  and ion exchange 
chrcroatography (see "Methods" section  5 ). Anti-(AChR) an tibodies 
were determined in myasthenic sera before p u rif ic a tio n  and in  the 
IgG fra c tio n  a f te r  p u rif ic a tio n  (see "Methods" section  8 ). Ihe 
recoveries of sp e c if ic  antibody a c t iv i ty  and y ie ld s of IgG frcm a 
se r ie s  of p reparations a re  given in Table 9.
Ihe second antibody fo r p rec ip ita tin g  immune ccmplexes in  the 
RIA was prepared by immunizing goats wih human IgG p u rified  frcm 
pooled normal human serum (see "Methods" section  6 ) . The re su ltin g  
serum was monitored fo r the production of an tibodies by the RIA 
procedure given (see "Methods" section  8 ) . Figure 18 shows a ty p ica l 
sa tu ra tio n  curve fo r the p rec ip ita tio n  of a fixed  concentration of 
AChR -  anti-(AChR) antibody ccmplex by increasing volumes of goat 
anti-(human IgG) antiserum . Repeated in jec tio n s  of IgG were given 
u n t i l  the volume of antiserum  required to  p re c ip ita te  5 p i of 
myasthenic serum was le s s  than 100 p i. Table 10 shows a summary of 
the r e s u lts  obtained frcm each se r ie s  of immunizations.
4.2 P a tie n t-sp e c if ic  antibody p a tte rn s .
14 myasthenic p a tien ts  representing d iffe r in g  d isease  s ta te s  
were stud ied  fo r varying tim es, frcm 1 - 6 0  months. A ll p a tien ts  
underwent a se r ie s  of plasma exchange and iimiunosuppression therapy 
during the period of in v estig a tio n , and th is  provided the 
opportunity to  monitor v a ria tio n s  in  antibody t i t r e s  accaipanying 
major changes in c lin ic a l  s ta te .
Ihere was considerable v a ria tio n  in the anti-(AChR) antibody 
t i t r e s  between p a tie n ts , vhether human AChR o r r a t  AChR was used as 
antigen in the RIA. Neither the antibody t i t r e  measured against
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I^b le  9. Recoveries of sp e c if ic  anti-(AChR) antibody and y ie ld  
of IgG fron myasthenic sera
P a tien t
number
Anti-(AChR) antibody Recovery
(pnoles [ I]c(.-BGT sp e c if ic  y ie ld
binding s i te s )  in antibody I ^
serum IgG (%) (mg)
182 57 31 56
10 510 411 82 80
11 76 40 53 10
14 54 22
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Figure 18. Saturation  curve for p rec ip ita tio n  of receptor-antibody 
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in jec tio n s
Volume antiserum  
required fo r Volume
p rec ip ita tio n  of antiserum
AChR-Ab carplex (pi) obtained




human AChR nor that against rat AChR correlated with the severity of
the d isease (see Figure 19). However, i t  was found th a t the antibody
t i t r e  measured ag a in st human AChR was always g rea te r than i f
extra-junctional rat A(ZhR (El-rat AChR) was used, v̂ ich was, in
turn, always higher than with junctional rat AChR (J-rat AChR) (see
Figure 20). The a n ti- (E J - ra t  AChR) antibody t i t r e  was 0 -  63% of the
anti-(human AChR) antibody t i t r e  (see Figure 21); whereas the
a n t i - ( J - r a t  AChR) antibody t i t r e  was 0 -  100% of the  a n ti- (E J - ra t
AChR) antibody t i t r e  (see Figure 22). Although the antibody t i t r e s
fo r an individual p a tie n t were found to  vary considerably with tim e,
the ratio of titres, both anti-(EJ-rat AChR) ; anti-(human AChR) and
anti'(J-rat AChR) : anti-(EJ-rat AChR) were relatively constant for
an individual p a tie n t over the period of study, desp ite  varying
treatment regimes. This is illustrated in Figure 23 (a - n).
If the RIA was modified by adding excess myasthenic sera to
125precipitate a limited amount of [ I]oc-BGT - labelled human AChR,
i t  was found th a t  the amount p rec ip ita te d  varied  between p a tien ts
(15 -  100%), but vas constant fo r  a given p a tie n t over the period of
study. Serum from one p a r tic u la r  p a tie n t (p a tien t 3) constan tly
p rec ip ita ted  100% of the av a ilab le  lab e lled  AChR, as judged by
DIAE-oellulose and ammonium sulphate p re c ip ita tio n  assays (see
"Results" section  3 ), so o thers were expressed as a percentage of
th is  (see Figure 24). The re la tiv e  a b i l i t i e s  of myasthenic sera  to  
125p re c ip ita te  [ I]oC-BGT -  lab e lled  human AChR provides fu rth e r 
evidence fo r the existance of a p a tie n t-sp e c if ic  antibody p a tte rn . 
Possible reasons fo r the percentage p re c ip ita tio n  e ffe c t a re  
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Figure 23. Anti-(human A(]hR) antibody titres and ratios of
a n ti-(ex tra ju n c tio n a l r a t  AChR) : anti-(human AChR) 
antibody t i t r e s  fo r 14 myasthenic p a tien ts  over various 
time periods: -
(a) P a tien t 1 - 3 3  months
(b) P a tien t 2 - 3 5  months
(c) P a tien t 3 - 2 6  months
* )il s J
•  Pre-plasmapheresis
Anti-(human ACZhR) antibody t i t r e
▲ Post-plasmapheresi
o Pre-plasmapheresis i Ratio anti-(EJ rat A(ZhR) : anti-
A Post-plasmapheresis J (human AChR) antibody titres
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Figure 23. Anti-(human AChR) antibody titres and ratios of
a n ti-(ex tra ju n c tio n a l r a t  AChR) : anti-(human AChR) 
antibody t i t r e s  fo r 14 myasthenic p a tien ts  over various 
time periods:-
(d) P a tien t 4 - 1 7  months
(e) P a tien t 5 -  2 months
(f) P a tien t 6 -  4 years
• Pre-plasmapheresis i
L Anti-(human AChR) antibody titre 
A Post-plasmaĵ eresis J
o Pre-plasmapheresis Ratio anti-(EJ rat AChR) : anti-
A Post-plasmapheresis J (human AChR) antibody titres
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Figure 23. Anti-(human AChR) antibody titres and ratios of
an ti-(ex tra ju n c tio n a l r a t  AChR) ; anti-(human AChR) 
antibody t i t r e s  fo r 14 myasthenic p a tien ts  over various 
time periods: -
(g) P a tien t 7 - 3 0  months
(h) P a tien t 8 - 3 1  days
(i)  P a tien t 9 - 2 5  months
# Pre-plasmagheres i s n 
▲ Post-plasmapheresis J
Anti-(human ACZhR) antibody titre
O Pre-plasmagheresis i Ratio anti-(EJ rat AChR) : anti-
A Post-plasmaj^eresis i (human AChR) antibody titres
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Figure 23. Anti-(human AChR) antibody titres and ratios of
a n ti-(ex tra ju n c tio n a l r a t  A(ZhR) : anti-(human A(ZhR) 
antibody t i t r e s  fo r 14 myasthenic p a tien ts  over various 
time p e rio d s:-
(j)  P a tien t 10 -  20 months
(k) P a tien t 11 -  5 years
(1) P a tien t 12 -  16 months
•  Pre-plasmapheresis -j 
A Post-plasm ajiieresis J
Anti-(human AChR) antibody t i t r e
o Pre-plasm aj^eresis i  Ratio an ti-(E J r a t  ACZhR) : a n t i -  
A Post-plasmapheresis j (human AChR) antibody t i t r e s
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Figure 23. Anti-(human AChR) antibody titres and ratios of
a n ti-(e x tra ju n c tio n a l r a t  AChR) : anti-(human AChR) 
antibody t i t r e s  fo r 14 myasthenic p a tien ts  over various 
time periods:-
(m) P a tien t 1 3 - 3  years 
(n) P a tien t 1 4 - 1  year
• Pre-plasmapheresis
I Anti-(human AChR) antibody titre 
A Post-plasmap̂ eresis J
o Pre-plasmapheresis -i Ratio anti-(EJ rat AChR) : anti- 
A Post-plasmagheresis J (human AChR) antibody titres
Results fran all these graphs are summarized in Table 11.
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Figure 24. P rec ip ita tio n  of [ I  ]o(-BGT labelled  human AChR ky 
repeat serum sanples from 14 d iffe re n t myasthenic 
p a tie n ts .
Excess of the serum was used, with goat anti-(human IgG) 
antiserum , to  p re c ip ita te  labe lled  AChR. The heights of the columns 
represent mean percentages of the amount of labelled  A(ZhR 
p rec ip ita ted  by serum from p a tie n t 3. The e rro r bars surmounting the 
columns represen t +SE, and the number of sairples assayed is  shown 
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ïhble 11. Summary of anti-(AChR) antibody titres and ratios of
anti-(AChR) antibody t i t r e s  obtained using human adu lt 
AChR, ex tra -ju n c tio n a l r a t  AChR, or junctional r a t  AChR as 
antigen in the RIA of myasthenic sera ; and percentage 
p rec ip ita tio n  of human AChR by excess myasthenic se ra .
H = anti-(human adult AChR) antibody titre 
JR = anti-(junctional rat AChR) antibody titre 
EJR = anti-(extra-junctional rat AChR) antibody titre
Antibody titres are expressed as nM o(-BGT binding sites
* A large proportion of assays done on samples from 
these patients were by T.S.M.
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1 *
Range H 1 9 - 9 3  49 -  279
Mean H 44 157
Range EJR 0 - 1  0 . 5 - 9
Mean EJR 0.3 4.9
Range JR 0 0
Mean JR 0 0
Ratio EJ:H mean 0.007 0.027
SEM 0.004 0.006
no. samples 10 7
Ratio J;EJ mean 0.000 0.000
SEM 0.000 0.000
no. samples 5 5
Human AChR p rec ip ita ted  mean 75 86
(%) SEM 3.2 0.7
no. samples 7 5
"Inh ib ition  fac to r"  -  -
Period of study (months) 33 35
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Patient
3 4 * 5 * 6 7
137 — 451 3 — 18 1 — 60 6 — 60 0.2 — 6
277 8 15 23 2
1 — 28 0.04 — 1.2 0 — 4.4 0.2 — 2 0 —0.7
8.4 0.4 1 1 0.2
1 - 1 0  0. 2  -  0. 8  0 - 1. 2  0 - 1  0 -  0.1
3.5 0.3 0.3 0.3 0.0
0.028 0.046 0.053 0.059 0.099
0.008 0.008 0.010 0.005 0.008
8 9 8 16 21
0.422 0.710 0.300 0.280 0.015
0.040 0.042 0.050 0.049 0.011
6 3 3 17 20
100 71 85 60 76
1.1 2.1 1.9 3.4
6 4 12 14
+















0.1  -  0 .8  0.2  -  1 .2  
0.5 2.9




























Period of study (moiths) 25
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Î tient
10 11 12 * 13 * 14
10 -  85 3 -  40 1 -  25 3 -  20 2 -  31
33 26 8 8 12
2.2 -  4 0.4 -  7.4 0.3 -  8 .8  0.5 -  5.0 1 -  16
3.2 3.0 2.0 2.2 3.7
0 - 1  0.4 -  7.4 0.1 -  2.0 0 . 3 - 2  1 - 1 3
0.5 3.3 0.4 1.1 2.4
0.122 0.202 0.279 0.297 0.617
0.014 0.012 0.037 0.016 0.020
14 8 11 15 33
0.162 1.100 0.188 0.502 0.742
0.025 0.070 0.034 0.069 0.024
14 3 4 7 33
82 93 67 48 82
1.9 1.9 2.3 0.6 2.1
14 14 7 5 14
36 61 16 36 12
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1254.3 Percentage p re c ip ita tio n  of [ IK-BGT -  lab e lled  AChR by 
excess myasthenic serum.
Sera fron myasthenic p a tie n ts , when used in  excess, vary in
1 OR
th e ir  a b i l i ty  to  p re c ip ita te  a l l  av a ilab le  [ I]<<-BGT -  lab e lled
AChR complex. Values vary from 15 -  100% (see "Results" section  4.2,
Figure 24), with a mean value of 75 + 2.3 (+SE, 73 determ inations).
I n i t i a l ly ,  add ition  of the various components a t  the d if fe re n t
stages of the RIA procedure vas checked to  ensure th a t incomplete 
125p rec ip ita tio n  of [ I ] oC“BGT -  lab e lled  AChR was not a r e s u l t  of the
use of sub-optimal conditions in the assay. Ihe AChR i s  known to  be
125fu lly  labe lled  w ith [ I]oc-BGT a f te r  the time and temperature of
125incubation used and with the concentration of [ I]oO-BGT used (see
Figure 42), so the e f fe c t  cannot be explained by incomplete
lab e llin g  of the recep to r. Ihe percentage p rec ip ita tio n  does not
appear to  c o rre la te  with the antibody t i t r e ;  th is  i s  shown in  Figure
25. IgG p u rified  from 4 myasthenic sera  were no more e ffe c tiv e  than
125the o rig in a l serum in p re c ip ita tin g  the av a ilab le  [ I]e(.-BGT -
lab e lled  AChR ( see Table 12 ). The h ighest t i t r e  serum represents a
1251000-fold molar excess of an tibodies over [ I]<-BGT-AChR, so
incomplete p rec ip ita tio n  i s  un like ly  to  r e s u l t  from in su ff ic ie n t
antibody. This was confirmed by increasing the volume of serum o r
125IgG used to  p re c ip ita te  the [ I]oC-BGT lab e lled  AChR complex, v^ich 
did not increase the percentage p re c ip ita tio n  achieved. Increasing 
the amount of goat anti-(human IgG) antiserum  added to  p re c ip ita te  
the labe lled  receptor-antibody complex a lso  had no e f fe c t  on the 
percentage p rec ip ita tio n  (see Figure 2 6 (a ,b )) , so the re s u lts  do not 
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125•fable 12. Percentage p rec ip ita tio n  of [ I]«-BGT -  lab e lled  AChR 
by myasthenic serum and
Percentage p rec ip ita tio n  of 
125[ '^^I]at-BGT -  AChR
serum igs
I^ tie n t  mean SE mean SE
13 70 2 .0 62 2 .0
6 59 3.5 62 3.0
14 78 1.5 83 2 .0
10 84 2 .0 86 1.5
fach value i s  the mean of 4 determ inations.
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Figure 26. E ffect of increasing the amount of goat anti-(human IgG)
125on the percentage p rec ip ita tio n  of [ I  ]o(-BGT lab e lled  
AChR by myasthenic serum o r IgG
Excess serum or IgG (5 [xD fron each of 4 MG p a tien ts  was
125used to  p re c ip ita te  a constant amount of [ I]*-BGT lab e lled  human 
adu lt AChR (0.02 pmol, 100 \xl), in the presence and absence of 
benzoquinonium ch lo ride , as described in "Methods" section  8 . 
Increasing volumes of goat anti-(human IgG) antiserum were added to  
e ffe c t p rec ip ita tio n  of the lab e lled  AChR-antibody complex.
131
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As the percentage p rec ip ita tio n  e ffe c t  observed did not seem 
to  be re la ted  to  the above t r i v i a l  fa c to rs , o ther p o s s ib i l i t ie s  were 
investigated .
4 .3 .1  Heterogeneity of anti-(AChR) antibody subpopulations
One possib le  explanation fo r inconplete p re c ip ita tio n  of
125[ I K - bgt -  AChR i s  the absence of p a rtic u la r  anti-(AChR) antibody
subpopulations from the sera  of ce rta in  myasthenic p a tien ts ; coupled
with heterogeneity  of toxin binding components. H iis p o s s ib il i ty  was
investigated  ky combining d if fe re n t sera together in an a tto n p t to
e ffe c t to ta l  p rec ip ita tio n  of [ Il^C-BGT -  AChR. Hie RIA fo r
125percentage p re c ip ita tio n  of [ I]<<-BGT by excess myasthenic serum
was performed in the usual way, but with one add itional step : -  a f te r  
125incubation of [ I]<<-BGT -  AChR with a  f i r s t  serum fo r 2 hours, a
second myasthenic serum was added fo r a fu rth e r  2 hours incubation
before addition  of goat anti-(human IgG) antiserum . The re s u lts  a re
shown in Table 13. Figure 27 shows a rep resen ta tive  s e t  of re su lts
obtained fo r addition  of d if fe re n t sera to  1 p a tie n t who ty p ic a lly
1 os
p rec ip ita ted  50% of av a ilab le  [ I]<-BGT lab e lled  AChR. O verall, i t  
can be seen th a t  the add ition  of a "h igh-precip ita ting" to  a 
"low -precip itating" serum did not increase the p rec ip ita tio n  above 
th a t caused by the f i r s t  add ition  alone. I t  i s  therefo re  evident 
th a t there  i s  no a d d itiv ity  between the sera  investiga ted .
1 o s
4.3 .2  [ I]«<r-BGT -  d isp lacing  antibodies
An a lte rn a tiv e  explanation fo r p a r t ia l  p re c ip ita tio n  of
125[ I]e^-BGT lab e lled  AChR involves the presence of an tibodies Wiich 
d isp lace fron [^^^I]«C-BGT lab e lled  AChR complex, e ith e r
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% ble 13. The e f fe c t  of canbining d if fe re n t myasthenic sera  on the
125percentage p rec ip ita tio n  of [ I]oC-BGT -  lab e lled  AChR
I^ tie n t ,  second addition
N 6 14 15 10 8 11 3
N 0 69 74 79 81 83 91 100
6 57 53 55 56 58 52 51 594->
% 14 68 64 59 59 58 54 63 60(0
+Jcn 15 73 74 79 75 78 74 83 76u•H4-1 10 68 66 67 68 67 62 62 65
■P
B 8 71 64 67 76 65 66 71 73
•H
s 11 92 75 82 87 82 85 97 97
3 102 82 87 96 91 86 101 98
Values a re  means of 4 determ inations.
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Figure 27. Partial precipitation of AChR by excess M3 sera -
i l lu s t r a t io n  of the re s u lts  obtained fron a se r ie s  of 
second additions to  serum from th a t of p a tien t 1
Ihe radioiirmunoassay fo r the percentage p rec ip ita tio n  of
125[ I  ]o(-BGT lab e lled  AChR by excess M3 serum was performed in  the 
usual way (see "Methods" section  7 .3 ), but with one add itional 
s te p :-  A fter incubation of [ I]oC-BGT labe lled  AChR with the f i r s t  
myasthenic serum fo r 2 h, a second myasthenic serum was added fo r a 
fu rther 2 h incubation before addition  of goat anti-(human IgG) 
antiserum (see a lso  Table 13).
135
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by binding a t  or near the ACh binding s i t e ,  or by binding elsewhere
and promoting a conformational change. Attempts to  demonstrate the
presence of an tibodies d irec ted  a t  the ACh binding s i t e  ( a n t i - s i te
antibodies) by the in h ib itio n  of [ I]oc-BGT binding to  A(ZhR
following pre-incubation with myasthenic serum have given equivocal
re su lts  (Fulpius, 1983). The re la tio n sh ip  between in h ib itio n  of 
125[ I]oC-BGT binding to AChR by nyasthenic sera and percentage 
125p rec ip ita tio n  of [ I]oC-BGT lab e lled  AChR in 12 p a tien ts  i s  shown
in Figure 28. I t  can be seen th a t sera fron  only a few p a tien ts
125a c tu a lly  in h ib it  the binding of [ I]o<.-BGT to  AChR, and th a t  there
125is  no d ire c t  c o rre la tio n  w ith the percentage p re c ip ita tio n  of [ I]
c(-BGT labelled AChR by sera from these patients.
One vay of looking fo r possib le  tox in -re leas ing  antibodies is
to  follow the time-dependent displacement of [^^^I]oc- bgt from
oC-BGT labelled AChR in the presence of myasthenic sera.
125[ I]oC-BGT -  AChR was incubated with b u ffer, normal human
125serum, unlabelled -BGT or myasthenic serum and any displaced [ I]
125«<-BGT was separated fron [ I]oC-BGT - AChR by gel filtration (see
"Methods" section  11) over a period of tim e. The disappearance of
radio label from the void volume peak and i t s  appearance in  the low
MW peak was monitored. The re s u lts  a re  shown in  Figure 29 and Table
14. Although th is  method danonstrated both the re lease  of rad io labe l
fron the high MW peak and i t s  appearance in  the low MW peak, i t  was
both slow and cumberscme, which precluded a more d e ta ile d  study. For
these reasons the separation  of bound and free  species was
subsequently achieved by ion-exchange filtration on DEAE-cellulose
f i l t e r  d iscs (see "Methods" section  7.2) .  This has the disadvantage
125of measuring only the [ !]<<-DGT -  AChR complex remaining, but th is
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125Figure 28. Relationship between inhibition of [ I]cc-BGT binding to
AChR by myasthenic serum and the percentage p rec ip ita tio n  
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125In h ib itio n  of [ I]«c-BGT binding was calcu lated  as the 
r a t io  of antibody t i t r e s  t i t r e  a
t i t r e  b
where t i t r e  a was determined by incubation of iryasthenic serum (5 pi)
with AChR (0.5 nM) fo r 2 hours a t  23°C followed by addition  of [^^^I]oc
-BGT (5 nM) fo r 2 hours a t  23°C followed by p rec ip ita tio n  with goat
a n t i - (hunan IgG) antiserum  (see "Methods" section  8 ) and t i t r e  b was
determined by the standard radioiirmunoassay procedure (see "Methods"
1 25section  8 ). The percentage p rec ip ita tio n  of [ I]cc-BGT lab e lled  AChR 
by excess iryasthenic serum was determined as described (see "Results" 
section  4.2) .
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Figure 29. Displacement of [^^^I]/<-BGT frcm [^^^I]o^-BGT labe lled  
AChR by myasthenic sera -  data  obtained fron gel 
f i l t r a t io n  chrcmatography
1 OR
Duplicate sairples [ I ] -̂BGT-AChR (100 p i ) ,  lab e lled  in
the presence and absence of benzoquinonium chloride, were incubated
with myasthenic se ra , o r w ith, as con tro ls , buffer or unlabelled
oC-BGT (5 -  150 p i) fo r various tim es, up to  6 hours, a f te r  which the
reaction  was term inated by gel f i l t r a t io n  on Sephadex (3-75.
Fractions were co llec ted  and a liquo ts counted for rad io a c tiv ity . The 
125amount of [ IK-BGT lab e lled  AChR a t  each time point was expressed 
as a percentage of the amount present a t  zero time.
Each lin e  represents the mean of 4 experiments, the 
points shown re s u l t  fron one ty p ica l experiment. Numbers re fe r  to  
serum samples frcm d if fe re n t  MG p a tien ts .
(a) disappearance of [^^^I]oC-BGT frcm [^^^I]«<-BGT labe lled  AChR 
in the void volume peak
125(b) appearance of [ I]oC-BGT in the low molecular weight peak
139
addition to 































l&ble 14. Displacetnent of [ I].<.-BGT fron  -  lab e lled
AChR : gel f i l t r a t io n
125Percentage [ I]^-BGT -  AChR 
remaining a t  time (h)
Addition of 2 5 24
buffer 99 99 107
oC-BGT 82 58 37
P atien t 3 94 88 73
P atien t 6 84 68 ND
P atien t 14 82 70 ND
ND = not determined
Values a re  means of 4 determ inations.
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i s  cxmpensated fo r by the advantages of speed, rep ro d u c ib ility  and
the opportunity of monitoring several samples in p a ra lle l ,  thus
fa c i l i ta t in g  d ire c t  comparisons between d if fe re n t  sera used. Figure
30 and Table 15 show the re s u lts  obtained from th is  method.
Ihe re s u lts  show th a t  sane iryasthenic sera were capable of
125accelera ting  the re lease  of bound [ I ] oc- bGT frcm i t s  recep tor
complex. The ex ten ts to  vhich th is  occurred showed an approximately
inverse re la tio n sh ip  with the a b i l i ty  of the sera  to  p re c ip ita te
receptor (see "Results" section  4.3.1) .  Control experiments v^ere 
125[ I]tf(-BGT lab e lled  AChR complexes were incubated in  the presence
of "h igh-precip itating" se ra , buffer o r normal human serum showed
125comparatively very slow d isso c ia tio n  of [ I]o(-BGT from such 
complexes.
4.4 In h ib itio n  Factor
In the RIA fo r anti-(AChR) an tibod ies, sera  from most
p a tie n ts , when s e r ia l ly  d ilu te d , p re c ip ita te  a corresponding amount 
125of [ I]o -̂BGT-AChR. However, there  a re  some p a tie n ts , approximately
12520%, whose sera p re c ip ita te  a higher amount of [ I]  -BGT-AChR
complex than would be expected with increasing d ilu tio n . This
suggested the presence, in  some se ra , of a fac to r  vhich in h ib ited  or
pro tected  the receptor-antibody in te rac tio n  and, when d ilu te d ,
125allowed binding of more [ I]o(-BGT-A(ZhR to  antibody. This fa c to r  i s
re fe rred  to  as the " in h ib itio n  fac to r" .
At f i r s t  i t  m s  thought th a t th is  observation may be re la te d
125to  the percentage p re c ip ita tio n  of [ I  ]«c.-BGT-AChR described in  the 
previous sec tion , as there  seemed to  be some co rre la tio n  between the 
two e ffe c ts  (see Figure 31). However, extension of the o rig in a l
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Figure 30. Displacanent of frcm labelled
AChR by iryasthenic sera -  data  obtained frcm 
DEAE-cellulose d ise  f i l t r a t io n
195Duplicate samples [ I ] «(.-BGT-AChR (100 p i ) ,  lab e lled  in
the presence and absence of benzoquinonium ch lo ride , were incubated
with nyasthenic se ra , or w ith, as co n tro ls , bu ffer, normal serum o r
unlabelled «(.-BGT (5 -  150 pi) fo r various t in e s , up to  24 h, a f te r
vhich the reaction  was term inated by ion-exchange f i l t r a t io n  on
DEAE)-œllulose f i l t e r  d iscs  (see "Methods" section  7.2) .  The amount 
125of [ I  ]o(-BGT lab e lled  AChR a t  each time poin t was expressed as a 
percentage of the amount p resent a t  zero time. The re su lts  shown a re  
the mean of 4 determ inations. Numbers re fe r  to  serum samples frcm 
d if fe re n t nyasthenic p a tie n ts .
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A ddi t ion  to 
f25 | ]a -BGT -  AChR  
at  Time z e r o
100
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T&ble 15. Displacement of fron [ I]^-BGT - labelled
AChR : DEAE-cellulose f i l t r a t io n
125Percentage [ I]o<.-BGT -  AChR 
remaining a t  time (h)
Addition of 2 5 24
buffer 94 108 97
o(-BGT 77 53 20
normal serum 95 86 63
P atien t 6 63 52 28
14 71 60 25
15 90 78 70
10 72 58 34
8 ND ND ND
11 88 90 92
3 93 88 73
ND = Not determined
Values a re  means of 3 determ inations
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Figure 31. R elationship between percentage p rec ip ita tio n  of 
[ I]oc-BGT lab e lled  AChR and the presence or 






























I n h i b i t i o n  f a c t o r
â  p r e l i m i n a r y  s t u d y  
■ a d d i t i o n a l  d a t a
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prelim inary study (see Figure 31) fa ile d  to  su b s tan tia te  the  i n i t i a l
re la tio n sh ip . The nature of the in h ib itio n  fac to r was then
investigated  by several approaches
1. Increasing volumes of myasthenic sera  were used to  p re c ip ita te
125[ I K - bgt lab e lled  AChR complexes, but th is  did not ranove the 
" inh ib ition  fac to r"  e f fe c t ,  n e ith e r did  increasing the amount of 
goat anti-(human IgG) antiserum  used to  p re c ip ita te  the lab e lled  
complexes. These re s u lts  suggest th a t  the " inh ib ition  fac to r" 
e ffe c t i s  not caused by in su ff ic ie n t o r excess myasthenic serum 
or second antibody.
2. Serum from 1 MG p a tie n t with the " in h ib itio n  fac to r"  was 
frac tiona ted  on a Sephacryl S-300 column. Ihe IgG frac tio n s  
obtained from th is  frac tio n a tio n  showed no " inh ib ition  fac to r"  
e f fe c t .  Adding the pu ta tive  inh ib ito ry  frac tio n s  back to  such IgG 
in the radioimmunoassay fa ile d  to  show the " inh ib ition  fac to r"  
e f fe c t ,  possibly because the frac tio n s  were too d ilu te  a f te r  
processing.
3. Serum from 4 MG p a tie n ts , two w ith, and two w ithout, the 
" inh ib ition  fa c to r" , were passed through a column of «(-toxin 
coupled to  Sepharose 4-B which had been incubated w ith detergen t 
e x tra c t of ad u lt human AChR. Ihe e luan t was then added back to  
myasthenic IgGs in the radioimmunoassay, but no " in h ib ition  
fac to r"  e f fe c t  vas observed, again possibly  re su ltin g  from 
d ilu tio n  of the samples during processing.
4. D ialysis of sera containing the " in h ib itio n  fac to r"  elim inated 
i t s  e f fe c t  in  1 out of 2 sera  te s te d . Ih is  equivocal r e s u l t  may 
ind ica te  a molecular weight of around 8000 fo r the component but 
more work is  obviously necessary to  c la r ify  th is .
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5. In te rac tio n  of detergent e x tra c ts  of human ad u lt and fo e ta l AChR
1 ot:
with [ I]oC-BGT
I t  has been previously shown (see "Results" section  4.2) th a t
a n t i -  (AChR ) antibody t i t r e s  measured using E J-ra t AChR as antigen in
the RIA are  higher than i f  J - r a t  AChR is  used, implying the presence
of an tigen ic  determinants on E J-ra t AChR which a re  recognized
uniquely by myasthenic se ra . Reports in the l i te r a tu r e  of the
s im ila r ity  of EJ- and embryonic AChR have led  to  the hypothesis th a t
embryonic AChR may represen t the autoimmunogen in MG. As the study
of r a t  AChR in th is  way can only provide lim ited  information about
the human system, th is  section  of R esults in v estig a tes  the binding
125of human fo e ta l AChR with [ I]«<-BCjr by inrnunohistochomical and
1 OK
k in e tic  methods and the binding of [ I]oc-BGT lab e lled  fo e ta l AChR 
with anti-(AChR) an tibodies in myasthenic se ra . Concurrently, these 
in te rac tio n s  a re  compared with those of human ad u lt AChR. Foetuses 
were obtained from prostaglandin-induced term inations, and were 13 -  
22 weeks g esta tio n . In order to  obtain su f f ic ie n t  fo e ta l muscle to  
give adequate y ie ld s of AChR (espec ia lly  fo r p u rif ica tio n ) fo r 
study, i t  was necessary to  pool muscle from several foetuses of 
d if fe re n t ages. I t  was necessary, th e re fo re , to  gain some ind ication  
as to  vhether the AChR undergoes major developmental changes over 
the age range used. D etailed analysis  was c le a r ly  im possible, but 
the age-dependence of o(-BGT binding s i te s  vas monitored as a 
possib le po in ter towards receptor v a ria tio n .
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5.1 Drmunohistochanical s tud ies  on human ad u lt and fo e ta l sk e le ta l 
muscle
Prelim inary attem pts were made to  v isu a lize  synapses in human 
fo e ta l and a d u lt sk e le ta l muscle by s ta in in g  <-BGT binding s i te s  
with the 'PAP' technique, by fluorescein  conjugated oC-BGT sta in in g  
and by AChE sta in in g , in order to  try  to  d is tin g u ish  between 
innervated and dennervated tis su e .
5.1 .1  Staining by the  'PAP' technique
Tissue sections from human fo e ta l and a d u lt sk e le ta l muscle 
were prepared (see "Methods" sections 13.1 & 13.2) and sta ined  with 
«(-BGT by using the 'PAP' technique (see "Methods" section  13 .3 ), a 
schematic diagram of vhich is  given in Figure 32, showing the 
d if fe re n t stages of the s ta in in g  procedure. Figures 33 -  38 show the 
sta in ing  of a d u lt and fo e ta l (12  & 18 weeks gesta tion) t is su e  by 
using th is  method. Apart from the contro ls in which normal rab b it 
serum replaced the anti-(<-BGT) antiserum , a l l  sections were 
uniformly s ta ined , irre sp e c tiv e  of the inclusion  of excess ligand to  
block oC-BGT binding, or vhether buffer was su b s titu ted  in place of 
c(-BGT in  the f i r s t  incubation s tep . This suggested th a t rab b it anti-(ot^ 
-BGT) antiserum  was binding non-specifica lly  to  the tis su e  types.
For th is  reason, 2 absorption methods were ca rried  out, using fo e ta l 
tis su e  (18 weeks gesta tion) only, in order to  attem pt to  reduce th is  
heavy non-specific  s ta in in g  (see "Methods" section  13 .4). Ihe f i r s t  
absorption, against normal human eythrocytes gave no reduction in 
the background sta in in g  ( re s u lts  not shown ) . A fter the second 
absorption, against muscle e x tra c t, the rab b it anti-(«^-BGT) 
antiserum reta ined  90% of i t s  an tigen ic  a c t iv i ty ,  as measured by RIA
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P e r o x i d a s e  a n t i - p e r o x i d a s e  
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Figures 33 -  38. S taining of human ad u lt and fo e ta l muscle sections 
with oC-BGT using the 'PAP' technique (see 
"Methods " section  13.3)
Figure 33. S taining of long itud inal sections of ad u lt muscle
(A) Hie sections were incubated with X-BGT, rabb it 
anti-(oC-BGT) antiserum , sheep a n ti- ( ra b b it  IgG) 
antiserum  and PAP complex
(B) The sections were incubated with oC-BGT, 
normal rab b it serum, sheep a n ti- ( ra b b it  
IgG) antiserum  and PAP complex.




Figure 33. Staining of longitudinal sections of human adult muscle
(C) The sections were incubated with c(-BGT following 
pre-incubation with d-tubocurarine, then with rab b it 
anti-(ot-BGT) antiserum, sheep a n ti- ( ra b b it  IgG) 
antiserum and PAP complex
(D) Ihe sections were incubated with bu ffer, rab b it 
anti-(tfC-BGT) antiserum, sheep a n ti- ( ra b b it  IgG) 




Figure 34. Staining of longitudinal sections of foetal (large)
muscle
(A) The sections were incubated with o(-BGT, rab b it a n ti-  
(oC-DGT) antiserum , sheep a n ti- ( ra b b it  IgG) antiserum 
and PAP complex
(B) The sections were incubated with o(;-BGT, 
normal rab b it serum, sheep a n ti- ( ra b b it  





Figure 34. Staining of longitudinal sections of foetal (large)
muscle
(C) Ihe sections were incubated with <̂-BGT following 
pre-incubation with d-tubocurarine, then with rab b it 
anti-(o(.-BGT) antiserum , sheep a n ti- ( ra b b it  IgG) 
antiserum  and PAP complex
(D) The sections were incubated with buffer, rab b it 
anti-(<<-BGT) antiserum , sheep a n ti- ( ra b b it  IgG) 




Figure 35. Staining of longitudinal sections of foetal (small)
muscle
(A) Ihe sections were incubated with <?(r-BGT, rab b it a n ti-  
(pC-BGT) antiserum , sheep a n ti- ( ra b b it  IgG) antiserum 
and PAP complex
(B) The sections vere incubated with ok-BGT, 
normal rab b it serum, sheep a n ti- ( ra b b it  





Figure 35. Staining of longitudinal sections of foetal (small)
muscle
(C) The sections were incubated with <<-BGT following 
pre-incubation with d-tubocurarine, then with rab b it 
anti-(oC-BGT) a n ti  serum, sheep a n ti- ( ra b b it  IgG) 
antiserum and PAP complex
(D) The sections were incubated with bu ffer, rab b it 
anti-(pC-BGT) antiserum , sheep a n ti- ( ra b b it  IgG) 
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Figure 36. Staining of foetal (large) muscle sections after
absorption of rabb it anti-(o(-BGT) against human muscle
Sections were incubated with <<-BGT, rab b it 
a n t i - («<-BGT) antiserum, sheep a n ti- ( ra b b it  IgG) 
antiserum and PAP complex
(A) Non-absorbed rabb it anti-(«(-B(?r) a n ti  serum
(B) Rabbit anti-((/.-BGT) antiserum absorbed against human 










Figure 37. Staining of foetal (large) muscle sections after
absorption of rab b it a n ti-  (o(-BGT) again st human muscle
Sections were incubated with cx̂ -BGT, 
following pre-incubation with d-tubocurarine, then with 
rab b it anti-(o(,-BGT) antiserum, sheep a n ti- ( ra b b it  IgG) 
antiserum and PAP complex
(A) Non-absorbed rab b it anti-(X.-BGT) antiserum
(B) Rabbit anti-(oC-BGT) antiserum absorbed against human 





Figure 38. Staining of foetal (large) muscle sections after
absorption of rab b it anti-«-BGT) against human muscle
Sections were not incubated with oC-BGT, but 
with bu ffe r, then with rabb it anti-(oC-BGT) antiserum, 
sheep a n ti- ( ra b b it  IgG) antiserum and PAP corplex
(A) Non-absorbed rab b it anti-(#(-BGT) antiserum
(B) Rabbit anti-(oi-BGT) antiserum absorbed against human 
muscle (see "Methods" section  1 3 .4 ( i i ) ) .




(see "Methods" section  9 ). The amount of non-specific  s ta in in g  was 
reduced (Figures 36 -  38), but th e re  was s t i l l  not enough d ifference  
between the sta in in g  pa tte rn s of the t is su e  types to  draw any 
conclusions concerning the d is tr ib u tio n  of end-plates in  these 
muscle sec tions.
5 .1 .2  Stain ing with fluorescein-conjugated »c-BGT
Muscle f ib re s  were teased fran  human ad u lt and fo e ta l (18 
weeks gesta tion) muscle and s ta ined  with fluorescein-conjugated 
«(-BGT as described (see "Methods" section  13 .5 ). Foetal muscle showed 
uniform weak fluorescence along rows of ntyotubes (re su lts  not 
shown). Adult muscle showed in tense  d iffu se  fluorescen t sta in in g  
which did not appear to  be lo ca lized  a t  end-p la tes, and vhich was 
abolished in f ib re s  pre-incubated w ith unlabelled  ô -BC3T (see Figure 
39 ) . Areas of fluorescence corresponded with areas vhich were 
counterstained with methyl green and viewed by transm itted  l ig h t .
5 .1 .3  Staining fo r A(]hE
In co n tras t to  the re s u lts  obtained fo r fluorescein  s ta in in g , 
ad u lt muscle f ib re s  showed no s ta in in g  fo r AChE, whereas fo e ta l 
muscle f ib re s  showed sta in ing  along the  v^ole length of muscle 
f ib re s ; th is  m s  abolished in the presence of neostigmine (see 
Figure 40).
As these studies were largely inconclusive, ac-BGT and 
anti-(AChR) antibody binding were examined in solubilized 
preparations of adult and foetal muscle.
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Figure 39. Staining of teased f ib re s  fron  human ad u lt muscle with 
fluorescein-conj ugated t̂ -BGT
Fibres were sta ined  as described in the 
"Methods" section  13.5.
(A) Transmitted light
(B) Fluorescence sta in in g  
M agnification x 150
When f ib re s  were p re -incuba ted  w ith unlabelled ot-BGT 




Figure 40. Staining of teased f ib re s  fron human fo e ta l muscle fo r 
AChE a c t iv i ty
Fibres were sta ined  as described in the 
"Methods" section  13.6.
(A) M agnification x 150
(B) M agnification x 600
(C) Teased f ib re s  sta ined  a f te r  pre-incubation with 
neostigmine, m agnification x 150
B
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1255.2 Determination of [ I]ec-BGT binding s i te s  versus fo e ta l age
1 o c
Levels of [ I]<-BGT binding in "crude" detergen t e x tra c ts
from indiv idual foe tuses, aged 13 -  19 weeks g esta tio n , were
compared ( see Figure 41 ) . Foetal age was assessed by crown-ruitp
length (Arey, 1954). The concentration of sp ec ific  oC.-bgT binding
s i te s  v a ries  between 0 .6  -  1 .8  pnol/g wet weight of tis su e  over the
age range stud ied , and th is  agrees w ell with the range fo r a d u lt
125muscle. There was no co rre la tio n  between the y ie ld  of [ I]^-BGT 
binding s i te s  and fo e ta l age.
1255.3 Determination of ra te  constants fo r  [ I]ot-BGT binding to  human
fo e ta l AChR and comparison with human a d u lt AChR
1 95The in te rac tio n  of [ I]o{.-BGT with detergent e x tra c ts  of 
human a d u lt and fo e ta l AChR were compared. Although the ammonium
sulphate assay was usually  the p referred  method fo r determ ination of
125[ IK-BGT equilibrium  binding in detergent ex trac ts  of AChR (see 
"Methods" section  7 .1 ) , i t  m s  found to  be unsuitable  fo r the  rapid  
term ination of binding necessary fo r  k in e tic  determ inations of 
assoc ia tion  and d isso c ia tio n  ra te  constants (see "Results" sec tion  
3 .1 ) . Therefore, the DEAE-cellulose f i l t r a t io n  assay (see "Methods" 
section  7 . 2 ) m s  used in stead , with high a c t iv i ty  e x trac ts  v^ich 
were d ilu te d  in order to  minimize adsorption of non-receptor 
p ro te ins to  the f i l t e r  d isc s . From the law of mass a c tio n ; -
R + L RL  1
The assoc ia tion  (k^^) and d isso c ia tio n  (k_^) ra te  constants 
can be defined in the following equation: -  
d(RL)
d t
= k^^[R][L] -  k_^[RL]
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1Figure 41. Determination of [ I]œ-DGT binding s i te s  











G e s t a t i o n  a g e  ( w e e k s )
T rip lica te  sairples (100 p i) of s e r ia l  two-fold d ilu tio n s  of
detergent ex trac ts  of fo e ta l sk e le ta l  muscle from individual foetuses
125were incubated with 5 nM [ I ]«r-BGT in the presence and absence of a 
large molar excess (10  ̂ M) of benzoquinonium ch lo ride , followed by 
p rec ip ita tio n  with ammonium sulphate a t  4°C for 16 h. Bound radio label 
was recovered by f i l t r a t i o n  on g lass f ib re  f i l t e r  d iscs as described 
in the "Methods" section  7.1.
175
5.3.1 Association Rate Constant )
125Ihe association rates for the binding of [ I]<<-BGT to 
detergent extracts of both foetal and adult AChRs were determined by 
2 methods
(a) Second order k in e tic s
For the second order treatm ent of k in e tic  data  the i n i t i a l  
ra te  of binding is  considered, i e .  the bound concentration is  
assumed to  be so low th a t k_^[RL] is  e sse n tia lly  zero. By 
manipulation and in teg ra tion  of equation 2 , the in teg rated  second 
order ra te  equation is  given a s ; -  
-  B)
In -    = k T  t  (L,̂ - B )  3^ B g  - B) +1 -T e
where:- B  ̂ = maximum concentration of binding s i te s  
B = concentration bound a t  time t  
= to ta l  ligand concentration 
t  = time
k^^ = assoc iation  ra te  constant
Figure 42 shows rep resen ta tive  se ts  of progress curves fo r 
125the reaction  of [ I]«C.-BGT with human ad u lt and fo e ta l AChR and 
Figure 43 the second order p lo ts  obtained from th is  da ta . The ra te  
constants so obtained a re  given in Table 16(a).
(b) Pseudo f i r s t  order k in e tic s
Ih is  method takes in to  account the reverse reaction  
(k_^[RL]), but assumes th a t the concentration of rad ioactive  ligand 
is  constan t. I f  the  reaction  is  allowed to  proceed to  equilibrium , 
i t  can be shown th a t the bound concentration (B) a t  any p rio r time 
is  re la te d  to  the equilibrium  concentration (B^) by the equation :-
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125Figure 42. Time course of specific binding of [ I]oC.-BGT at
125increasing [ I]o(-BGT concentrations
Samples of detergent e x trac ts  of ad u lt o r fo e ta l AChR
125(100 p i) were incubated with increasing concentrations of [ I]o(-BGT 
in the presence and absence of a large  molar excess of unlabelled 
o(rBGT fo r  various time in te rv a ls . Binding was stopped ky the addition  
of cold toxin binding assay buffer and rapid  f i l t r a t io n  as described 
in the "Methods" section  7 .2 .
A 1 . 0 .6 6 nM 125[ l]o(-BGT
□ 2 . 1.32 nM 125[ l]oC-BGT
O 3. 1.98 nM 125[ 1](<-BGT
V 4. 2.64 nM 125[ 1]̂ <-BGT
9 5 . 3.30 nM 125[ IK-BGT
O 6 . 3.96 nM 125r^ lU -B G T
The amount of rad io label bound a t  equilibrium  (90 min) 
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Figure 43. Second order treatment of binding data in Figure 42.
The slopes of the  l in e s  give values fo r the assoc iation  
125ra te s  a t  the d if fe re n t [ I]oCrBGT concentrations used
A dult;- 1. 17.30 x 10^ m" V
2. 12.70 X 10^ m “ V
3. 9 .81  X  10^ m“V
4. 8.43 X 10^ m "V
5. 7.73 X 10^ m "V
6 . 7.61 X 10^ m“V
F o e ta l:-  1. 15.30 x 10^ m" V
2 . 9.50 X 10^ m“V
3. 8.47 X 10^ m "V
4. 10.78 X 10^ m ’ V
5. 6 . 6 1 x 1 0 ^ m " V
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B
In ----------- = k , t
B -Be
and k^^ =
So, i f  k ĵ  ̂ i s  determined a t  several ligand concentrations y 
allowing the deriva tion  of a fam ily of pseudo f i r s t  order p lo ts , 
then p lo ttin g  k^j  ̂ ag a in st w ill give a s t r a ig h t  l in e  with slope 
equal to  k^^ and y -in te rce p t equal to  k_^. Figure 44 shows the 
pseudo f i r s t  order deriva tions fron  the i n i t i a l  progress curves 
shown in Figure 42, and Figure 45 the p lo ts  of k^^ against 
obtained from these da ta . The ra te  constants so obtained are  given 
in  Table 16(b).
5 .3 .2  D issociation ra te  constant (k_ĵ )
125Ihe ra te  constant fo r d isso c ia tio n  of [ I  ]o4-BGT-AChR 
conplex was determined in 2 vays:-
(a) Frcm the re la tio n sh ip  = k^^L^ + k_̂ ^
Ih is  i s  explained in the previous sec tion  and the re su lts  
given in Table 17.
125(b) Displacement of [ I]o -̂BGT by unlabelled  oc-BGT
Ihe equation:-  
d(RL)
----------= k . , [R] [L] -  k T [RL]
d t




i f  the rebinding of the rad ioactive  ligand i s  prevented 1:^ , fo r
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Figure 44. Derivation of assoc iation  ra te  constants fron pseudo 
f i r s t  order treatm ent of binding data in Figure 42.
The slopes of the lin e s  give values fo r k 
For explanation see te x t.
Ob'
A dult:- 1. 10.44 x 10 ^ s
2. 14.24 X 10"^ s“
3. 18.70 X  lO"'^ s “
4. 21.26 X  lO '^ s”
5. 24.90 X  10"^ s“
6 . 29.05 X 10”  ̂ s"
F b e ta l:-  1. 10.23 x 10—4 —
2. 13.01 X  10-4 -
3. 17.67 X  10—4 —
4. 32.60 X  10—4 —
5. 29.13 X 10—4 —



















F o e t a l
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Figure 45. A p lo t of the values obtained fran  the previous 
graph aga in st ligand concentration
Ihe slope i s  equal to  the assocation ra te  constant, 
the y -in te rce p t i s  equal to  the d isso c ia tio n  ra te  constant, k_^; and 
the - X - in te rcep t i s  equal to  the equilibrium  constant, Kĵ , giving 
values o f : -
\ l = 5.52 X 10^ M ■
^ -1 = 7.01 X 10 ^ s
= 1.27 X -9 10 M
F o e ta l:-  k̂ ĝ  = 6.94 x 10^ M ^ s ^
k  T = 5.36 X 10 ^ s ^—1
= 0.77 X  10"9 M

























125Table 16. Kinetic constants for association of [ I]e(-BGT to AChR
(a) Second order treatm ent of data
AChR type SD n
5 -1 -1 (xlO^M s
Adult 1 10.60 3.79 6
2 8.20 1.93 6
Foetal 1 12.41 3.63 6
2 9.71 3.10 6
(b) Pseudo f i r s t  order treatm ent of data
AChR type k^^ k_^
(xIO^m"^ s"^) (xlO"^ s"^) (nM)
Adult 1 5.52 7.01 1.27
2 5.96 3.19 0.54
Bbetal 1 10.27 2.54 0.25
2 6.94 5.36 0.77
Each value i s  the mean of 2 determ inations
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example, adding a large  excess of non-radioactive ligand so th a t  a l l  
f ree  binding s i te s  become occupied by the added unlabelled  ligand . 
In teg ra tion  of equation 5 gives 
B
In — = -k  , t  ............ 6
and p lo ttin g  In B/B^ aga in st t  gives a l in e  with slope equal to
I OR
-k_^. The binding reaction  between [ I]oC-BGT and AChR was allowed
to  proceed to  equilibrium , a f te r  which, a t  an a rb itra ry  time ( t  =
1250), the rebinding of [ I]e(-BGT was prevented by the add ition  of a
large  excess of unlabelled  ««.-bgt, and the amount bound was
determined a t  various times th e re a f te r . Representative time courses
1 25fo r d isso c ia tio n  of fo e ta l AChR -  [ I  ]x.-BGT and a d u lt AChR -  
125[ I]oi-BGT complexes a re  shown in  Figure 46 and the re su ltin g  
logarithm ic p lo ts  in  Figure 47. The slopes of the lin e s  from the 
logarithm ic p lo ts  give estim ates of k_g .̂ The d isso c ia tio n  in both 
cases was seen to  be b iphasic , w ith a g rea te r con tribu tion  by the 
fa s te r  i n i t i a l  gjiase vdiich represented 60 -  80% lo ss  of bound ligand 
in 4 -  6 hours. A summary of the d isso c ia tio n  ra te  constants so 
obtained is  given in  Table 17.
5.3.3 Equilibrium D issociation Constant (K̂ )
(a) From the equation = k_^/k^^
See "Results" section  5 .3 .1  "Association Rate Constants" and
surtmary of re su lts  in Table 18.
1 8 7
125Figure 46. Dissociation of [ I ]o(-BGT-AChR complexes measured
a f te r  addition  of excess unlabelled  oC-BGT a t  equilibrium
Samples of detergen t ex trac ts  of human ad u lt o r fo e ta l 
125AChR were incubated with [ I]d-BGT in  the  presence and absence of
a large molar excess of unlabelled  ot-BGT. Excess unlabelled ligand 
-5(10 M) vas added and the reaction  stopped a t  various time 
in te rv a ls  by the add ition  of cold toxin binding assay buffer and 
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Figure 47. Logarithmic plots of the dissociation data in Figure 46.
The slopes of the lin e s  give values of which a re :-
A dult;- 0.58 x lO"* s ^
"6 “1 7.50 X  10 s
F o e ta l:-  0.70 x 10 ^ s ^
" 6  —*1 5.85 X  10 ° s
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125Tkble 17, K inetic  constants fo r d isso c ia tio n  of [ I]oC-BGT 
lab e lled  AChR ccmplexes
AChR type ( fa s t)  (slow)
—A —1 " 6  —1
(X  10 s (X  10 s
Adult 1 0.58 7.50
2 0.73 12.80
Foetal 1 0.70 5.85
2 0.74 9.10
Eàch value i s  the mean of 2 determ inations
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1 9R(b) Equilibrium binding of [ I]oC-BGT
125[ I]Ai-BGT binding to  de te rgen t-so lub ilized  fo e ta l and ad u lt
125AChR was studied  over a range of [ I ] pC-BGT concentrations, and 
represen ta tive  sa tu ra tio n  curves a re  shown in  Figure 48.
Non-specific binding, vAiich vas measured in the presence of excess 
unlabelled ot-BGT, was lin e a r  and accounted fo r 25 -  85% of the  to ta l  
binding. The sp e c ific  binding was sa tu rab le , describ ing  a 
rectangular hyperbola \diich can be reduced to  a s tra ig h t  l in e  form 
ky the Scatchard equation (Scatchard, 1949):- 
B -B  B
—  =   + _ 5 E L   7
F Ko ^
where:- B = concentration of binding s i te s
B = maximum concentration of binding s i t e s  ( ie . a tmax
equilibrium )
F = concentration of free  s i te s
= equilibrium  binding constant
Ihe i s  the negative rec ip rocal of the slope of the  l in e
and B i s  the in te rce p t on the abscissa . Figure 49 shows such max ^
s tra ig h t l in e  p lo ts  obtained fran  the data in  Figure 48 vhich
ind icate  a s in g le  c la ss  of binding s i t e s .  The B obtained frcm  ̂  ̂ max
Scatchard analysis agreed w ell w ith values obtained in  aitmonium 
sulphate assays. The re s u lts  were a lso  subjected to  analysis  by H ill  
p lo ts  (H ill, 1910):- 
B




125Figure 48. Equilibrium binding of [ IM-BGT to  detergent 
so lub ilized  human a d u lt AChR
Sairples of detergent ex trac ts  of adu lt and fo e ta l AChR
125were incubated with increasing concentrations of [ I]^-BGT in  the 
presence and absence of a large  molar excess of unlabelled o(-BGT, 
followed by p rec ip ita tio n  with ammonium sulphate. Bound 
rad io a c tiv ity  was recovered by f i l t r a t io n  on g lass f ib re  f i l t e r  
d iscs (see "Methods" section  7 .1 ).
125
A Total [ I]o(rBGT bound 
•  Non-specific binding 
o Specific  binding
Binding data fran  a rep resen ta tive  experiment. Points 
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Figure 49. Scatchard analysis and Hill plots of equlibrium binding
data frcm Figure 48.
Scatchard analysis
A dult:- K^(app) = 0.31 nM
P
binding s i te s
1OC.
®max = O'GO pnoles/ml [ "l]oC-BGT
r^ = 0.99
F o e ta l:-  K^(app) = 0.10 nM
P
binding s i te s
®inax = 0-45 pnoles/ml [^^^lU-BGT
r^ = 0.99
H ill p lo ts
A du lt:- = 0.90
r^ = 0.96
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125where:- B = concentration of [ I]o(-BGT bound
B = maximum number of binding s i te s  (determined franm x ^
in te rce p t on the y-ax is in the Scatchard p lo t)
125F = concentration of [ I]©<-BGT free
= a composite constant composed of the in tr in s ic  
d isso c ia tio n  constant, and in te rac tio n  fac to rs  
th a t determine the degree to  which i s  a lte re d  a t  
each d isc re te  binding s tep  
n = N„ = H ill c o e ff ic ien t
rl
Ihe p lo t q u an tita te s  the deviation  of a receptor-ligand 
in te rac tio n  fran  the c la s s ic  mass action  hyperbola, the  slope of the 
l in e  giving the H ill  c o e ff ic ie n t. Figure 49 shows the p lo ts  obtained 
fran  the data given in  Figure 48, fran  vhich i t  can be seen th a t 
s tra ig h t lin e s  were obtained, with slopes of 1.01 and 0.86 fo r ad u lt 
AChRs and 0.93 and 0.94 fo r  fo e ta l AChRs, which ind ica tes a s in g le  
c lass of binding s i t e s .  Table 18 gives a summary of the apparent 
values and H ill c o e ffic ien ts  obtained.
In summary, the re s u lts  show no d ifference  in  the in te rac tio n
125of AChR from human fo e ta l o r a d u lt muscle with [ I]«c-BGT. Both 
receptor types showed sim ila r assoc ia tion  and d isso c ia tio n  k in e tic s , 
and the d isso c ia tio n  d isp lays biphasic c h a ra c te r is tic s . Scatchard 
and H ill p lo ts  ind ica te  a s in g le  c la ss  of binding s i t e s .  Hie 
observed equilibrium  binding constants fran  the analysis  a re  higher 
than those obtained fran  the r a t io  of ra te  constan ts, because the 
AChR concentration used was higher than the in  order to  achieve 
se n s it iv i ty  in the assay (Cuatrecasas & Hollenberg, 1976).
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Ihble 18. Equilibrium binding constants and H ill  co e ffic ien ts  fo r
125binding of [ I]oC.-BGT to  detergent e x trac ts  of AChR
AChR type SD Ng
(xlO ^M)
SD
Adult 1 2.35 0.79 1.01 0.03
2 0.35 0.11 0.86 0.20
Etoetal 1 1.06 0.71 0.93 0.14
2 0.28 0.13 0.94 0.07
Each value i s  the mean of a t  le a s t  3 determ inations.
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6. In te rac tio n  of human ad u lt and fo e ta l AChRs with anti-(AChR) 
an tibodies in myasthenic serum and IgG
Ihe natu re  of the an tig en ic ity  of the fo e ta l AChR was 
canpared w ith th a t  of the ad u lt AChR,
6.1 R elationship  between an tig en ic ity  of fo e ta l AChR and fo e ta l age
125Increasing concentrations of [ I]o(-BGT -  lab e lled  fo e ta l
AChR fran  ind iv idual foetuses were incubated with a fixed  amount of
myasthenic serum (p a tien t 10), producing a sa tu ra tio n  curve fran
which the anti-(AChR) antibody t i t r e  was determined. Figure 50(a)
shows the  p lo t  of anti-(AChR) antibody t i t r e  against fo e ta l  age,
fran  vhich i t  can be seen th a t the antibody t i t r e  measured stays
fa ir ly  constan t with fo e ta l age and agrees well with values obtained
by using a d u lt muscle AChR. Ihe assay was a lso  performed "in
reverse", vhere a large  molar excess of the same myasthenic serum
125was incubated w ith a constant lim ited  amount of [ I]oC-BGT -  
labe lled  AChR to  give the percentage p rec ip ita tio n  of the lab e lled  
complex. Fran Figure 50(b) i t  can be seen th a t the percentage 
p rec ip ita tio n  of labe lled  AChR remained constant with increasing 
fo e ta l age.
Since there  did not appear to  be any s ig n if ic a n t d ifference  
in the in te rac tio n  of anti-(AChR) antibody with AChR of increasing 
fo e ta l age, d if fe re n t  aged foetuses were canbined together to  
provide s u f f ic ie n t  muscle to  attem pt p u rif ic a tio n  of AChR and 
conparison w ith p u rified  ad u lt AChR.
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Figure 50. R elationship  between an tig en ic ity  of fo e ta l AChR and 
fo e ta l age
125Duplicate samples of [ I]<<-BGT lab e lled  AChR (100 p i, 
lab e lled  in  the presence and absence of benzoquinonium ch lo rid e ), 
were incubated w ith a fixed  volume of myasthenic serum (frcm p a tie n t 
10), followed by p rec ip ita tio n  with goat anti-(human IgG) antiserum  
and recovery by cen trifugation  (see "Methods" section  8 ). Each point 
represen ts the mean of 3 separate determ inations.
125(a) R elationship  between antibody t i t r e  and fo e ta l age. [ I]oC-BGT 
lab e lled  AChR (0.1 -  1.0 nM) vas incubated with a fixed 
concentration of myasthenic serum (5 p i ) ,  followed by 
p re c ip ita tio n  of the immune complex as described above.
125(b) R elationship  between percentage p rec ip ita tio n  of [ I]oC-BGT
125lab e lled  AChR by excess myasthenic semm and fo e ta l age. [ I] 
o(-BGT lab e lle d  AChR (0.15 nM) was incubated with a la rge  molar 
excess (10 p i) of serum, followed by p rec ip ita tio n  of the  immune 
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6.2 A ccmparison of the in te rac tio n  of ad u lt and fo e ta l human AChRs 
with myasthenic sera  and IgG
Serum and IgG fran  each of 3 nyasthenic p a tien ts  were assayed 
fo r anti-(AChR) antibodies using 'crude' and p u rified  
preparations of fo e ta l and ad u lt human AChR in the radioiirmunoassay 
(see "Methods" section 8 ). In each case, increasing concentrations 
of antigen were te s te d , producing a sa tu ra tio n  curve from which 
antibody t i t r e  and a f f in i ty  were determined. Representative 
sa tu ra tio n  curves fo r the binding of a f f in i ty  p u rif ied  a d u lt and 
fo e ta l human AChR to  anti-(AChR) antibodies from one myasthenic 
serum and corresponding IgG are  shown in Figures 51 -  53. The 
and apparent values frcm the sa tu ra tio n  curves fran  th is  and 2 
other p a tien ts  a re  given in Table 19. Ihe curves were f i t t e d  by the 
Maximum Liklihood Method (Silvey, 1975), which, since normal e rro rs  
of y-values were assumed, i s  the same as the le a s t  squares method 
fo r l in e a r  regression , ie  the sum of squared d istances from the 
p lo tted  points to  the f i t t e d  curve a re  minimized. The concept of 
curve f i t t i n g  is  stra igh tforw ard , but the nature of the  curve makes 
i t  necessary to  perform the minimization i te ra t iv e ly . In order to  do 
th is  a ccmputer standard minimization package vas used, and the 
curve f i t t e d  was of the form:-
Y* - 1
y = oC —̂   where : —
r +  /S
y  = a measure of how quickly y approaches as
X increases
log (2+/3)
 ____  —  is the x-value at half maximal saturation.
log y
2 0 3
Figure 51. Saturation curves for the binding of purified adult
(SVD) AChR preparations with anti-(AChR) antibodies in 
myasthenic serum and IgG fran  P a tien t 10.
An appropriate d ilu tio n  of serum o r IgG was assayed with 
increasing concentrations of antigen (see "Methods" section  8 ). Each 
po in t i s  the mean of duplicate  determ inations. The values a re  taken 





























Figure 52. Saturation curves for the binding of purified adult
(RTA) AChR preparations with anti-(AChR) antibodies in
nyasthenic serum and fran  P a tien t 10.
An appropriate  d ilu tio n  of serum or IgG was assayed with
increasing concentrations of antigen (see "Methods" section  8 ). Each
point i s  the mean of dup licate  determ inations. The values a re  taken 
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Figure 53. Saturation curves fo r the binding of pu rified  fo e ta l 
AChR preparations with anti-(AChR) antibodies in 
myasthenic serum and IgG frcm P atien t 10.
An appropriate  d ilu tio n  of serum or IgG was assayed with 
increasing concentrations of antigen (see "Methods" section  8 ). Each 
po in t i s  the mean of dup licate  determ inations. The values a re  taken 





























Table 19. Comparison of binding data for myasthenic sera and 
IgG with d iffe re n t human AChR preparations
Data a re  taken fran : 3 independent se ries  of assays 
using 2 d if fe re n t fo e ta l AChR preparations; 3 independent 
se rie s  of assays using 3 d iffe re n t adu lt SVD (severe vascular 
d isease) preparations; 1 se rie s  of assays using 1 a d u lt RTA 
(road t r a f f i c  accident) AChR preparation. values are  
re fe rred  to  as app. (apparent K^) in th a t they represen t 
average values fo r each sample of polyclonal an tise ra  te s te d .
* Number of points on binding curve.
-10+ A nti- (AChR ) antibody t i t r e  x 10 M.
2
X is  a measure of the s im ila rity  of pairs of binding
curves (see "Results" section  6 .2 ). S ign ifican t
d ifference  a t  the 95% leve l between the two curves 
2
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The curve i s  of s im ila r form to  the Michaelis-Menten equation Wiich 
can be expressed a s : -
o(x
y =
0  +  X
and gives a rectangular hyperbola. The in troduction  of the  term y
in to  th is  equation enables the curve to  f la t te n  out a t  lower values
of X  than is  otherwise possib le . S tra ig h t l in e  deriva tions fran  the
sa tu ra tio n  curves had been t r ie d , but were discounted since they did
not f i t  well due to  the bias obtained when double- or
h a lf-rec ip ro ca l p lo ts  were f i t t e d .  Even the use of weighted l in e a r
regression fa ile d  to  give estim ates of K and V vhich were  ̂  ̂ m max
consisten t with values obtained by "eye" d ire c tly  fran  the o rig in a l
sa tu ra tio n  curves. Standard e rro rs  fo r the parameter estim ates were
2conputed fran  the estim ated values of (h , y , c r  ( the  estim ated
variance) and the x- and y- values. The usual approximate 95%
confidence in te rv a l i s  then p + 2 x S.E. (p), vrtiere p i s  the  parameter
estim ate. The Maximum LiM.ihood Theory makes i t  possib le  to
construct an asymptotic lik iihood  r a t io  t e s t  which can be used to
determine whether the same curve can be f i t t e d  to  2 data s e ts .  In
order to  determine whether V and the apparent K, fo r a d u lt andmax d
fo e ta l antigens are  the same the following n u ll hypothesis 
te s te d :-
: the two curves, both of the form:-
yX -  1 
y = üL  -------
y x + f
are  the same, ie  the , Y  parameters are  the
same fo r both curves 
against the a lte rn a tiv e  hypothesis:-
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: the  two curves are  d if fe re n t, ie  they have
d iffe r in g  o(,/S , y  param eters.
2
The s t a t i s t i c  X m s  looked a t ,  where
2 RSS fo r pooled curve
X = (s ize  of pooled sairple) x log
RSS curve 1 + RSS curve 2 
RSS = res idua l sum of squares
= sum of squares of d istances of poin ts from the 
f i t t e d  curve.
2 % I f  the  two curves are  the same, then X w ill  have an approximately X
(chi-squared) d is tr ib u tio n  with 3 degrees of freedom; whereas i f  the
2 2 curves a re  d if fe re n t, the value of X w ill  be la rg e r . From X
ta b le s , using 3 degrees of freedom, i t  can be seen th a t the value of 
2
X needs to  exceed 7.8 to  be s ig n if ic a n t a t  the 95% le v e l, ie  a 
2value of X g rea te r than 7.8 would mean th a t the curves were
2
s ig n if ic a n tly  d if fe re n t. X values fo r the p a irs  of sa tu ra tio n
curves obtained fran  p u rified  preparations a re  given in Table 19.
Parameters obtained fran  the various sa tu ra tio n  curves a re  shown in
Thble 19, in vhich i t  can be seen th a t the values of anti-(AChR)
antibody t i t r e  and apparent fo r a given serum or IgG sample a re
very s im ila r irre sp ec tiv e  of whether p u rified  ad u lt AChR or p u rif ied
2
fo e ta l AChR is  used as the antigen . This i s  re fle c ted  in the X 
values obtained frcm p a irs  of f i t t e d  curves, which in no case 
exceeds 4.10. Crude e x tra c ts , in which receptor concentrations were 
frequently  below 0.5 nM, were le ss  su itab le  fo r these purposes, 
since concentration of the antigen , necessary in  order to  obtain 
complete sa tu ra tio n , led  to  a g rea te r s c a tte r  of poin ts and 
incomplete binding curves. The v a lid ity  of using amputated muscle 
from p a tien ts  with d iab e tic  gangrene or severe vascular d isease  as a
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source of normal junctional AChR in  the assay was checked by using 
AChR p u rified  frcm normal ad u lt muscle amputated following a road 
t r a f f i c  accident to  assay serum and IgG frcm p a tie n t 10. No 
s ig n if ic a n t d ifference  was found between the f i t t e d  sa tu ra tio n  
curves so obtained and those obtained with AChR frcm ischaemic 
muscle (Figure 52, Table 19).
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DISCUSSION
For many years the neuromuscular junction has been recognized 
as the general region of the defec t in the human d isease  myasthenia 
grav is (Walker, 1934). This complex neurological syndrome i s  the 
re s u l t  of an autoimmune response d irec ted  ag a in st the n ic o tin ic  AChR 
a t  the post-synap tic  membrane, where the impairment of the function 
of the recep to r c h a ra c te r is t ic a lly  produces fla c c id  p a ra ly sis  and 
s u s c e p tib il ity  to  fa tigue  of sk e le ta l muscle.
The physio log ical function of the AChR a t  the neuromuscular 
junction i s  to  in te ra c t  with the neurotransm itter acety lcholine  
(ACh ), thus producing a ohange in perm eability  of the post-synaptic  
membrane, vhioh eventually  leads to  muscle con trac tion . D irect 
measurement of AChR function in  i t s  membrane environnent by 
e lec trophysio log ica l methods has been complemented by the more 
recen t advances in  biochemical techniques vhich, f a c i l i ta te d  by the 
unique ligand ot-BGT and a rich  source of AChR, namely Torpedo 
electrop laques, have enabled the iso la tio n  and ch arac te riza tio n  of 
the AChR -  th is  has necessita ted  the development of appropriate  
biochemical assays. The most widely used method fo r assay of 
iso la ted  AChRs r e l ie s  on the fa c t  th a t the binding s i t e  fo r the 
na tu ra l tran sm itte r  i s  a highly sp e c ific  one. However, in p ra c tic e , 
ACh i s  not the p refe rred  ligand fo r use, as the  in te rac tio n  of ACh 
with i t s  recep to r i s  read ily  rev e rs ib le  under experimental 
conditions (K  ̂ ^  10”^M), which is  to  be expected i f  the 
neurotransm itter i s  not to  cause pharmacological blockade; and a lso , 
"crude" p reparations of AChR contain high lev e ls  of endogenous AChE 
vhich leads to  rap id  hydrolysis of ACh (Eldefrawi e t  a l . ,  1972). The
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requirements fo r a highly sp e c if ic , high a f f in i ty ,  non-degradable 
ligand a re  met by oC-BGT, which can be rad io labe lled  to  high sp e c ific  
a c t iv i ty  without serious loss of b io log ical a c t iv i ty .  A dditionally , 
the  recep to r-ligand  complex can be separated from free  ligand on the 
b asis  of MW, charge d ifference  and immunoreactivity and thus 
provides a highly v e rs a ti le  too l fo r id e n tif ic a tio n  and q u an tita tio n  
of AChR. Furthermore, by using the toxin in conjunction w ith hurran 
AChR, i t  has been possib le  to  develop se n s itiv e  methods fo r the 
de tec tion  and determ ination of anti-(AChR) an tibod ies in sera  from 
MS p a tie n ts  (Lindstrom e t  a l . ,  1976a).
[ I]o^BGT as a probe fo r n-AChR
Ligands fo r binding assays are  commonly rad io labe lled  with
tr itiu m , o r , in  the case of p ro te in s , with iodine. Because tr itiu m
replaces H atoms usually  present in  the ligand , t r i t i a t i o n  produces
lab e lled  ligands which a re  b io lo g ica lly  ind istingu ishab le  from th e i r
native  coun terparts. A fu rth er advantage stems from the long
radiochemical h a lf  l i f e  of tr itiu m  (12.26 years) vhich, coupled with
i t s  low rad ia tio n  energy (0.0186 Mev), allows extended storage
without the need fo r frequent preparation or re -p u r if ic a tio n .
However, sp e c if ic  ra d io a c tiv it ie s  obtained from the in troduction  of
[^H] in to  a molecule are  much lower than can be achieved by
rad io iod ination  eg 1 atom of provides the same number of
3 131d is in te g ra tio n s  per u n it time as 600 atoms of [ H]. [ I]  i s  
u n a ttrac tiv e  because of i t s  sh o rt h a lf  l i f e  (8 days), compared w ith 
[125i] j^yg) and i t  i s  therefo re  which i s  usually  the  I
isotope used fo r rad io lab e llin g . A disadvantage of using 
rad io iodinated  pro teins i s  the radiation-induced d estruc tion  vhich
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frequen tly  a l te r s  b io log ica l a c t iv i t ie s  of p ro te ins and produces
v a riab le  m ixtures of labe lled  products with d if fe re n t  p ro p e rtie s .
However, th is  disadvantage is  often  o f fs e t  by the high re la tiv e
sp e c if ic  ra d io a c tiv it ie s  achieved, vhich have proved invaluable in
de tec ting  small q u a n titie s  of b io log ical m ate ria ls .
A number of t r i t i a t i o n  methods have been applied  to
neurotoxins (eg oc- bCjT) th a t  sp e c if ic a lly  re a c t with n-AChRs. Mono
[^H]acetyl-o(-BGT (Barnard e t  a l . ,  1971) has the same a f f in i ty  fo r
muscle recep tors as native toxin (Barnard e t  a l . ,  1975), but has
sp e c if ic  ra d io a c tiv it ie s  too low fo r se n s itiv e  analyses of most
c e l lu la r  recep to rs. N-[p ro p io n y l-^ ] propionylated ô BGT (Dolly e t
a l . , 1981) on the o ther hand, has a sp e c if ic  ra d io a c tiv ity  of 46
Ci/mmol, is  90 -  100% b io log ica lly  ac tiv e  and has been shown to  be 
125as se n s itiv e  as [ I]ot-BGT in  the determ ination of A(ZhR and
anti-(AChR) an tibod ies. In view of the cumbersome counting
procedures associated  with [^H], iodination  was se lec ted  fo r rou tine
use and gave consis ten tly  lab e lled  pro tein  with high sp e c ific
ra d io a c tiv it ie s  (see "Results" section  1 .1 ) . When the mono- and
d i-io d in a ted  deriva tives of ot-BGT were compared, w ith [^H]<-BGT, in
th e ir  reac tion  with n-AChR in binding assays, [̂ H]oC-BGT,
125unfractionated  [ I]«t-BGT and mono-iodinated ot-BGT gave sim ila r 
re s u l ts ,  v a lid a tin g  th is  choice. The binding of d i-iod ina ted  ot-BGT 
m s co n sis ten tly  lower (see "Results" section  1 .6 ) , an observation 
a lso  reported  by Vogel e t  a l .  (1972) and a ttr ib u te d  to  a p a r t ia l  
unfolding of the toxin molecule leading to  a reduced a f f in i ty  
towards toxin  binding s i te s  (Lucasiewicz e t  a l . ,  1978).
The values obtained here fo r b io log ical a c t iv i t ie s  of the 
d if fe re n t  lab e lled  toxins depended on the method of separation of
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bound and free  species -  values obtained by gel f i l t r a t i o n  being
co n sis ten tly  higher than those obtained fran  f i l t r a t i o n  on
DEAE-cellulose f i l t e r  d isc s . One possib le  explanation fo r th is  could
be th a t iodinated «c-BGT might aggregate, and v h ile  th is  would s t i l l
pass through DEAE-cellulose f i l t e r s  as a function of i t s  charge,
125aggregates may co-chronatograph with [ I  ] «x-BGT-AChR upon gel 
f i l t r a t io n  and give the apparent increase in b io lo g ica l a c t iv i ty  
observed (Krohn e t  a l . ,  1972; Sherman e t  a l . ,  1974; Ja ilkhan i e t  
a l . ,  1984).
Detergent ex trac tion  and p a r t ia l  p u rif ica tio n  of AChR
AChRs fran  severa l species were so lu b ilized  using the
non-ionic detergent T riton X-100. Sane detergent e x tra c ts  of human
ad u lt and fo e ta l AChR were p u rified  by a f f in i ty  chranatography on
oC-toxin coupled Sejiiarose-4B followed by b io sp ec ific  e lu tio n  with
carbachol and concentration on DEAE-cellulose.
Yields of AChR obtained fran  marrmalian muscle are
consisten tly  lower than those obtained fo r Torpedo (see Table 20),
vhich n ecessita tes  the use of a bulk source of t is s u e . Post mortem
muscle is  one such source, but the low y ie lds of AChR obtained fran
125such tis su e  (0.1 pmol [ I]«<-BGT binding s i te s /g  muscle) makes i t  
an unsa tisfac to ry  s ta r tin g  m ateria l. Denervation of muscle, vhich is  
followed by p ro life ra tio n  of AChR (see "In troduction" p. 1o) i s  one 
method vhich has been used in  experimental aniitals to  increase the 
y ie ld  of AChR; however, su rg ica l denervation of human ad u lt muscle 
is  c le a rly  not fe a s ib le . Arrputated limbs fran  diseased p a tien ts  are  
a read ily  ava ilab le  source of muscle, and have the added advantage 
th a t the muscle can be quickly d issec ted  and frozen, so reducing the
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lik lihood  of p ro teo ly tic  degradation (Manoi & Lennon, 1982). Muscle
from some p a tien ts  may be ischemic and p a r t ia l ly  denervated, but by
no means provides a  co n sis ten t source of ex tra -ju n c tio n a l AChR (see
below). The AChR content of human ad u lt muscle e x tra c ts  m s
v a riab le , ranging fran  0.23 -  2.19 pmol oC-BGT binding s i te s /g
muscle, vrfiich i s  w ithin the range quoted by o ther workers (see Table
20). There a re  severa l possib le  reasons fo r the v a r ia b il i ty  observed
-  p ro teo lysis  may occur between amputation and freezing  of muscle a t
-80°C, and although the duration of th is  in te rv a l m s  rou tine ly  le s s
than one hour, the  inadequate y ie ld s of AChR obtained fran  post
mortem tis su e  supports the lik lihood  th a t post mortem d e te rio ra tio n
occurs. I t  i s  a lso  possib le  th a t muscle sto red  a t  -80°C may lo se  i t s  
125[ I]o<-BGT binding a c t iv i ty  during the freeze-thaw cycle o r during 
prolonged sto rage, however, there  m s  no evidence to  suggest th a t 
th is  m s  so. The most l ik e ly  explanation fo r the v a r ia b il i ty  of AChR 
y ie ld  is  the inheren t v a ria tio n  in the muscle samples used. Most 
muscle samples were obtained from p a tien ts  su ffe ring  from vascular 
problems or d iab e tic  gangrene, and i t  i s  l ik e ly  th a t  th is  tis su e  has 
varying degrees of ischemia with accompanying tis su e  a u to ly s is .
Also, most amputees were older than 60 years of age and motor 
innervation in such p a tien ts  i s  reduced (Tanlinson & Irv ing , 1977). 
This, th e re fo re , increases the lik lihood  of p ro life ra tio n  of AChR 
and production of a heterogenous population of AChRs in these muscle 
samples (Dolly, 1979). One muscle sample which could be c la s s if ie d  
as normal, innervated tis su e  (obtained fran  the victim  of a road 
t r a f f i c  accident) gave a y ie ld  of 0.39 pmol oc-B(?r binding s i te s /g  
muscle. Although th is  value i s  a t  the lower end of the range of 
values obtained, i t s  in te rac tio n  with anti-(A(3hR) antibodies in
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T&ble 20. Yield of AChR frcm mammalian skeletal muscle types
Species Yield AChR 
(pmol/g wet weight)
Reference
(Torpedo > 1700 Eldefrawi e t
a l . ,  1972)







Almon e t  a l . ,  1974 
Berg e t  a l . ,  1972 
Berg e t  a l . ,  1972 
Dolly & Barnard, 1977 
Miledi & P o tte r, 1971
Chick -  innervated
-  denervated
-  embryonic
0.5 -  0.8 ^
14 -  31 
27 -  36 J
Sumikawa e t  a l . ,  1982b




(3otti e t  a l . , 1983
Cat -  denervated 88 Dolly & Barnard, 1977
Calf -  fo e ta l 2.5 -  5.3 
4.1
(3otti e t  a l . ,  1982 
Einarson e t  a l . ,  1982
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Species Yield AChR Reference
(pmol/g wet weight)






-ce reb ra l d isease 
-d iab e tic  and 
peripheral neuropathy '>2.25 -  5, 
-m alignant bone tumour 0.44 -  1, 
-myasthenic 0.12
-road t r a f f i c  accident 0.39
0.04 -  0
0.18 -  2
0.23 -  2
Mcmoi & Lennon, 1982
Stephenson e t  a l . ,  1981 






th is  th e s is
Human -  fo e ta l
-prostaglandin  induced 0.6 -  1.9 th is  th e s is
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myasthenic serum was comparable with th a t  of muscle samples giving 
higher i n i t i a l  y ie ld s  of AChR (see "Results" section  6 .2 ).
Foetal muscle i s  another source of human AChR, and generally
represents normal, undiseased muscle. The y ie ld s  of AChR obtained
12Sfrom such tis su e  (0.61 -  1.89 pnoles [ I]ct-BGT binding s i te s /g  
muscle, mean value + SE (n) = 1.20 + 0.10 (15)) were f a i r ly  constant 
over the age range studied  (see "Results" section  6 .1 ), and were 50% 
higher than those obtained fo r ad u lt muscle. In viev of the fa c t 
th a t AChRs are  p resen t over the e n tire  surface of developing 
nyotubes (Bevan & Steinbach, 1977), the y ie ld s  of AChR in fo e ta l 
muscle might have been expected to  be much higher than those fo r 
ad u lt AChR. However, denervation of a d u lt muscle re su ltin g  in 
p ro life ra tio n  of receptors may explain these re s u l ts .
Detergent e x trac ts  of r a t  muscle A(ZhR provided a  much more 
consisten t y ie ld  of AChR (see "Results" section  2 .3 ) , probably 
representing a more homogenous source of AChR types.
The method used fo r p u rif ic a tio n  of AChR was e s se n tia lly  the 
same as th a t described by Stephenson e t  a l .  (1981), vhich i s  a 
m odification of methods described Wonnacott e t  a l .  (1980) fo r  the 
p u rif ic a tio n  of Torpedo AChR. The method aims to  reduce p ro teo ly sis  
e ffe c ts  by reducing the time taken fo r the preparation to  a minimum, 
m aintaining a l l  operations, where possib le , a t  4°C, and including a 
broad spectrum of protease in h ib ito rs  and a n ti-b a c te r ia l  agents. The 
use of an ti-p ro teases  has been shown to  improve the recovery of 
in ta c t  p ro teins upon p u rif ic a tio n  (Silman e t  a l . ,  1978; Dolly & 
Barnard, 1975; Lindstrcm e t  a l . ,  1979a) with the proviso th a t th is  
is  accompanied hy accelera ted  p u rif ic a tio n  times and use of low 
(4°C) tem perature. The presence of lysosomal enzymes has been
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danonstrated in muscle c e l ls  of immature animals (Gutmann e t  a l . ,  
1976), ad u lt r a t  diaphragm (Parsons & Pennington, 1976) and human 
muscle (Bury & Pennington, 1975), and i t  i s  therefo re  l ik e ly  th a t 
a f te r  homogenization and ex trac tion  of muscle, p ro teo ly tic  enzymes 
are  re leased . For th is  reason a number of an ti-p ro teases were added 
(see Table 21).
The use of a l l  these measures perm itted the iso la tio n  of
p u rified  ad u lt AChR with sp ec ific  a c t iv i t ie s  w ithin the range of
values quoted in  the l i te ra tu r e  (see Table 22). Values fo r a d u lt
human AChR were 0.01 -  0.8 pmol o(-BGT binding s i te s /g  p ro te in , and
for fo e ta l AChR were 0.01 -  0.1 pmol o<rBGT binding s i te s /g  muscle;
compared with a range of 0.19 -  11 |jmol/g reported by o ther workers.
The re la tiv e ly  low sp e c if ic  a c t iv i t ie s  may be due to  measurement of
non-receptor p ro te in , and although co -p u rifica tio n  of recep tor and
non-receptor p ro teins i s  possib le , i t  i s  more l ik e ly  to  r e s u l t  from
an over-estim ation of the p ro tein  concentration, vhich in most cases
was a t  the lower end of the s e n s i t iv i ty  of the assay. Also, since
the receptor i s  an in te g ra l membrane pro te in  with bound detergent
(Meunier e t  a l . ,  1972b; K arlin e t  a l . ,  1979), i t  may behave
d iffe re n tly  from the standard p ro tein  used in the assay. The
function of the receptor may be a lte re d  during the p u rif ic a tio n
125procedure, which iray a l t e r  i t s  a b i l i ty  to  bind [ I]oC-BGT. I t  i s  
known th a t T riton X-100 in h ib its  receptor function (Fischbach &
Lass, 1978), so so lu b iliz a tio n  of the receptor may con tribu te  to  
lo ss  of a c t iv i ty .  The receptor i s  a lso  exposed to  high 
concentrations of agonist (carbachol) during e lu tio n  from the 
(6toxin a f f in i ty  column, and th is  i s  thought to  cause d esen s itiza tio n  
of the recep tor, accaipanied by a slow change in conformation and
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*fable 21. Mode of action of protease inhibitors
In h ib ito r Mode of action Reference
EDTA In h ib its  calcium -activated Dayton e t
proteases a l . ,  1976
Benzethonium
chloride
Bacteriocide Povl Elo, 1963
IMSF Irre v e rs ib le  block a t  





In h ib its  b a c te ria l growth
B acitracin A ntib io tic  polypeptide 
from B acillus s u b t i l is  
and licheniform is
Desbuquois e t  
a l . ,  1974
Benzamidine In h ib its  conversion of 
collagen to  procollagen
Byers e t  a l . ,  
1975





Thble 22. Specific  a c t iv i t ie s  of p u rif ied  AChR fran  mammalian 
sk e le ta l muscle
Species
Specific
a c t iv i ty
(pnol/|ig)
Reference





2.8 -  7.5
Brockes & H all, 1975a 
Kemp e t  a il., 1980 
Brockes & H all, 1975a 
Kemp e t  a l . ,  1980





Sumikawa e t  a l . ,  1982
Rabbit -  denervated 4.1 G otti e t  a l . ,  1983
Cat -  denervated 10 -  11 Shorr e t  a l . ,  1978; 1981
Càlf -  fo e ta l 1.5 -  2.5 
6
7.5
Lindstrcm e t  a l . ,  1979b 
G otti e t  a l . ,  1982 
Einarson e t  a l . ,  1982
Human -  ad u lt
Human -  fo e ta l
5 - 7  Mcmoi & Lennon, 1982
0.5 -  3.5 Stephenson e t  a l . ,  1981
0.01 -  0.8 th is  th e s is
0.01 -  0.1 th is  th e s is
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125lo ss  of a b i l i ty  to  bind [ I]e>d-BGT (Heidmann & Changeux, 1979).
125Ih is  may account fo r the low (less  than 20%) recovery of [ I]oC-BGT 
binding a c t iv i ty  a f te r  the o(-toxin a f f in i ty  chromatography stage, 
although the use of much lower concentrations of the more potent 
agonist benzoquinonium chloride instead  of carbachol as the 
competitor does not lead to  b e tte r  recoveries (G ill Turnbull, 
personal communication). The absorption of AChR from muscle ex trac ts  
to  immobilized oc-toxin vas found here to  be 90 -  95%, vhich is  
g rea te r than th a t obtained by Mcmoi & Lennon (1982), vho rou tine ly  
absorb 52% AChR and G otti e t  a l .  (1982) who find  49 -  66% absorption 
of AChR. The subsequent recovery of AChR from (/-toxin beads found 
here i s  a lso  higher (20%, compared to  10%), which m y be a 
re f le c tio n  of the higher degree of su b s titu tio n  of (/-toxin onto the 
Sepharose-4B beads used here.
The very low sp e c ific  a c t iv i t ie s  obtained fo r p u rif ied  human 
fo e ta l AChR can possibly be a ttr ib u te d  to  i t s  unstable toxin binding 
a c t iv i ty  (see "Results" section  2 .2 ) , both in detergent e x trac ts  and 
in p u rif ied  preparations, whicdi m y  r e s u l t  from the high lev e ls  of 
proteases p resen t in fo e ta l t is su e , as discussed above. Reduced 
amounts of l ip id s  present in fo e ta l t is su e  compared w ith ad u lt 
(Hall, 1981) m y a lso  con tribu te  towards th is  observation. Lindstr(3n 
and co-workers (19  806 have shown th a t  the continual presence of 
soybean l ip id  in mixed m icelles , with (oholate, i s  required to  
prevent ir re v e rs ib le  in ac tiv a tio n  of the cation  channel in  Torpedo. 
Greater in s ta b i l i ty  of ot-BGT binding s i te s  in  fo e ta l humn brain as 
cxmpared w ith ad u lt r a t  has a lso  been observed (Sue Wonnacott, 
personal communication). In s ta b i l i ty  of fo e ta l AChR compared with 
ad u lt AChR m y r e f le c t  s tru c tu ra l d ifferences between the two
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receptor types, since s ta b il iz a tio n  of AChR does not accur u n t i l  
synaptogenesis is  complete (Changeux & Danchin, 1976; Anderson,
1983) and may occur as a r e s u l t  of p o s t- tra n s la tio n a l m odifications 
(see "Introduction" p. 17 ).
Radioimmunoassay of anti-(AChR) antibodies
The radioimmunoassay fo r de tection  of anti-(AChR) antibodies 
125uses [ IK-BGT -  lab e lled  human AChR as an tigen , vhich i s  used to
p re c ip ita te  anti-(AChR) antibodies in myasthenic serum, and th is
complex is  then p rec ip ita ted  using a second antibody (see
"Introduction", Figure 6 ). Basic radioimmunoassay procedures have
been reported ty  a number of groups of workers (Lindstrcm e t  a l . ,
1976a; Lindstrcm, 1977; Monnier & Fulpius, 1977; L efvert e t  a l . ,
1978; Newscm-Davis e t  a l . ,  1978; Dwyer e t  a l . ,  1979; T indall e t  a l . ,
1981). Hcwever, the assay ccmprises several stages which engenders
considerable v a ria tio n s in seme aspects of the published procedures,
p a rtic u la rly  the exact experimental conditions. The procedure
described here optimizes the conditions of the radioimmunoassay,
providing an overa ll method which i s  f le x ib le , reproducible and
su itab le  fo r routine app lica tion , and can, i f  necessary, supply a
speedy determ ination fo r the c lin ic ia n .
Maximal formation of lab e lled  antigen was achieved by
125incubating a 10-fo ld  molar excess of [ I]cC-BGT with AChR, a f te r  
vhich, incubation of labe lled  toxin-AChR ccmplex w ith myasthenic 
sera was performed, and found to  be ccmplete a f te r  16 h a t  4°C or 2 
h a t  23°C. Incubation of [^^^I]ef-B(3T-AChR-antibody ccmplex w ith goat 
anti-(human IgG) was s im ila rly  ccmplete a f te r  16 h a t  4°C or 2 h a t  
23°C. T itres  f e l l  s l ig h tly  when incubation times of g rea te r than 48
I l l
h were used. S e ria l d ilu tio n s  of sera were made in order to  ensure
su f f ic ie n t  molar excess of antigen , and ra tio s  of 3:1 were found to
be su f f ic ie n t  to  ensure maximal p rec ip ita tio n  of anti-(AChR)
an tibod ies. Maximal fonnation of receptor-antibody complexes
requires a lso  a minimum concentration of AChR v^ich depends upon the
the d isso c ia tio n  constants of the receptor-antibody complexes. A 
125value of 0.5 nM [ I](/-BGT binding s i te s  m s  su f f ic ie n t  to  ensure
maximum fonnation of complex, although higher concentrations of
receptor may well be advantageous in the case of some sera  fo r vhich
0.5 nM may be a minimum acceptable fig u re .
S u ffic ien t antigen concentration of e x trac ts  having only low
amounts of AChR could be achieved by vacuum d ia ly s is  concentration,
so th a t most detergent ex trac ts  could be u t i l iz e d  in the
radioimmunoassay. AChR e x trac ts  concentrated in th is  way showed an
125increase in the non-specific binding of [ I]oC-BGT, but 
nevertheless appeared to  lead to  accurate antibody t i t r e s .
Although there  has been one repo rt (Bradley e t  a l . ,  1978) 
th a t the use of r a t  muscle AChR as an antigen in the 
radioimmunoassay gives the same anti-(AChR) antibody t i t r e  as when 
pu rified  human AChR is  used, most o ther groups find  th a t the  use of 
r a t  AChR as antigen gives lower antibody t i t r e s  than vhen human AChR 
is  used, and the percentage of p o sitiv e  re s u lts  i s  generally  lower 
(60 -  70%, compared with 80 -  90% fo r human -  M ittag e t  a l . ,  1981; 
1984; Savage-Marengo e t  a l . ,  1979; Komfeld e t  a l . ,  1981). The use 
of muscle fran  o ther mammalian species as an a lte rn a tiv e  source of 
AChR is  not to  be reccmmended a s , although such tis su e  may give a 
higher, more consisten t y ie ld  of AChR, i t  i s  c le a r  th a t  these , too, 
give r is e  to  generally  lower anti-(AChR) antibody t i t r e s  when used
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in  the RIA (Roses e t  a l . ,  1981; Mickle e t  a l . ,  1983; G otti e t  a l . ,
1983; Williams e t  a l . ,  1984).
The procedure fo r radioimmunoassay of anti-(AChR) antibodies
outlined in the "Methods" (section 8) allows the determination of
reproducible t i t r e s .  Repeat determ inations on an individual serum
125sample using a s in g le  e x tra c t of AChR and fresh ly  prepared [ I]
1 25(k-BGT gave values of 2.99 + 0.04 nM [ IK-BGT binding s i te s  (+SE, 15
assays ). Repeat assays of the same serum sample using a sing le
125e x tra c t of AChR and 4 d if fe re n t preparations of [ I]oC-BGT gave
125values of 3.23 + 0.08 nM [ I]oC-BC3T binding s i te s  (+SE, 15 assays).
Repeat assays of a  d if fe re n t serum sample using a sin g le  preparation
125of [ IloC-BCxT and 4 d iffe re n t AChR e x trac ts  gave values of 1.80 +
] oc:
0.07 nM [ I]̂ -BGT binding sites (+SE, 10 assays). Thus despite the
125variability resulting fran different [ I]oC-BGT and AChR
preparations, values d iffe red  ly  le s s  than 15%. T itre s  obtained fo r
a given serum sample using a single AChR extract and sample of
labe lled  toxin changed l i t t l e  over a period of 2 weeks. Storage of
labe lled  toxin fo r periods of longer than 3 weeks led  to  much
g rea ter v a ria tio n  in antibody t i t r e s  and toxin was therefo re  not
used beyond th is  p o in t. There was no evidence of system atic
v aria tio n s in  antibody t i t r e s  of given serum samples a ris in g  fran
changes in AChR e x trac ts  on storage a t  4°C fo r up to  3 months. The
125consistency of assays obtained by using s in g le  [ I]^c-BGT and AChR 
preparations suggests th a t there  may be seme advantage in storage of 
s e r ia l  serum samples taken frcm an indiv idual p a tie n t over a period 
of treatm ent in order to  assess most accurately  the e f fe c t  of such 
treatm ent on anti-(AChR) antibody t i t r e s .  Hcwever, changes of 
antibody t i t r e  re su ltin g  from plasma exchange and immunosuppression
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a re  genera lly  much g rea te r than d ifferences re su ltin g  fran  the use
125of d if fe re n t  [ I]«c-BGT and AChR preparations.
Obviously i t  would be d esirab le  to  have a d ire c tly  lab e lled
an tigen , ra th e r  than having to  re ly  on an ex ternal ligand because
125the occupancy of the ACh binding s i t e  by [ I]«*.-BGT excludes
measuronent of an tibodies d irec ted  a t  th is  s i t e .  These fac to rs  a re  
discussed more fu lly  la te r  on (see "Discussion" p. 233 ).
Specific  fea tu res  of antibody pa tte rn s in  myasthenia gravis
The radioimmunoassay fo r anti-(AChR) an tibodies discussed 
above provides a  usefu l a id  to  the diagnosis of MG, since 
approximately 80 -  90% of c l in ic a lly  diagnosed myathenic p a tien ts  
have antibody t i t r e s  vhich a re  e levated above normal co n tro ls , when 
assayed using human AChR as the antigen (Lindstrcm e t  a l . ,  1976a; 
Seybold e t  a l . ,  1981). This value i s  reduced to  60% i f  r a t  AChR is  
used as the antigen in the assay (Mittag e t  a l ,  1981; 1984).
Antibody t i t r e s  obtained from s e r ia l  assays on serum samples fran  a 
given myasthenic p a tie n t can, in many cases, r e f le c t  the c l in ic a l  
s ta te  of the p a tie n t, an observation which has been most 
convincingly demonstrated in s e r ia l  samples obtained fran  p a tien ts  
undergoing plasma-exchange coupled with immunosuppressive therapy 
(Newsom-Davis e t  a l . ,  1978; 1979; C arter e t  a l . ,  1980). Plasma 
exchange has became an increasing ly  popular treatm ent in  many 
inmunopathological d iseases (eg. denyelinative neuropathies, 
inflammatory myopathies, Lambert-Eh ton Myasthenic syndrome, m ultip le  
sc le ro s is  e t c . ) .  Firm evidence fo r the therapeu tic  benefits  of 
plasma-exchange in neurological d iso rders i s  lim ited  to  MG, but even
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here no la rg e  scale  randomized con tro lled  t r i a l s  have been 
performed, and th is  form of treatm ent tends to  be confined to  
p a tien ts  undergoing myasthenic c r i s i s  o r to  those with rap id ly  
progressing severe d isease which is  unmanageable ky drug treatm ent 
or thymectomy alone (Lisak, 1984; Dau, 1984). The e ffe c ts  of 
plasma-exchange, which can produce a rapid  and marked c lin ic a l  
improvonent, are  usually  associated  w ith a sharp f a l l  in  anti-(AChR) 
antibody t i t r e  and have been reported by a number of groups of 
workers (Pinching e t  a l . ,  1976; Dau e t  a l . ,  1977; Behan e t  a l . ,
1979). However, such benefits  a re  usually  sho rt term, and the long 
term response is  no b e tte r  than th a t produced by medication alone 
(Newsom-Davis e t  a l . ,  1979; Havkey e t  a l . ,  1981; Keesey e t  a l . ,  
1981).
Across a range of p a tien ts  the co rre la tio n  between 
anti-(AChR) antibody t i t r e  and sev erity  of c l in ic a l  symptoms is  poor 
(Lefvert e t  a l . ,  1978; Barkas e t  a l . ,  1979; Vincent & Newsom-Davis,
1979), suggesting th a t th is  radioimmunoassay might not accurately  
r e f le c t  lev e ls  of p a rtic u la r  an tibodies with immediate relevance to  
the d isease  s ta te .  Convincing evidence fo r an important, although 
not n ecessa rily  primary ro le  fo r AChR in the aetio logy of MG is  
provided by the observation th a t in je c tio n  of experimental animals 
with xenogeneic AChR leads to  EAMG (Patrick  & Lindstrcm, 1973). I t  
i s  conceivable th a t the p a rts  of the recep tor molecule most l ik e ly  
to  be conserved between species are  those most re levan t to  the 
functioning of the receptor and th a t  an tibodies d irec ted  against 
such determinants could represen t subclasses with most sign ificance  
in the d isease  s ta te .  However, the use of a lte rn a tiv e  mammalian AChR 
species as antigens in the RIA, although co n sis ten tly  giving lower
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antibody t i t r e s  than v^en human AChR was used as an tigen , gives no 
b e tte r  co rre la tio n  with the d isease  s ta te  (Savage-Marengo e t  e l . ,  
1979; 1980; Harrison e t  a l . ,  1981; McAdams & Roses, 1980; M ittag e t  
a l . ,  1981; 1984).
P a tie n t-sp e c if ic  antibody pa tte rn s
The presence of d isc re te  sub-populations of anti-(AChR) 
antibodies in myasthenic sera  a re  c le a rly  re f le c ted  by the d iffe r in g  
anti-(AChR) antibody t i t r e s  obtained by using AChR preparations fran  
d if fe re n t  species. Many groups of workers have demonstrated 
heterogeneity  of anti-(AChR) antibodies by using d if fe re n t assay 
methods (Mittag e t  a l . ,  1978; Lindstrom e t  a l . ,  1978a; Vincent & 
Newscm-Davis, 1979; Weinberg & H all, 1979; M ittag e t  a l . ,  1981; 
L efvert e t  a l . ,  1981; (Sarlepp e t  a l . ,  1981; T indall, 1981; Barkas e t  
a l . ,  1982; Z ie linsk i e t  a l . ,  1982; Vincent e t  a l . ,  1983; Whiting e t  
a l . , 1983); but reports of the ex ten t to  which pa tte rn s of antibody 
d iv e rs ity  a re  constant and c h a ra c te r is tic  of an individual 
myasthenic p a tie n t have been lim ited  ((Sarlepp e t  a l . ,  1981; Tzartos 
e t  a l . ,  1982; Kalies e t  a l . ,  1984).During the course of 
investiga tions using r a t  AChR antigens to  try  to  co rre la te  
anti-(AChR) antibody t i t r e  with the sev erity  of the d isease , i t  was 
found th a t  the r a t io  of a n t i - ( r a t  AChR) antibodies to  anti-(human 
AChR) antibodies varied between p a tien ts  but was constant fo r a 
given p a tie n t over the period of study (Savage-Marengo e t  a l . ,
1980). The re su lts  in  th is  th e s is  (see "Results" section  4.2) have 
confirmed and extended th is  study. A proportion of samples frcm 6 of 
the p a tien ts  studied are  those given in Savage-Marengo e t  a l . ,  1980; 
a fu rth e r number are  given in  Harrison e t  a l . ,  1981.
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Anti-(AChR) antibody t i t r e s  were determined, using junctional 
r a t ,  ex tra -ju n c tio n a l r a t  and human AChRs as an tigens, in sera frcm 
14 MG p a tie n ts , a l l  of vhcm experienced a range of c l in ic a l  s ta te s  
and widely varying anti-(human AChR) antibody t i t r e s  while 
undergoing plasma-exchange and immunosuppression therapy during the 
period of investiga tion  (Behan e t  a l . ,  1979; C arter e t  a l . ,  1980).
In agreement with Weinberg & Hall (1979) i t  m s  found th a t the 
t i t r e s  obtained with junctional r a t  AChR as antigen in  the 
radioimmunoassay were always lower than those obtained hy using 
ex tra -ju n c tio n a l AChR. The re la tiv e ly  constant proportions of both 
a n ti- ( ju n c tio n a l r a t  AChR) and an ti-(ex tra-junctionalA C hR ) 
antibodies to  anti-(human AChR) antibodies in  individual p a tien ts  
over periods of time upto fiv e  years, desp ite  f lu c tu a tin g  antibody 
t i t r e s ,  suggests th a t the o v e ra ll p a tte rn  o f an tibodies i s  sp ec ific  
fo r th a t  p a tie n t. This view is  supported by the consistency of the 
percentage p rec ip ita tio n  of AChR shown by each p a tie n t (see 
"R esults" section  4.2 & 4.3) v^ich provides fu rth er support fo r a 
p a tie n t-sp e c if ic  antibody p a tte rn . The constancy of the pa tte rn s 
observed suggests th a t the d e ta ile d  nature of the response is  
c h a ra c te r is tic  of a given p a tie n t and can be most simply explained 
by an i n i t i a l  lim ited  exposure of the AChR antigen to  the immune 
system, ra th e r than a repeating response to  a changing modified 
receptor v^ich might r e s u l t ,  fo r  example, from the shedding of 
receptor frcm the muscle surface . In the l a t t e r  case the antibody 
p a ttern  would be expected to  vary with each presen tation  of the 
antigen to  the immune system.
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Percentage precipitation of AChR by excess myasthenic serum
The re la tiv e  a b i l i t i e s  of d if fe re n t myasthenic sera to  
125p re c ip ita te  [ I]ei-BGT lab e lled  AChR complexes (see "Results"
sections 4.2 & 4.3) were a lso  found to  be sp e c if ic  fo r a given
p a tie n t . These findings can be explained in terms of heterogeneity
of toxin  binding components coupled with the presence of d isc re te
sub-populations of an tibodies in  myasthenic se ra . However, the
re s u lts  of combining myasthenic sera (see "Results" section  4.3.1)
argue ag a in st the suggestion th a t increased p rec ip ita tio n  of AChR by
c e rta in  sera  i s  caused by absence of p a r tic u la r  antibody
sub-populations.
An a lte rn a tiv e  explanation involves the presence of
125an tibod ies th a t  cause re lease  of bound [ I]cV-BGT, such antibodies
may o r may not represent vhat o ther workers rep o rt as a n t i -  (z/r-BGT
binding s i te )  antibodies ( " a n ti- s i te "  an tib o d ies). In the  commonly
used radio  immunoassay procedure, the ACh binding s i t e  i s  blocked by 
125the presence of [ I]oC.-BGT, so precluding the measuranent of these 
an tibodies (see Figure 54). The possib le  im plications of such a 
c la ss  of an tibodies is  discussed in the "Introduction" (p. 25) .
"A n ti-site"  an tibodies were f i r s t  described by Almon e t  a l .  
(1974a); many groups since then have attempted to  show conclusively 
th a t such an tibodies are  p resen t in  myasthenic se ra , and vhether or 
not they a re  re levan t to  the d isease  s ta te .  E lectrophysiological 
s tud ies have shown th a t serum or IgG from p a tien ts  with MG (Anwyl e t  
a l . ,  1977; Bevan e t  a l . ,  1977; Harvey e t  a l . ,  1978) and animals with 
EAMG (Patrick  e t  a l . ,  1973) cause reduced s e n s i t iv i ty  of muscle 
c e l ls  in cu ltu re  to  applied ACh. In h ib itio n  of </-BGT binding to  
normal human muscle was shown in 75% of p a tien ts  by histochem ical
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Figure 54. Schematic represen ta tion  of possible s i te s  of attachment 
of anti-(AChR) antibody causing ' blockade' of the AChR
!
A C h R M e m b r a n e
1. The antibody a ttaches to  the ACh binding s i te
2. The antibody a ttaches near the ACh binding s i te  
and s te r ic a l ly  hinders the binding of ACh
or a-BGT
3. The antibody does not d ire c tly  in te r fe re  with 
the ACh binding s i t e ,  but a l te r s  the AChR 
molecule, thus in h ib itin g  the ACh or oc-BGT 
binding s i t e .
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means (Bender e t  a l . ,  1975; 1976). More recen t s tud ies have used
immunoprécipitation methods, which are  much more convenient than
those mentioned above. Putative assays fo r " a n ti- s i te "  an tibodies
involve q u an tita tiv e  evaluation of the competition between
antibodies and (/-BGT fo r binding to  AChR from d if fe re n t sources.
Such assays have revealed th a t sera from 7 -  90% of MG p a tien ts
contain " a n ti- s i te "  an tibod ies.
A few groups of workers have attempted to  show some
re la tio n sh ip  between " a n ti- s i te "  an tibodies and c l in ic a l  s ta te .
Vincent & Newsom-Davis (1979) in  a study of 73 myasthenic p a tien ts
showed th a t 65% of these had " a n ti- s i te "  an tibod ies. They were
unable to  re la te  the presence of such antibodies to  the c l in ic a l
s ta te  of the p a tie n ts , but did show th a t  no p a tien ts  in remission
had s ig n if ic a n t " a n ti- s ite "  antibodies although many had high to ta l
anti-(AChR) antibody le v e ls . Zum & Fulpius (1977), using rabb its
immunized with e le c tr ic  f ish  AChR, found th a t lev e ls  of " a n ti- s i te "
antibodies were increased seven-fold in rab b its  with myasthenic
p a ra ly s is . Fulpius e t  a l .  (1980) la te r  showed the presence of
" a n ti-s ite "  antibodies in 4 MG p a tie n ts , d e ta ile d  analysis of one of
these p a tien ts  revealed th a t antibody binding to  chicken embryo
125myogenic cu ltu res competed with [ I]eC-BGT and cholinerg ic  ligands,
and th a t binding of th is  sp e c ific  antibody accelera ted  degradation.
These investigations were subsequently extended (Fulpius e t  a l . ,
1981) and stud ies on a group of 21 MG p a tien ts  revealed th a t IgG
purified  frcm 10 of these p a tien ts  showed varying degrees of 
125in h ib itio n  of [ I  ] @(-BGT binding to  chick muscle -  these p a tien ts  
were those with the most severe myasthenic symptoms. Drachman e t  a l .  
(1981) found th a t 88% of an unspecified  number of MG p a tien ts  have
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immunoglobulins which block </.-DGT binding to  cultured  muscle c e l ls .  
This blockade vas accanpanied by an accelera tion  of receptor 
degradation, and was found a lso  to  co rre la te  with the sev e rity  of 
the d isease  in  these  p a tie n ts . Desouki e t  a l .  (1981) found th a t IgG 
frac tio n s  p u rif ie d  frcm a n tise ra  frcm rab b its  and sheep immunized 
with Torpedo AChR in h ib ited  AChR function by in te rfe rin g  with the 
agonist-induced conformational changes in the receptor-channel 
ccmplex, and, in  ad d itio n , th a t immune rab b it IgGs a lso  inh ib ited  
[^H]ACh binding to  the  recep to r. These an tibodies would therefo re  
in h ib it  recep to r function by blocking i t s  conformational changes 
w ithout occupying the agonist and an tagonist binding s i t e s .
M ittag e t  a l .  (1984) suggest th a t  the high percentage of MG
patients who do not have an anti-(AChR) antibody titre may reflect
the presence of exclusively  " a n ti- s i te "  antibodies in these
patients. Although present at low concentrations (0.1 -  0.7 nM,
compared with 0.5 -  130 nM for antibodies not directed at the
«/-toxin binding s i t e ) ,  such antibodies may con tribu te  s ig n if ic a n tly
to the pathological condition. One obvious vay of looking for
" a n ti- s i te "  an tibod ies i s  to  rad io label the receptor d ire c tly , thus
leaving the A(Zh binding site free, after vhich it may be possible to
d e te c t an tibod ies which were previously unable to  bind to  the
recep to r. Torpedo ACZhR has been successfu lly  iodinated (Aharonov e t
al., 1977; Lindstrcm et al., 1981) and has been used for probing
anti-(AChR) an tibod ies (Souroujon e t  a l . ,  1983; Moshly-Rosen e t  a l . ,
1979 ). Prelim inary attem pts to  iod inate  p u rified  human ad u lt AChR by
using the standard chloramine-T method used for iodination of -BGT
(see "Methods" section 1.1) were not very premising. Incorporation 
125of [ I ]  in to  the p ro te in  was only 2%, the b io log ica l a c t iv i ty
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(assessed by i t s  a b i l i ty  to  bind to  myasthénie serum) vas le s s  than 
or equal to  1%, and th is ,  coupled with high background counts meant 
th a t the AChR lab e lle d  by th is  method was not usefu l fo r probing MG 
se ra . Further in v estig a tio n s along th is  l in e  would n e cess ita te  the 
development of a more gentle  iodination  procedure v^ich would y ie ld  
lab e lled  AChR of much higher b io log ica l a c t iv i ty .  I t  would a lso  be 
d esirab le  to  increase the y ie ld  of AChR obtained frcm e lu tio n  a f te r  
the a f f in i ty  chrcmatpgrajhy stage of AChR p u rif ic a tio n  as the y ie ld  
of p u rif ied  recep to r obtained fo r iodination  under the ex is tin g  
conditions i s  a lso  a  lim itin g  fa c to r . The success of using iodinated 
Torpedo A(ZhR stems frcm the high y ie ld  of pro tein  obtained frcm i t s  
p u rif ic a tio n .
The production of r a t  monoclonal an tibodies (ra ised  again st 
Torpedo AChR) (Lennon & Lambert, 1980) vhich bound to  muscle AChR a t  
a s i t e  removed from the binding s i t e  fo r cholinerg ic  ligands, and 
vhich caused impairment of neurcmuscular transm ission in  mice, ra ts  
and guinea-pigs suggested th a t " a n ti- s i te "  an tibodies may not be the 
major pathogenic agent in  MG. Many groups since then have produced 
monoclonal an tib o d ies , seme of which, l ik e  the polyclonal a n tise ra  
of Zum & Fulpius (1977), produce pharmacological blockade of AChR 
(Gcmez & Richman, 1983; Souroujon e t  a l . ,  1983); and o th ers , l ik e  
those of Lennon & Lambert (1980) vhich bind a t  a s i t e  removed frcm 
the ligand binding s i t e  and s t i l l  induce EAMG (Richman e t  a l . ,
1980). There i s  s t i l l ,  th e re fo re , much controversy regarding the 
involvement of " a n t i- s i te "  an tibod ies, and th e ir  importance in  the 
pathogenesis of MG remains unclear (Vincent, 1980; Fulpius, 1983; 
Drachman, 1983).
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The p resen t re su lts  (see "Results" sections 4.2 & 4.3) showed
that myasthenic sera vary in their ability to precipitate a limited
amount of [ I  ]ok-BGT-labelled AChR, frcm 15 -  100%. Sera frcm MG
p a tien ts  vhich p rec ip ita ted  low amounts of tox in -recep to r ccmplex
did not show appreciable inhibition of oC-BGT binding to the receptor
- one observation that indicates that "low-precipitating" sera may
effect loss of labelled toxin by a mechanism other than inhibition
of toxin binding, for example by binding to AChR at a determinant
removed frcm the  A(3h binding s i t e  and vAich nay be s im ila r to  the
observations of Lennon & Lambert (1980) and Richman e t  a l .  (1980)
described above. Binding a t  such a s i t e  may prcmote a conformational
125change which causes accelera ted  re lease  of [ I]o(-BGT. The re s u lts
obtained here (see "Results" section  4.3) show th a t seme MG sera are
125capable of acce lera tin g  the re lease  of bound [ I]«/-BGT frcm i t s
receptor ccmplex, and th a t such sera  a re  those which give low values
for the percentage precipitation of AChR by excess myasthenic serum
125(see Figure 30, Table 13). The slow ra te  of re lease  of [ iK-BGT
in the presence of "high-precipitating" sera, normal serum or
125buffer can be explained by assuming that [ I]oC-BGT is bound
t ig h tly  to  the  AChR, but even so, w ill  slowly d isso c ia te . The
d isso c ia tio n  curve obtained in the presence of an excess of
unlabelled «C-BGT i s  s im ila r to  th a t obtained frcm k in e tic
experiments for determining the dissociation constant (k_̂ )̂ (see
"Results" sec tion  5 .3 .2 ) , where rebinding of the rad ioactive  ligand
a t  equilibrium  i s  prevented by the presence of excess cold ligand.
125Reports of accelerated  d isso c ia tio n  of [ I]«x-BGT frcm 
tox in-recep tor ccmplexes have a lso  been reported by o ther workers 
using polyclonal a n tise ra  and monoclonal an tibod ies. Barkas &
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Simpson (1982) and K alies e t  a l .  (1984) find  th a t a n tise ra  or IgG 
frcm MG p a tien ts  can d isp lace bound toxin frcm the recep to r, Boulain 
& Menez (1982) have s im ila rly  denonstrated accelera ted  d isso c ia tio n  
of neurotoxin frcm AChR brought about by the binding of polyclonal 
and monoclonal an tibodies to  cobra vencm and Naja n ig r ic o lis  tox ins, 
respec tive ly . IVo monoclonal an tibodies ra ised  again st chick muscle 
AChR were found to  in h ib it  the reaction  of e/-BGT with hcmologous 
AChR, although these antibodies were not d irec ted  p rec ise ly  to  the 
neurotoxin binding s i t e  of the receptor (Mehraban e t  a l . ,  1984), 
polyclonal a n tise ra  exh ib iting  such an a b i l i ty  have a lso  been 
reported (Dolly e t  a l . ,  1983) and in these cases the observed 
blockade has been a ttr ib u te d  to  a s te r ic  or conformational 
co n stra in t exerted by IgG molecules. One of the monoclonal 
antibodies ra ised  aga in st chick muscle AChR was able to  cause rapid 
d isso c ia tio n  of tox in -recep to r ccmplexes (T^ = 0.5 h a t  23°C, and 
th is  has again been a ttr ib u te d  to  an antibody-induced conformational 
change in the AChR oligomer (Mehraban e t  a l . ,  1984).
However, using the methods described here, it is not possible
to  d istingu ish  between ( i)  competition fo r an id en tica l s i t e  ( i i )
s te r ic  hindrance from an adjacent s i t e  or ( i i i )  a  conformational
change from binding to  a d is ta n t  s i t e ,  in the in h ib itio n  o r re lease  
125of [ I]^/-B(3T binding to AChR by anti-(AChR) antibodies.
Furthermore, oC-BGT is much bigger than the native ligand (oi-BGT has 
MW of 8000, compared with 182 for ACh) and may not bind at the ACh 
site, so this can confuse the issue and it remains to be seen 
whether an «/-BGT displacing antibody may be relevant to the 
physiology of MG.
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C learly , the development of su itab le  methods fo r the 
q u an tita tio n  and charac te riza tion  of " a n ti- s ite "  and anti-(«.-BGT) 
d isp lacing  antibodies i s  s t i l l  required before th e i r  iirportance in 
the disease s ta te  can be fu lly  assessed.
Inh ib itio n  fac to r
The presence of an " inh ib ition  fa c to r" , vhich apparently 
inh ib ited  the AChR-antibody in te rac tio n , was found in  the sera  of 
approximately 20% of MG p a tie n ts . Prelim inary investiga tions 
suggested th a t th is  fac to r was a serum component, as IgG frac tio n s  
frcm such sera d id  not d isp lay  the same c h a ra c te r is t ic s . In order to  
study th is  phenomenon fu rth e r , i t  may be necessary to  find  out a t  
which stage of the radioimmunoassay th is  " in h ib itio n  fac to r"  has i t s  
e f fe c t  -  a t  the in te rac tio n  of lab e lled  AChR with anti-(AChR) 
antibody or a t  the in te rac tio n  of AChR-antibody ccmplex w ith goat 
anti-(human IgG). Inh ib itio n  of antibody binding to  AChR by 
«^fetoprotein in v i t ro  has been reported (Abramsky & Brenner, 1979; 
Brenner e t  a l . ,  1980; Brenner & Abramsky, 1981). The lev e ls  of 
«/-fetoprotein are  increased above normal lev e ls  in  pregnant wonen, 
espec ia lly  those in  the l a t t e r  term of pregnancy, and i t  has been 
suggested th a t «/-fetoprotein p ro tec ts  the neonatal neurcmuscular 
junction frcm maternal an tibod ies. The " in h ib itio n  fac to r"  observed 
here m s no t, however, confined to  sera from women only. Among the 
non-pregnant population, ra ised  serum /-fe to p ro te in  lev e ls  a re  a lso  
found in most cases of primary hepatoma and non-seminatomous germ 
c e l l  tumours (Ruoslahti & H ira i, 1978). However, o ther workers have 
been unable to  reproduce the in h ib itio n  observed by Brenner and 
co-workers (T indall, 1981; L efvert & Osterman, 1983; Heininger e t
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a l . ,  1984), suggesting th a t «/-fetoprotein may not be inço rtan t as a 
p ro tec tiv e  agent in  neonatal myasthenia g rav is , o r , indeed, as the 
" in h ib itio n  fac to r"  observed here.
Ccxnparison of the  in te rac tio n  of human a d u lt and fo e ta l sk e le ta l
125muscle AChRs w ith [ I]«/-BGT and anti-(AChR) an tibodies
In view of the reported s im ila r i t ie s  between ex tra -ju n c tio n a l 
and embryonic AChR (Burden, 1977a; Schuetze e t  a l . ,  1978) and the 
finding by Weinberg & Hall (1979) th a t serum frcm one myasthenic 
p a tie n t showed the same antibody t i t r e  vhether ex tra -ju n c tio n a l r a t  
AChR o r AChR frcm 18-day old r a t  embryos was used as an antigen in 
the assay , i t  i s  possib le  th a t  the ccmposition of a n t i -(AChR) 
antibodies in myasthenic sera  could r e f le c t  an e a rly  exposure of 
embryonic AChR to  the immune system. This i s  obviously p e rtin en t to  
questions concerning the aetio logy of MG.
Iirmunohistochenical s tud ies on human a d u lt and fo e ta l muscle
Prelim inary stud ies fo r the ccmparison of a d u lt and fo e ta l 
AChRs employed histochemical techniques, vdiich have been used 
ex tensively  to  study the d is tr ib u tio n  of AChRs over the surface of 
muscle c e l ls  (Daniels & Vogel, 1975; Moody-Corbett & Cohen, 1981; 
Steinbach, 1981; Ishikawa & Shimada, 1981; 1982). These stud ies 
ccmplement those of e lec tro jh y sio lo g ica l methods vhere membrane 
p o ten tia ls  a re  recorded during loca lized  iontophoretic app lica tion  
of ACh to  the c e l l  surface. The s im ila r i t ie s  observed by other 
workers between embryonic and ex tra -ju n c tio n a l AChR suggested th a t  
in fo e ta l muscle AChRs are  d is tr ib u te d  over the c e l l  su rface , 
con trasting  w ith the d is tr ib u tio n  of AChRs in ad u lt muscle, vhere
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they a re  lo ca lized  a t  the synapse (see In troduction  p. 12 ).
S taining of human a d u lt and fo e ta l muscle sections with (/r-BGT 
using the 'PAP' technique were disappointing, the  high background 
sta in ing  seen w ith the  ra b b it anti-(«/-BC3T) antiserum  (see "Results" 
section  5.1) meant th a t  no conclusions could be drawn fran  these 
s tu d ies . F luorescein s ta in in g , although o ffering  no am plification , 
provides a d ir e c t  method fo r v isu a liza tio n  of recep to rs. Teased 
human ad u lt muscle f ib re s  showed s ta in in g  throughout the f ib re , with 
occasional a reas of more in tense s ta in in g . The p a tte rn  of s ta in ing  
did not correspond w ith th a t  observed by Ringel e t  a l .  (1975) vho 
found th a t AChRs were c lu s te red  in  the post-synaptic  fo lds of the 
muscle f ib re . Foetal muscle f ib re s  showed weak sta in in g  along rows 
of regu larly  arranged c e l ls ,  which may represen t developing muscle 
f ib re s  (Minguetti & Mair, 1982). The d is tr ib u tio n  of AChE did not 
correspond w ith the p a tte rn  of fluorescein  s ta in in g  observed -  there 
vas no s ig n if ic a n t s ta in in g  fo r AChE on human ad u lt muscle f ib re s , 
vhich may r e s u l t  fran  a decrease in  lev e ls  of AChE in ischemic 
muscle frcm o lder p a tie n ts  (Bourgeois e t  a l . ,  1978; Betz e t  a l . ,  
1980). S taining fo r AChE in fo e ta l muscle f ib re s , on the other hand, 
vas observed a l l  over the surface of the f ib re s .
These prelim inary a tte n p ts  to  in v estig a te  the  d is tr ib u tio n  of 
AChR in human a d u lt and fo e ta l muscle were inconclusive and were not 
pursued; however, a d e ta ile d  study could be en lightening.
A lternative  methods fo r comparing a d u lt and fo e ta l AChRs were then 
studied , namely th e i r  in te rac tio n s  with </-BGT and anti-(AChR) 
antibodies from myasthenic se ra .
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125[ I ] pc-BGT binding c h a ra c te r is tic s  of AChRs in detergen t e x trac ts  
of human ad u lt and fo e ta l sk e le ta l muscle
The k in e tic  constants fo r a sso c ia tio n , d isso c ia tio n  and 
125equilibrium  binding of [ I]/-BGT to  AChR were determined. For a
receptor binding experiment:-
R + L +  I  RL + RI 
where:- R = concentration of free  binding s i te s  
I  = concentration of unlabelled  drug 
RL = concentration receptor bound to  rad ioactive  ligand 
= parameter measured 
RI = concentration receptor bound to  unlabelled  drug 
Lsp = to ta l  ligand concentration 
= L + RL
L = concentration free  rad ioactive  ligand 
3 basic  types of experiment a re  usualy performed w ithin th is  
framework : -
1. K inetic  experiments in  vhich RL is  determined as a function of 
time with L^ held constant
2. S aturation  experiments in which L^ i s  increased and RL determined 
a t  equilibrium
3. In h ib itio n  experiments in vhich RL is  determined as the 
concentration of unlabelled  drug i s  increased and L^ i s  held 
constan t.
There a re  many repo rts  in  the l i te r a tu r e  fo r such experiments 
on the k in e tic  and equilibrium  binding of rad io labe lled  
curare^nmnetic neurotoxins with n-AChR frcm c en tra l and peripheral 
tis su e  (Lukas e t  a l . ,  1981). D irect comparisons of data obtained 
frcm w ithin and between species a re  o ften  d i f f ic u l t  because of the
2 4 4
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of oC-BGT with detergent extracts of AChR
mammalian skeletal muscle
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0.72 7.5 0.51 th is  th e s is
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different states of purification of receptor types, the degree of
iodination  of to x in s , times and temperatures of incubations, e t c . ,
used fo r such determ inations. Therefore, extensive comparison of
binding data obtained here with those from the l i te r a tu r e  *is not
meaningful. Hcwever, Table 23 shows comparisons of binding data  in
detergent e x tra c ts  from sane mammalian muscle species. Some reports
in the l i te r a tu r e  v^ich compare the use of d if fe re n t  iodinated ^-BGT
species have ind icated  th a t d i-iod inated  o<c-BGT d if fe r s  from
mono-iodinated and na tive  oC-BGT, e sp ec ia lly  in  i t s  ra te  of
assoc iation  with p u rif ie d  AChR (Wang & Schmidt, 1980; James e t  a l . ,
1980). Lukas e t  a l .  (1981) a lso  demonstrated anomalous biphasic
d issoc ia tion  k in e tic s  using d i-iod ina ted  eC-BGT and suggested th a t
d e ta iled  binding s tu d ies  should not be m de using m ixtures of the
d if fe re n t iodinated oO-BGT species. The rou tine  preparations of 
125[ I]oC-BGT used here comprise g rea te r than or equal to  70%
mono-iodinated oC-B(3T (see "Results" section  1 .2 ) , and as the  aim of
these experiments vas to  compare the binding c h a ra c te r is tic s  of
fo e ta l and a d u lt AChR, ra th e r than to  undertake a d e ta ile d  k in e tic
125study, unfractionated  [ IK-B3T was considered to  be su itab le  fo r 
these s tu d ies .
Ihe binding data  observed in  the s tud ies  performed here
125showed no s ig n if ic a n t d ifferences between the in te rac tio n  of [ I]
o(-BGT with AChR from human a d u lt o r fo e ta l AChR. Scatchard analysis
and H ill p lo ts  (see "Results" section  5.3) of the binding data
125ind icate  a sing le  c la ss  of [ IloC-BCST binding s i te s  fo r both ad u lt 
and fo e ta l AChRs, w ith values fo r in the nanomolar range. The 
observed mean equilibrium  binding constants from Scatchard analysis 
(1.35 nM fo r a d u lt and 0.67 nM fo r fo e ta l)  a re  higher than the true
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Kĵ  values obtained from the r a t io  of ra te  constants (0.91 nM fo r 
a d u lt, 0.51 nM fo r fo e ta l) .  This i s  to  be expected because the 
apparent obtained fran  equilibrium  binding is  equal to  the true  
Kĵ  (obtained frcm the r a t io  of ra te  constants) only i f  the 
concentration of binding s i te s  used is  much lower than the K^, 
which, in  a high a f f in i ty  systan , i s  d i f f ic u l t  to  achieve 
experimentally because of the lower lim its  of detection  of 
rad io labelled  ligands (Bylund, 1980; Cuatrecasas & Hollenberg,
1976). The values obtained fo r a re  in the order of those reported 
by o ther workers fo r d if fe re n t  mammalian muscle types (see Table 
23).
125Association k in e tic s  between [ I ] o4-bgt and AChR were rap id , 
and showed a sing le  "on-rate". The re s u lts  were analyzed by 2 
methods:-
1. Pseudo f i r s t  order k in e tic s , vhich take in to  account the reverse 
reaction
2. Second order k in e tic s , which uses i n i t i a l  ra te s  of reaction  
(Dolly, 1979).
Ihe values obtained by the 2 methods give good agreement (see 
"Results" section  5 .3 .1 ) ; the values obtained frcm the P seudo-first 
order determ inations a re  generally  s l ig h tly  lower than those 
obtained from second order determ inations, which would be expected 
i f  the reverse reaction  is  s ig n if ic a n t.
In co n tra st to  the  re su lts  obtained by Stephenson (1980), the
125d issoc ia tion  of [ I  ]oi-BGT frcm lab e lled  ad u lt and fo e ta l AChR 
complexes gave biphasic k in e tic s  w ith both f a s t  and slow components. 
The fa s te r  i n i t i a l  phase accounted fo r 80%, and the slower phase fo r 
approximately 20%. This p ro f ile  i s  s im ila r to  th a t  obtained fo r
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125d isso c ia tio n  of [ I]o(.-BGT frcm Torpedo membranes (Hanley, 1978). 
One would expect the equilibrium  binding to  be dominated by the low 
a f f in i ty  s i t e ,  although both f a s t  and slow components d isso c ia tio n  
ra te s  should con tribu te  d ire c tly  to  the measured so th a t : -
K ^ =  k.Kg +
k+1
where:- = equilibrium  binding constant
Ky = d isso c ia tio n  constant fo r high a f f in i ty  s i t e  
= d isso c ia tio n  constant fo r low a f f in i ty  s i t e  
= association  ra te  
k = ra t io  of number of high to  low a f f in i ty  s i te s
(Oswald & Freeman, 1979)
Diphasic d isso c ia tio n  k in e tic s  have a lso  been reported by 
Vincent & Nafsom-Davis (1979) fo r various human AChR preparations 
using d i-io d in a ted  oC-BGT; and by Brockes & Hall (1975a) fo r r a t  
junctional and ex tra -junc tiona l diaphragm muscle using 
mono-iodinated cC-BCST. Brockes & Hall (1975a) a lso  document a 
b iphasic a sso c ia tio n , and explain th e i r  re su lts  in  tenns of the 
presence of 2 independent c lasses of binding s i t e s ,  although th is  
does not exclude o ther in te rp re ta tio n s , such as negative 
co -o p era tiv ity  between id e n tic a l s i t e s ,  or d is t in c t  s i te s  th a t a re  
in conformational equilibrium . In p rin c ip le , these p o s s ib i l i t ie s  
could be d istinguished  by rap id  reaction  techniques, but the minute 
amounts of AChR present in  mammalian muscle preclude such s tu d ies . 
Lukas e t  a l .  (1981) find  th a t biphasic d isso c ia tio n  of 
tox in -recep to r complexes i s  more apparent vAien using iodinated <<-BGT 
(espec ia lly  d i-iod inated  o(.-BGT) ra th e r than [^]^-BGT, and suggest
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th a t a lte ra tio n s  in receptor binding a c t iv i ty  shown by d i-iod inated  
oC-BGT may re s u l t  frcm a lte ra tio n s  in the conformation of o(-BGT 
induced by progressive iodination of an exposed ty rosine  residue 
(Lukas(iewicz) e t  a l . ,  1978). Ihe presence of b iphasic d issoc ia tion  
k in e tic s  in r a t  brain  (Brockes & H all, 1975), human fo e ta l brain 
(Whyte e t  a l . ,  1984) and goldfish  brain  (Oswald & Freeman, 1979) has 
been a ttr ib u te d  to  the presence of two c lasses  of binding s i te s  
while Maelicke (1977) explains the presence of biphasic d isso c ia tio n  
by the presence of paired toxin binding s i te s  vhich are  
in te rconvertib le  between a high and low a f f in i ty  s ta te .  However, the 
stud ies performed here suggest the presence of one c la ss  of binding 
s i t e  only, although the presence of more than one can not be 
dism issed.
In te rac tion  of human ad u lt and fo e ta l AChRs with anti-(AChR) 
antibodies in myasthenic sera and IgG
Ihe f i r s t  demonstration of a p re fe re n tia l in te rac tio n  of 
myasthenic IgG with ex tra -ju n c tio n a l ra th e r than junctional AChR was 
by Almon & Appel (1975), who showed th a t such IgG in h ib ited  the 
binding of o(-BGT to  AChR frcm denervated, but not normal, muscle; 
and, in the radioimmunoassay, th a t denervated r a t  muscle m s  
p rec ip ita ted  whereas normal muscle was no t. This finding  was 
confirmed and extended by Weinberg & Hall (1979) vho showed th a t in 
radioimmunoassay of ten p a tie n ts , anti-(AChR) antibodies measured 
using junctional or ex tra -ju n c tio n a l r a t  AChR as antigen d iffe red  
with the antigen , and th a t  the r a t io  of t i t r e s  varied  frcm 1.0 to  
2 .4 . These observations ind ica te  the presence on ex tra -ju n c tio n a l 
r a t  AChR of an tigen ic  determinants recognized uniquely by myasthenic
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se ra . A n ti-( r a t  AChR) an tibod ies, vÆiether a n t i - (ex tra -junctional r a t  
AChR) or a n t i - ( junctional r a t  AChR), co n s titu te  only a small 
proportion of the to ta l  anti-(human A(ZhR) antibody population 
(Savage-Marengo e t  a l . ,  1979; 1980; Harrison e t  e l . ,  1981), so the 
re su lts  above cannot necessarily  be extended to  the corresponding 
human AChR types. Furthermore, i t  i s  obviously much more re levan t to  
a human d isease to  examine the composition of anti-(human ACiiR) 
an tibod ies, and fo r  th is  reason the stud ies here were extended to  
investiga te  the in te rac tio n  of fo e ta l human AChR with anti-(AChR) 
an tibod ies.
Some evidence fo r a p re fe re n tia l in te rac tio n  of d if fe re n t 
human muscle AChR types with anti-(AChR) an tibodies in myasthenic 
sera i s  provided by two groups of workers. Vincent & Newscm-Davis
(1979) compared "normal" ad u lt human AChR (from p a tien ts  with 
a r te r io s c le ro tic  ischemia) with "denervated" ad u lt human AChR (from 
pa tien ts  with d iab e tic  ischemia and peripheral neuropathy) as 
antigens in the radioimmunoassay fo r anti-(AChR) an tibodies in 
myasthenic se ra , and found e sse n tia lly  no d ifferences between the 
two se ts  of t i t r e s .  Subsequent work hy the same authors (Vincent & 
Newscm-Davis, 1982b) made fu rth er comparative stud ies in vhich th e ir  
"normal" AChR was derived post^mortom from a p a tie n t w ith cerebra l 
d isease, and th e ir  "denervated" AChR was obtained as previously. The 
observation here was th a t ,  in co n tra s t to  previous re s u l ts ,  the 
antibody t i t r e s  obtained using "normal" AChR were found to  be 
v a riab le , but s l ig h tly  lower than those obtained using "denervated" 
AChR, and the authors suggested th a t the previously observed 
equality  of t i t r e s  may re s u l t  from p a r t ia l  denervation of the 
ischemic "normal" muscle used in the e a r l ie r  work. A lte rna tive ly ,
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post mortem changes to  the "normal" muscle may lead  to  the 
v a r ia b il i ty  observed.
"Denervated" AChR, again obtained frcm p a tie n ts  with d iab e tic  
ischemia and peripheral neuropathy, has a lso  been ccnpared with 
"normal" AChR, th is  time frcm muscle amputated frcm p a tien ts  with 
malignant bone tumours, by Lefvert (1981; 1982), vho found th a t in 
the radioimmunoassay, 40% of the myasthenic sera d id  not re a c t with 
"normal" AChR, but of those th a t d id , anti-(AChR) antibody t i t r e s  
were found to  be approximately 50% lower than the corresponding 
t i t r e s  obtained using "denervated" AChR as antigen .
Ihe aim, th ere fo re , of the comparison of human ad u lt and 
fo e ta l AChR in  the  radioimmunoassay was to  show v^ether there  was a 
p re fe re n tia l in te rac tio n  of anti-(AChR) an tibodies in  myasthenic 
sera with fo e ta l  AChR. Ihe re su lts  obtained (see Table 19) showed no 
s ig n if ic a n t d ifference  between antibody t i t r e s  obtained using ad u lt 
or fo e ta l AChR as antigen . Furthermore, the apparent K^s fo r binding 
of adu lt and fo e ta l  AChR to  anti-(AChR) antibodies were id e n tic a l, 
ind icating  th a t  the a f f in i ty  of an tibodies d irec ted  ag a in st the two 
receptor types were the same. Like Vincent & Newscm-Davis (1979), 
the ccmparisons were made here large ly  by using "normal" AChR 
obtained from p a tien ts  with severe vascular d isease . Muscle frcm a 
healthy ind iv idual who had suffered  a road t r a f f i c  accident provided 
the opportunity to  ccmpare d ire c tly  the binding of an tibodies to  
th is  e s se n tia lly  normal AChR with th a t derived frcm p a tien ts  with 
severe vascular d isease; and i t  m s  found th a t again , the two muscle 
types showed v ir tu a lly  id e n tic a l sa tu ra tio n  curves (see Figures 51 -  
53). So, while seme muscle amputated frcm p a tien ts  with vascular 
d isease may be a t  le a s t  p a r t ia l ly  denervated, th a t used in the
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experiments here can be regarded as providing an tig en ica lly  normal 
ad u lt human AChR with respect to  i t s  in te rac tio n  with myasthenic 
serum.
Ihe suggestion th a t fo e ta l human AChR c a rr ie s  unique an tigen ic  
s i te s  which a re  not present on normal ad u lt AChR, and which are 
recognized by myasthenic se ra , is  not supported by the data  reported 
here. I t  i s  possib le , however, th a t such s i te s  could have been lo s t  
during the p u rif ic a tio n  procedure, espec ia lly  in  view of the f a s t  
i n i t i a l  degradation of the fo e ta l receptor; o r th a t the numbers of 
such corresponding antibodies in the sera te s te d  a re  very low, and 
so beneath the lim its  of de tec tion . Vincent & Newscm-Davis (1982b) 
reported , w ithout da ta , th a t myasthenic sera reacted s im ila rly  with 
AChR frcm a d u lt muscle or cu ltu red  fo e ta l muscle, but th e ir  ad u lt 
muscle was denervated and had previously given r i s e  to  higher 
antibody t i t r e s  than th e ir  "normal" muscle. However the d ifferences 
observed between the two types of ad u lt muscle a re  not g rea t, and 
a lso  th e i r  fo e ta l AChR is  not d ire c tly  ccmparable with th a t used 
here, which was obtained frcm foetuses aged between 14 and 22 weeks. 
I t  i s  possib le  th a t AChR obtained frcm younger or o lder foetuses 
might be an tig en ica lly  d if fe re n t . I t  has been noted previously th a t 
sera frcm d if fe re n t  myasthenic p a tien ts  vary in th e ir  s p e c if ic i t ie s ,  
and in th e i r  a b i l i ty  to  d is tin g u ish  between junctional and 
ex tra  junctional r a t  AChR (see "Results" section  4.2; Savage-Marengo 
e t  a l . ,  1980; Harrison e t  a l . ,  1981). However, d i f f e re n t ia l  
in te rac tio n s  between r a t  receptors are  not necessarily  re f le c ted  in 
the case of human recep to rs, since p a tien ts  14, 11 and 10 shown here 
have a n ti- ( ju n c tio n a l r a t  A(ZhR) to  anti-(extra-junctional/A C hR ) 
antibody t i t r e  ra tio s  of 0.74, 1.00 and 0.16 respec tive ly .
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S tru c tu ra l stud ies of a f f in i ty  p u rif ied  a d u lt and fo e ta l
human AChRs have revealed th a t the two receptor types a re  sim ila r in
th a t they both possess 4 subunits (apparent molecular weights 44000,
51000, 58000, 66000), they have sim ila r is o e le c tr ic  po in ts and
sedimentation c o e ff ic ie n ts . However, although in both cases a l l  4
125subunits can be lab e lled  with [ I ] - la b e lle d  Concanavalin A, the 
44000 subunit of the fo e ta l AChR binds le ss  than the corresponding 
subunit of ad u lt AChR, ind icating  a d ifference  in the  degree of 
g lycosylation of the receptor (Turnbull e t  a l . ,  1984). The observed 
d if f e r e n t ia l  in te rac tio n  of MG sera  with e x tra -ju n c tio n a l and 
junctional r a t  AChRs has been a ttr ib u te d  to  d ifferences in  the 
carbohydrate composition of the receptor types. Dwyer e t  a l .  (1981a) 
found, l ik e  Almon & Appel (1975) th a t  an tibodies frcm MG p a tien ts  
in h ib it  the binding of cjC-BGT to  ex tra -ju n c tio n a l AChR more 
e ffe c tiv e ly  than to  junctional AChR. A fter glycosidase treatm ent of 
e x tra -ju n c tio n a l AChR, the in h ib itio n  was reduced, but not 
abolished, so th a t ex tra -ju n c tio n a l AChR more c lo se ly  resanbled 
junctional AChR (Dwyer e t  a l . ,  1981a). They proposed th a t  the 
observed d ifferences between the two receptor types re su lte d  frcm 
add itiona l an tigen ic  determinants on ex tra -ju n c tio n a l receptors 
which a re  located close to  the toxin binding s i t e ,  and which 
ccmprise carbohydrate. Antibodies frcm 1 MG p a tie n t have been 
reported (Hall e t  a l . ,  1983) to  recognize an <-BGT binding s i t e  on 
only ex tra -ju n c tio n a l or embryonic, but not on junctional r a t  AChR, 
these antibodies block tcx in  binding to  so lu b ilized  Torpedo AChR fcy 
50%. This blockade can be completely in h ib ited  by N -acetyl 
glucosamine, but not by N-acetylgalactosamine, s i a l i c  a c id , mannose, 
galactose  or glucose. The authors suggest th a t the recep tor
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undergoes a change in glycosylation near one of the toxin binding 
s i te s  during p o st-n a ta l maturation of end-p lates.
The re la tiv e  absence of carbohydrate on the  «^subunit of 
fo e ta l human AChR compared with ad u lt human AChR obtained by 
Turnbull e t  a l .  (1984) can be explained i f  one proposes th a t  the 
carbohydrate serves to  sh ie ld , ra th e r than con tribu te  to , an tigen ic  
s i te s  in the immature form of the recep tor.
I t  is  therefo re  apparent th a t in order to  draw any 
conclusions concerning the involvement of the fo e ta l AChR as the 
auto-immunogen in MG, more extensive stud ies should be undertaken 
using a g rea te r range of myasthenic sera and a wider age range of 
fo e ta l muscle than has been the case in these s tu d ies . I t  i s  a lso  
possib le  th a t  i f  an immunohistochemical technique could be 
e s tab lish ed , the in te rac tio n s  of a range of myasthenic anti-(AChR) 
an tibodies with a range of fo e ta l receptors could be v isua lized  and 
may w ell a id  the immunological s tud ies performed here.
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CONCLUSIONS AND PROSPECTS
A carefu l study has been made of the steps involved in  the 
radioiirmunoassay fo r anti-(AChR) antibodies in myasthenic se ra , and 
a r e l ia b le  combination of experimental procedures has been 
developed, leading to  a reproducible rou tine  assay (Carter e t  a l . ,
1981).
Using th is  assay, the lev e ls  of anti-(human AChR) an tibod ies, 
a n t i - ( J - r a t  AChR) antibodies and a n ti- (E I - ra t  AChR) an tibodies have 
been monitored in 14 MG p a tien ts  fo r periods of up to  5 years. These 
stud ies have confirmed and extended the findings of Savage-Marengo 
e t  a l .  (1980), and reveal th a t  although the antibody t i t r e s  of 
indiv idual p a tien ts  f lu c tu a te  widely during the period of 
in v estig a tio n , the ra tio s  of a n ti- (E J - ra t AChR) antibodies : 
anti-(human AChR) antibodies and the ra tio s  of a n t i - ( J - r a t  AChR) 
an tibodies : a n ti- (E J - ra t  AChR) an tibodies are  constant fo r a given 
p a tie n t during th is  time, and vary between p a tien ts  frcm 0 - 0 . 6  and 
0 - 1 . 0  respec tive ly . Further evidence fo r th is  p a tie n t-sp e c if ic  
antibody p a tte rn  was obtained frcm experiments where an excess of 
myasthenic serum was used to  p re c ip ita te  lim ited  amounts of AChR.
The p rec ip ita tio n  of AChR varied  between p a tien ts  frcm 15 -  100% of 
th a t p rec ip ita te d  ky serum frcm one p a rtic u la r  p a tie n t, but was 
re la tiv e ly  constant fo r a given p a tie n t over extended periods of 
tim e. Such observations are  most consisten t with a sing le  in i t ia t in g  
event in  the d isease , ra th e r than with a continued re -p resen ta tion  
of A(ZhR antigen to  the immune systan (Harrison e t  a l . ,  1981).
The mechanism of incomplete p rec ip ita tio n  of AChR by 
myasthenic sera v^s investigated  in two ways;- f i r s t ly ,  by combining
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d if fe re n t  sera together in an a tterrp t to  e f fe c t  to ta l  p rec ip ita tio n  
125of [ I]oC-BGT labe lled  AChR, vhich in no case led  to  any g rea te r
p rec ip ita tio n  than th a t caused by the f i r s t  serum alone. Secondly,
attem pts were made to  show the presence of an tibodies which might
d isp lace  bound toxin frcm tox in -recep tor complexes, by investiga ting
the time-dependent displacement of toxin in the presence of
myasthenic se ra . The re su lts  obtained showed th a t seme myasthenic
sera a re  capable of acce lera ting  the re lease  of bound toxin frcm i t s
receptor complex, and th a t th is  a b i l i ty  showed an approximately
inverse re la tio n sh ip  with the a b i l i ty  of the sera  to  p re c ip ita te  
125[ I]oC-BGT lab e lled  AChR. However, such observations do not
d is tin g u ish  between ( i)  competition fo r an id en tica l s i t e  ( i i )
s te r ic  hindrance from an adjacent s i t e  o r ( i i i )  a  confonnational
change from binding to  a d is ta n t  s i t e .  The present investiga tions
would be complemented by the use of d ire c tly  lab e lled  p u rif ied  human
125AChR, which, unlike [ I]o(-BGT lab e lled  AChR, may have the capacity  
to  d e tec t a n ti-( to x in  s i te )  an tibod ies. The procedure fo r the 
p u rif ic a tio n  of human AChR which i s  necessary fo r th is  approach i s  
now a routine technique in the laboratory ; however, the developnent 
of a gen tle  iodination  procedure allowing f u l l  re ten tio n  of 
b io log ica l a c t iv i ty  i s  a necessary p re -re q u is ite  to  such stud ies in 
order to  achieve both s e n s i t iv i ty  in the assay and a su f f ic ie n t  
quan tity  of labe lled  p ro te in .
The development of monoclonal antibody technology in  recen t 
years has s ig n if ic a n tly  contributed  to  advances in  the 
charac teriza tion  of the AChR and i t s  binding s i te s  fo r anti-(AChR) 
an tibod ies. Several groups now have monoclonal an tibodies to  AChR
2 5 7
fran electric fish and mairmalian skeletal muscles, and have
characterized  the binding s p e c if ic i t ie s  of an tibodies in MG sera by
competition experiments (Tzartos, 1984). Such experiments could be
performed here, in order to  id en tify  the nature of the  binding of
125anti-(AChR) antibodies causing accelerated  re lease  of [ I]o(-BGT
1 p c
from [ I]o(-BGT lab e lled  AChR complexes, and to  id e n tify  
sub-populations of antibodies in polyclonal sera  vAich have 
p a rtic u la r  relevance to  the disease s ta te .
In the course of stud ies using d if fe re n t muscle antigens in 
the radioimmunoassay, i t  was found th a t anti-(AChR) antibody t i t r e s  
obtained using E J-ra t AChR as antigen were co n sis ten tly  higher than 
v^en J - r a t  AChR was used, an observation made a lso  by Weinberg &
Hall (1979), who proposed th a t in view of the s im ila r i t ie s  between 
ex tra -ju n c tio n a l and embryonic AChR, embryonic AChR may c o n s titu te  
the autoimmunogen in MG. This has been investigated  here by 
comparing the in te rac tio n  of human adu lt and fo e ta l AChRs with cC-BGT 
and anti-(AChR) an tibod ies. The binding of d-BGT w ith t is su e  
sections and teased muscle f ib re s  from ad u lt and fo e ta l muscle were 
compared immunohistochemically using the 'lAP' technique and by 
fluorescein  s ta in in g . The re s u lts  of these immunohistochemical 
stud ies were disappointing and were large ly  inconclusive. However, a 
more d e ta iled  study could be enlightening, p a r tic u la r ly  i f  a contro l 
p a tte rn  of sta in ing  could be estab lished  beforehand, fo r example in 
r a t  muscle types. The use of monoclonal an tibodies w ith varying 
s p e c if ic i t ie s  m y  again be usefu l probes fo r following the  
development of AChR in  muscle f ib re s ; furthermore such s tu d ies  m y  
c la r ify  the s im ila r it ie s  and d ifferences between fo e ta l.
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extra-junctional and junctional receptors.
AChRs were iso la ted  and p a r t ia l ly  p u rified  fran  human ad u lt 
and fo e ta l muscle, and th e ir  binding to  anti-(AChR) antibodies in 
myasthenic sera  and IgG were canpared. No s ig n if ic a n t d ifference  m s  
observed between the binding c h a ra c te r is tic s  of the two receptor 
types, ind icating  the absence, a t  le a s t  in 14 -  22 week old 
foetuses, of ligand binding or an tigen ic  s i te s  unique to  fo e ta l 
AChR. This work should be extended to  look a t  a wider range of 
fo e ta l muscle types (including cultured  fo e ta l muscle), and a lso  a 
wider range of myasthenic se ra , i f  conclusions concerning the 
involvement of fo e ta l AChR as the autoimmunogen in M3 a re  to  be 
drawn.
D ifferences in the in te rac tio n  of r a t  muscle AChRs with
myasthenic sera have been a ttr ib u te d  to  d iffe r in g  ex ten ts of
glycosylation (Dwyer e t  a l . ,  1981a; Hall e t  a l . ,  1983) of junctional
and ex tra -ju n c tio n a l AChRs. Although such d ifferences have not been
observed here, i t  has been show th a t the 44000 molecular weight
subunit of human fo e ta l AChR is  le s s  heavily lab e lled  with 
125[ I  iConcanavalin A than the corresponding subunit of human ad u lt 
AChR (Turnbull e t  a l . ,  1984). Further s tud ies on the carbohydrate 
canposition of ad u lt and fo e ta l AChRs may give in s ig h t in to  
s tru c tu ra l d ifferences between the two recep tor types, and a lso  in to  
the pathways involved in p o s t- tra n s la tio n a l m odifications to  the 
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PATIENT-SPECIFIC ANTI-ACETYLCHOLINE 
RECEPTOR ANTIBODY PATTERNS IN 
MYASTHENIA GRAVIS
R. H arrison, G. G. Lunt, H . M orris, and T. Savage M arengo
Biochemistry Department 
University o f Bath 
Bath, United Kingdom
P. O. Behan
Institute o f Neurological Sciences 
Southern General Hospital 
Glasgow, United Kingdom
A ssay of anti-acetylcholine receptor (anti-A C hR ) antibodies in the sera of 
m yasthenic patients by the commonly used radioim m unoassay procedures^"* 
shows elevated antibody titers com pared with the results obtained from  non- 
m yasthenic controls.^ The assay accordingly is a useful aid to diagnosis o f the 
disease. Nevertheless, the correlation of anti-hum an A C hR  antibody titer with 
the severity of clinical symptoms is poor '  and we recently investigated the 
possibility tha t the use of rat A ChR rather than hum an A C hR  as antigen in 
the radioim m unoassay might lead to a better correlation of disease state with 
antibody titer.® A crude rationale for such an approach can be found in com ­
parison of the schematic diagrams of hum an and ra t A C hR  shown in F igure  1. 
Both receptor molecules are depicted as having, in addition to  the a-bungaro- 
toxin-binding site, a limited num ber of antigenic determ inants only some of 
which (two in F igure  1) are com mon to ra t and hum an A C hR . M yasthenic 
sera probably contain a range of antibodies, each specific for one of the anti­
genic determ inants on hum an A ChR, and assay of such sera by using an excess 
of hum an A C hR  as antigen might be expected to detect ail these antibodies. 
Assays carried out by using rat A ChR, on the o ther hand, should detect only 
those antibodies directed towards the com m on antigenic sites. In  so far as it 
is reasonable to assume that the conserved sites are relatively im portant in the 
functioning o f the receptor molecule, then antibodies directed tow ards those 
sites could represent subclasses with particular relevance to the disease state 
in m yasthenia gravis.
N ine m yasthenic patients representing a gradation of degrees of disease 
severity were chosen to com pare the results of using ra t and hum an A C hR  in 
the radioim m unoassay for anti-A C hR antibodies. The titers obtained are shown 
in F igure 2 in which the patients A to I are arranged in o rder of increasing 
severity of disease. Tw o points clearly emerge from  the data. F irstly the 
an ti-(rat A C hR ) antibody titer is consistently lower than the an ti-(hum an 
A ChR) titer and secondly neither the an ti-(hum an) nor the an ti-(ra t) antibody 
titers show any clear correlation with disease state.
The ratio o f an ti-(ra t A C hR ) to an ti-(hum an A C hR ) antibody titer showed 
considerable variation between patients. Nevertheless, assays on serial serum 
samples from  individual myasthenic patients suggested that for a given patient 
the ratio might be relatively constant. We accordingly instituted a m ore com-
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Human AChR Rat e.j. AChR
F igure 1, Schematic diagrams of human AChR and rat AChR. The asterisk 
represents a-bungarotoxin at its specific binding site. The remaining geometrical 
shapes represent exposed antigenic sites only two of which are shown as being 
common to human and rat AChR.
Anti-(human AChR) H  
and
Anti-(e.j. rat AChR) 5  
antibody titres 
( nM toxin sites)




Patient, severity of symptoms ^
Figure 2. Anti-(human AChR) and anti-(extrajunctional rat AChR) antibody 
titers of serum samples from nine different myasthenic patien's. Titers are expressed 
as nM a-bungarotoxin binding sites.
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prehensive study in which serum samples from  a selected group of myasthenic 
patients w ere systematically analyzed fo r both anti-(extrajunctional rat A C hR ) 
and an ti-(hum an A C hR ) antibodies over an extended period of time. In order 
tha t the study might extend over periods during w hich the patients experienced 
both  a range of clinical states and widely varying anti-(hum an  A C hR ) antibody 
titers, partients were selected so that each underw ent a t least one series of 
plasm a-exchange during the course of the investigation.®
The overall results of the investigation are shown in F igure  3. The ratio  
o t anti-(extrajunctional ra t A ChR) to an ti-(hum an A C hR ) antibody titer was 
found to vary considerably between the thirteen patients exam ined, ranging 
from  0.01 to 0.63. Nevertheless, the ratio for a given patient was found to 
rem ain rem arkably constant over periods of up to 36 m onths (F igure  3) 
despite the fact tha t in all cases the an ti-(hum an  A C hR ) antibody levels 
fluctuated widely during the period of investigation, particularly  during plasma- 
exchange and subsequent periods of immunosuppression.® T he detailed be­
havior o f antibody titers is typified by the patterns shown in F igure  4  for 
patient 12 ( F igure  3 ) . This 64-year-old male patient underw ent two courses 
o f plasm a exchange coupled with immunosuppressive therapy during the study 
and his clinical response to these treatm ents has been described in detail by 
Behan et al.^^ A t the beginning of the present investigation, the patient was 
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Figure 3. Ratios of anti-(extrajiinctional rat AChR) antibodies: anti-(human 
AChR) antibodies for repeat serum samples from thirteen different myasthenic 
patients. The heights of the columns represent mean ratios. ±  Standard deviations 
are shown by the error bars surmounting the columns and the number of samples 
assayed is shown above each column. Mean anti-(human AChR) antibody titers 
shown below the histograms are expressed as nM a-bungarotoxin binding sites.













F igure 4. Ratios of anti-(extrajunctional rat AChR) antibodies: anti-(human 
AChR) antibodies and anti-(human AChR) antibody titers for patient 12 (F igure 
3) over a 36-month period. Titers are expressed as nM a-bungarotoxin binding 
sites.
to a course of six plasm a exchanges over an eight-day period (PE  1 F igure 4) 
at the end of which he showed little clinical improvement or overall change in 
anti-(hum an A C hR ) antibody titer. Five months later his condition worsened 
dramatically and his anti-(hum an A ChR) antibody titer rose sharply.® Through 
a second course of five plasm a exchanges (PE  2 F igure 4) his antibody titer 
fell in a familiar zig-zag pattern to a lower level and the patient showed 
marked clinical improvement. Immunosuppression was maintained over a 
three month period which resulted in further improvement in the patient. 
This improvement has now been sustained for two and a half years and
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corresponds to a lowered and stabilized anti-(hum an A ChR) antibody titer 
(F igure 4 ) .  Throughout these fluctuations in antibody titer and clinical 
condition, the ratio of anti-(extrajunctional ra t A C hR ) to anti-(hum an A ChR) 
antibody has varied little about a m ean value of approximately 0.3. It is 
tempting to see some importance in the sharp fall in ratio coincident with the 
m yasthenic crisis occurring after five months and the subsequent rise in ratio 
corresponding to the clinical improvement accompanying plasm a exchange. 
However the inverse relationship between anti-(hum an A C hR ) antibody titer 
and  the an ti-(ra t A ChR) antibody to anti-(hum an A ChR) antibody ratio 
apparent in F igure 4  was not always observed in other patients and discussion 
of the significance of these variations must await further data.
A further detailed example is shown in the case of patient 9, a thirty-year-old 
woman who was classified as Osserman G rade 3 initially and following an 
eleven day course of eight plasma exchanges, coupled with im munosuppres­
sion,^® improved to G rade 0, a state which has been m aintained for two years. 
In parallel w ith this clinical improvement the anti-(hum an A C hR ) antibody 
titers fell and stabilized at a lower value whereas the ratio of anti-(extrajunc­
tional ra t A C hR ) antibodies to anti-(hum an A ChR) antibodies remained 
rem arkably constant at approximately 0.1 throughout these changes (F igure 
5 ). Comparison of the data for patient 12 (F igure 4) with corresponding 
values for patient 9 (F igure 5) suggests the possibility of an inverse relation­
ship between anti-(hum an AChR) antibody titer and the an ti-(rat A C hR ): 
anti-(hum an A ChR) antibody ratio for different patients. A n exam ination of 
the data shown in F igure 3, however, shows that while there may be a general 
tendency for low anti-(rat A C hR )— anti-(hum an A ChR) ratios to be associated 
with high mean anti-(hum an AChR) antibody titers— there is no clear inverse 
correlation between the two values across the range of patients studied.
In addition to the anti-(extrajunctional ra t A ChR) antibodies, the anti- 
( junctional ra t A ChR) antibodies were also systematically assayed in the sera 
of the same thirteen myasthenia patients. In agreement w ith W einberg and 
H all we find that the titers obtained by using junctional rat A ChR as antigen 
in the radioimmunoassay are almost always lower than those obtained by using 
extrajunctional ra t AChR. In our study the ratio of anti-(junctional ra t A ChR) 
antibodies to anti-(extrajunctional ra t A ChR) antibodies was found to vary 
from  0.0 to 1.0 depending on the patient but to be relatively constant for a 
given patient (F igure 6) over periods of up to 34 months which, as discussed 
above, included wide variations in both clinical state and anti-(hum an A ChR) 
antibody titer. W einberg and Hall reported data from  ten samples of myas­
thenic sera and found ratios of anti-(junctional ra t A ChR) antibodies to anti- 
( extrajunctional ra t A C hR ) antibodies ranging from  0.6 to 1.0. They suggested 
that the apparent selectivity of some myasthenic antibodies for extrajunctional 
receptors might be m ade use of in the detection and purification of such recep­
tors. The feasibility of this approach is supported and extended by our results 
which show that particular patients (e.g., patient 2, F igure 6) can have sera 
with relatively high anti-(extrajunctional ra t A ChR) antibody titer and yet no 
detectable antibodies to junctional rat receptor.
The relatively constant proportions of both anti-(junctional ra t A ChR) 
antibodies and anti-(extrajunctional rat A ChR) antibodies to anti-(hum an 
AChR) antibodies within an individual patient over extended periods suggests 
that the overall pattern of anti-AChR antibody subpopulations is specific for 
that patient. It is also apparent from  our results that the pattern can vary













F igure 5. Ratios of anti-(cxtrajunctional rat AChR) antibodies: anti-(human 
AChR) antibodies and anti-(human AChR) antibody titers for patient 9 (F igure 
3) over a 24-month period. Titers are expressed as nM a-bungarotoxin binding 
sites.
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Figure 6. Ratios of anti-(junctionaI rat AChR) antibodies: anti-(extrajunctional 
rat AChR) antibodies for repeat samples from the myasthenic patients shown in 
Figure 3. The heights of the columns represent mean ratios. ±  Standard deviations 
are shown by the error bars surmounting the columns and the number of samples 
assayed is shown above each column. Mean anti-(extrajunctional rat AChR) anti­
body titers shown below the histograms are expressed as nM a-bungarotoxin binding 
sites.
widely between patients. Complementary but more ambiguous evidence for 
the same phenomenon is provided by a different set of experiments w ith sera 
taken from  ten of our thirteen (F igures 5 and 6) m yasthenic patients over 
periods of several months which, as before, included at least one plasma 
exchange with associated changes in clinical state and anti-(hum an A ChR) 
antibody titer. Excess of each sample of myasthenic serum  was used, in com ­
bination with goat anti-(hum an IgG ) antiserum  to precipitate bungaro-
toxin-labelled A ChR from  a hum an muscle extract. F igure 7 shows the results 
of these experiments in which the am ount of labelled A C hR  precipitated is 
expressed as a percentage of that precipitated by sera from  patient 3, an am ount 
arbitrarily defined as 100% . The am ount of ^-^I-a-bungarotoxin-labelled A ChR 
precipitated varies between patients from 48%  to 100% but is essentially 
constant for a given patient over the period of study (F igure 7 ) . These findings 
might result from  the absence o f particular anti-AChR antibody subpopulations 
in the sera from certain myasthenic patients. This explanation would also 
require heterogeneity in the toxin-binding components of the muscle extract 
which could well reflect the presence of proteolysis-induced fragments in the 
crude detergent solution. A second possible explanation involves the presence 
in different myasthenic sera of different concentrations of antibodies directed 
at the a-bungarotoxin binding site of the receptor molecule. Such antibodies 
could displace -̂"’I-labelled toxin from the toxin-AChR complex, so diminishing 
the am ount of labelled AChR precipitated by the relevant antiserum  sample.
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Preliminary experiments carried out by us favor the former explanation for 
partial precipitation of '^^-a-bungarotoxin-labelled AChR by excess of certain 
myasthenic sera in that incomplete precipitation of labelled AChR by excess 
of certain myasthenic sera can be increased to that characteristic of serum 
from  patient 3 by addition of the latter serum. This question is being further 
investigated in our laboratory.
W hether either one or both of the above explanations is valid, the constant 
value for a given patient of the percentage precipitation of labelled AChR 
shown in F igure 7 provides further evidence for a patient-specific pattern of 
anti-AChR antibody subpopulations in myasthenia gravis. The unchanging 
nature of this an til^dy  pattern suggests that the pattern is established in all 
cases before the start of our investigations and would be consistent with an 
initial limited exposure of the AChR antigen to the immune system. The data 
argue against the production of autoantibodies to AChR as a response to a 
continuous presentation of antigen that might result, for example, from  the 
shedding of receptor from the muscle surface or its exposure in modified form 
at that site. In this case the immune response would be secondary to some 
prim ary pathogenic factor and the antibody pattern would be expected to vary 
with each representation of antigen.
Exam ination of the case histories of this group of patients from  the time 
of our initial results has not revealed any interesting relationship between 
antibody subpopulation patterns and a particular clinical history. However, it 






Patltn t 10 11 12
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pi study
(months) 6 8 1 3 9  2 1 1 4 7 1
F igure 7. Amounts of “̂I-a-bungarotoxin-labelled human AChR precipitated by 
repeat serum samples from ten of the patients shown in F igure 3. Excess of the 
myasthenic serum was used in combination with goat anti-(human IgG) antiserum 
to precipitate labelled AChR and values are expressed as percentages of the amount 
of labelled AChR precipitated by serum from patient 3 under identical circumstances. 
The heights of the columns represent mean percentages. ±  Standard deviations are 
shown by the error bars surmounting the columns and the number of samples 
assayed is shown above each column.
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anti-AChR antibody subpopulation patterns in myasthenic sera may shed some 
light not only on the aetiology of the disease but also on its particular progress 
in individual patients.
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D iscu ssion
A. V in c e n t : We have a series of patients whose serums were unable to 
fully precipitate the receptor. This appeared to be due to a subpopulation of 
antibodies that are capable of displacing the toxin off the receptor. Have you 
looked at this phenomenon?
R. H a r r iso n : We have not. We assumed that failure to obtain complete 
precipitation was due either to the absence of subpopulations of antibody that 
bind toxin, or to proteolysis of receptor in the assay.
A m  Clin Biochem 1981; 18:146-152
An assessment of radioimmunoassay procedures 
for determination of anti-acetylcholine receptor 
antibodies in the sera of patients with myasthenia 
gravis
B C A R T E R ,  R H A R R I S O N ,  G G L U N T ,  H M O R R I S ,
T S A V A G E - M A R E N G O ,  A N D  F A S T E P H E N S O N
From the Department o f Biochemistry, University o f Bath, Claverton Down, Bath BA2 7A Y
SUMMARY A reproducible radioimmunoassay procedure for the determination of anti-acetylcholine 
receptor antibodies in the sera of patients with myasthenia gravis is described and examined in 
detail. The assay combines features of a number of methods previously outlined and allows repeat 
determinations of antibody titre in a given myasthenic serum sample with coefficient of variation 
6 %. The mean ±  standard deviation for normal human serum anti-acetylcholine receptor antibodies 
was found by this procedure to be 0*024 i  0*033 nmol/1 a-bungarotoxin binding sites whereas the 
range for myasthenic patients was 0-139 • 14 nmol/1 with a mean value of 7* 55 nmol/1 a-bungarotoxin 
binding sites.
Myasthenia gravis is generally recognised to be an 
autoimmune disease in which patients develop an 
immune response to self nicotinic acetylcholine 
receptor (AChR) at the neuromuscular junction.^ 
Approximately 90% of myasthenia patients show 
elevated serum levels of anti-AChR antibodies,^ and 
there is an increasing demand for determination of 
such levels as an aid to diagnosis. Despite the usual 
presence of anti-AChR antibodies in the sera of 
myasthenia gravis patients, correlation of antibody 
titre with severity of symptoms is generally poor 
between patients.®”® Nevertheless, titres followed for 
a given patient over a period of time can reflect the 
clinical state of the patient, and serial assays can be 
used to monitor the effects of particular treatment 
regimens.®
A basic radioimmunoassay for the determination 
of anti-AChR antibody titres in human sera has 
been reported by a number of groups of workers.®
The assay involves specific labelling of human AChR 
with radiolabelled snake venom a-toxin followed 
by the use of the labelled AChR, in excess, to 
precipitate anti-AChR antibodies present in the 
patient’s serum. The assay is relatively complex, and 
a number of aspects of the published procedures 
differ widely, depending upon the authors. In many 
cases, moreover, exact experimental details are 
unclear, and the reasons underlying the choice of a
particular technique or set of conditions are un­
specified. We now report an examination of a 
number of variable factors in the radioimmuno­
assay, the results of which lead to an overall method 
suitable for routine application.
Material and methods
Myasthenic and normal human sera were quickly 
frozen and stored at — 20°C before assay. Human 
muscle was obtained from lower limb amputations. 
Within 15 minutes of amputation, calf muscle was 
crudely dissected free from fat, tendon, and skin, 
transported in icç or solid carbon dioxide (approx. 
20 minutes), and stored at — 80°C.
a-Bungarotoxin from Bungarus multicinctus was 
purchased from Boehringer, Mannheim, West 
Germany as a lyophilised powder (1 mg), which 
was dissolved in 0*05 mol/1 potassium phosphate 
buffer, pH 7*5 (2 ml), and stored at —20^0 before 
use. Na ®̂®I in dilute NaOH solution (100 mCi/ml) 
was supplied by the Radiochemical Centre, Amer- 
sham, UK, and benzoquinonium chloride was a 
generous gift from Stirling Winthrop Inc, Rensse­
laer, NY,' USA. All other chemicals were from 
Sigma Chemical Co, Kingston upon Thames, UK, 
or from BDH Chemicals, Poole, Dorset, UK.
^®®I-Labelled a-bungarotoxin was prepared
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essentially according to the procedure of Urbaniak et 
alf^ as follows. Stock solutions (20 |j l 1) of a-bungaro­
toxin and Na (10 jxl) were mixed with 0-25% 
(w/v) chloramine T in 0*05 mol/l potassium phos­
phate buffer, pH 7*5 (20 [jil), and stirred for 1 minute 
at 22°C. 0*016% (w/v) Sodium metabisulphite in 
0*05 mol/l potassium phosphate buffer, pH 7-5 
(750 [tl), and 1 % (w/v) KT in the same buffer (200 [l\) 
were added to the iodination mixture to stop the 
reaction, giving a final total volume of 1 ml. 
Labelled a-bungarotoxin was separated from free 
by passage of the reaction mixture down a 
column (27 cm x 1 cm) of Sephadex G-25, which 
had been equilibrated with 0 01 mol/l potassium 
phosphate buffer, pH 7*5, containing 1% (w/v) 
bovine serum albumin. The column was eluted with 
the same buffer. Fractions (1 ml) were collected, 
and samples (10 [x]) were counted for radioactivity. 
Fractions corresponding to the first protein-contain­
ing peak of radioactivity were combined to give 
approximately 0*4 [xmol/1 ^®®I-labelled a-bungaro­
toxin with specific activity approximately 0*3 
mCi/ml. The labelled toxin was stored at 4°C for up 
to three weeks.
Alternatively, ̂ ^®I-labelled a-bungarotoxin is avail­
able from the Radiochemical Centre, Amersham, 
UK.
Goat anti-(human IgG) antiserum was obtained 
by repeated (three-weekly) intramuscular injections 
of purified̂ ® human IgG [1*5 mg in Freund’s 
adjuvant (0*5 ml) (‘complete’ for the first injection 
and ‘incomplete’ thereafter)]. After all injections but 
the first, serum (200 ml) was taken, and the presence 
of anti-(human IgG) antibodies was established by 
double-diffusion against human IgG.̂ ® The presence 
of adequate antibody titres was checked by use 
directly in the radioimmunoassay (see Results and 
Discussion section) of a standard sample of myas­
thenic serum when maximum titres should be 
obtained by incubation of 100-200 fxl goat anti­
serum. Suitable titres were normally achieved after 
the third injection.
Goat anti-(human IgG) antiserum of suitable 
titre was alternatively purchased from Miles 
Laboratories, Stoke Poges, Bucks, UK.
^^®I-Radioactivity was routinely counted in an 
LKB 1280 Ultrogamma counter.
EXTRACTION OF HUMAN A Ch R
Frozen human muscle (approx. 200 g) was chopped 
finely and homogenised in a Sorvall Omnimix at 
maximum speed for 1 minute at 4°C in 0*02 mol/l 
potassium phosphate buffer, pH 7*5 (4 volumes), 
containing 1 mmol/1 EDTA, 0*5 mmol/1 phenyl- 
methylsulphony] fluoride, 0*1 mmol/I benzethonium 
chloride, and 0*01 % (w/v) NaNg and centrifuged at
2000 g for 45 minutes at 4°C. The pellet was resus­
pended and homogenised as before in the above 
buffer (1 volume) containing additionally 2*5% 
(v/v) Triton X-100 (extraction buffer), stirred for 
16 hours at 4°C (or for 3 hours at 20°C), and 
centrifuged at 20 000 g for 5 minutes at 4°C followed 
by 100 000 g for 45 minutes at 4°C. The resulting 
supernatant was filtered through glass wool and 
stored at 4°C.
Re-extraction of the muscle homogenate was 
occasionally found to be profitable in the case of 
preparations with relatively high activity. Thus the 
pellet obtained from centrifugation at 100 000 g was 
rehomogenised in extraction buffer (1 volume) as 
described above, stirred for 16 hours at 4°C, and 
centrifuged as above to give a second supernatant 
with a-toxin-binding activity.
d e t e r m i n a t i o n  o f  A C hR  CONCENTRATION 
The concentration of AChR in soluble extracts of 
human muscle was determined by the specific 
binding of ̂ ^®I-labelled a-bungarotoxin. The receptor 
extract (100 (xl) was incubated with 15 nmol/1 
^^®I-labelled a-bungarotoxin solution in extraction 
buffer (50 (xl) for 15 minutes at 22°C before addition 
of saturated (NHJg SO4 solution to give 40% 
saturation overall and further incubation for 24 
hours at 4°C. The resulting precipitate was col­
lected by vacuum filtration in a Millipore filter 
tower on Whatman GFC glass fibre filters (0*5 cm), 
washed with 40% saturated aqueous (NH4)gS04 
solution, and counted for radioactivity. Sufficient 
excess of a-toxin was ensured by repetition of the 
assay using serial two-fold dilutions of receptor 
extract in extraction buffer (100 fxl) when a linear 
relationship between dilution number and pre­
cipitated radioactivity should be obtained.
Specific binding of a-toxin was blocked in parallel 
incubations performed as above but containing 
additionally 1*0 nmol/I benzoquinonium chloride 
or 0 1 mmol/1 d-tubocurarine. Subtraction of the 
counts so obtained gave specifically-bound radio­
activity in the test sample.
ASSAY OF A NT I - A C h R  ANTIBODIES
Detergent extract (5 ml) of human muscle containing 
approximately 0*5 nmol/1 specific toxin-binding 
sites (see below) was incubated with a 10-fold molar 
excess of ^^®I-labelled a-bungarotoxin in extraction 
buffer (<100 (xl) for 15 minutes at 22°C. A sample 
(100 [xl) of the resulting solution was incubated with 
myasthenic serum (5 fxl) for 16 hours at 4°C (or for 
2 hours at 22°C), and the labelled AChR-antibody 
complex was precipitated by addition of goat anti- 
(human IgG) antiserum (100-200 [xl, see Methods 
section) and storage for 24 hours at 4°C (or for 2
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hours at 22°C). The resulting precipitate was 
separated by centrifugation at 3000 g for 10 minutes, 
and the pellet was washed twice with 0 01 mol/l 
potassium phosphate buffer, pH 7-5, containing 
0-15 mol/l NaCl, 1 % (v/v) Triton X-100, and 01  % 
(w/v) NaNg and counted for radioactivity. Specific 
binding of a-toxin was blocked in parallel incubations 
performed as above but containing additionally 
1 0 mmol/1 benzoquinonium chloride (or 01  
mmol/I d-tubocurarine or O T mmol/1 non-radio­
active bungarotoxin). Subtraction of the counts so 
obtained gave specifically-bound radioactivity in the 
test sample, which can then be related to the concen­
tration of a-bungarotoxin-binding sites in the AChR 
extract. Thus the antibody titre is expressed as moles 
of specific a-bungarotoxin binding sites precipitated 
per litre of serum.
Maximal formation of AChR-antibody complexes 
was routinely checked by repeating the assay using 
serial twofold dilutions (with normal human sera) 
of antisera in order to ensure a linear relation 
between the volume of undiluted serum and pre­
cipitated radioactivity.
Results and discussion
The concentration of soluble AChR in the primary 
detergent extracts of human muscle was found to 
vary from OT to 2-5 nmol/1 a-bungarotoxin- 
binding sites over 20 preparations with a mean value 
of 0*52 nmol/I toxin-binding sites. This represents a 
mean recovery of 0*49 pmol toxin-binding sites per 
gram muscle.
The wide variation in a-bungarotoxin-binding 
activities of different muscle samples may reflect 
differences in the clinical state of the muscle samples 
before amputation. Muscle was always obtained 
from legs amputated because of either vascular 
disorders or diabetic gangrene, and it is possible 
that the different samples had been subjected to 
varying periods of ischaemia with attendant partial 
autolysis. Moreover most amputees were patients 
over 60 years of age who are known^^ to be subject 
to significant and varying degrees of motor de­
nervation. This raises the further possibility of 
variable extents of acetylcholine receptor prolifer­
ation̂ ® in the muscle samples we examined, al­
though this was not reflected in binding studies 
carried out by us on purified receptor preparations.^®
Attempts to prepare useful extracts of acetylcho­
line receptor from postmortem muscle proved to be 
generally unsatisfactory, giving receptor concen­
trations of less than OT nmol/1 toxin binding sites. 
This probably reflects the occurrence of autolysis 
during the extended periods (more than 6 hours) 
elapsing between death and freezing of the muscle.
With regard to the method of extraction of AChR, 
the inclusion in the buffers of phenylmethylsulphonyl 
fluoride and benzethonium chloride as anti-proteo­
lytic agents was found generally to improve the 
yield of AChR. Similar yields of AChR were found 
whether extraction in Triton-containing buffer was 
carried out for 16 hours at 4°C or for 3 hours at 
20°C.
The concentration of AChR extract (0*5 nmol/1) 
recommended in the Methods section for use in the 
radioimiuunoassay of anti-AChR antibody titres is 
only slightly less than the mean value in the extracts. 
This inevitably means that many preparations 
contain concentrations of receptor suboptimal for 
this purpose, and re-extraction of the muscle 
homogenate (Methods section) was found to give 
secondary extracts whh 46 ± 3 3 % ( ±  SD, 6 
preparations) of the toxin-binding activity of the 
primary extract. Such re-extraction was often 
worthwhile in the case of relatively high-activity 
receptor preparations in order to supplement stocks 
of useful receptor.
Storage of AChR extracts at 4°C for periods of up 
to three months led to less than 40% loss of toxin^ 
binding activity.
In the determination of AChR concentration, 
pre-incubation of AChR with ^2®I-labelled a- 
bungarotoxin for periods of longer than 15 minutes, 
up to 5 hours, was found not to affect the results. 
On the other hand, incubation of the AChR-toxin 
complex with (NH4)gS04 for less than 16 hours led 
to diminished precipitation of radioactivity.
Separation of AChR-toxin complex from free 
toxin can be effected alternatively by filtration 
through DEAE cellulose filter discs on a Millipore 
filtration system̂ ® followed by washing the discs with 
0*01 mol/l potassium phosphate buffer, pH 7*5, 
containing 0*1% (w/v) bovine serum albumin, 
0*01% (w/v) NaNg, and 1*0% (v/v) Triton X-100. 
In our hands, specifically-bound radioactive counts 
were consistently found to be 60-85% lower than 
those obtained by using (NHJgSO^ precipitation, a 
decrease that is at least partially attributable to 
saturation of the filters by the high levels of protein 
in the extract.® These levels can be reduced by 
dilution of the extract before filtration, which can 
lead, however, to unacceptable loss of sensitivity in 
the case of lower activity extracts. The DEAE filter 
assay is, nevertheless, much faster than that based 
on (N H J2SO4 precipitation and can be used to give 
rapid estimates of AChR concentration for use in 
the radioimmunoassay of anti-AChR antibodies.
A third method of separation of AChR-toxin 
complexes from free toxin in the routine assay of 
AChR concentrations involves the addition of 
excess myasthenic serum followed by goat
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anti-human y-globulin serum, as described by 
Lindstrom.® Varying results can, however, be 
obtained by using sera from different patients in 
this assay, and care must be taken to use serum from 
a selected individual if values given by this method 
are to be consistent and comparable with those 
obtained by other means. In a study of serum 
samples taken from 10 myasthenic patients over a 
period of several months, we found that amounts of 
AChR-toxin complex precipitated from a standard 
extract of AChR by excess of myasthenic serum 
varied between serum samples but was constant for 
sera from a given patient.^® The greatest precipitation 
of complex was consistently effected by sera from 
one particular patient and represented 80-90% of 
that brought down by (NHJgSO^. Sera from the 
remaining nine patients precipitated 46-86% of the 
highest value.
Identical results in the assay for AChR were 
obtained when either 1 0  mmol/1 benzoquinonium 
chloride or 0 1  mmol/I d-tubocurarine were used to 
block specific binding of ^^^I-labelled a-bungaro­
toxin to the receptor. We found that lower con­
centrations of the respective blocking agents led to 
decreased inhibition of toxin binding. Closely 
similar results were also obtained when specific 
binding was eliminated by treatment of the control 
samples with excess (in this case 0 1  mmol/1) of 
unlabelled a-bungarotoxin, as described by Newsom- 
Davis et The use of a large excess of unlabelled 
ligand in this way is a commonly used technique in 
studies of receptor binding. The method depends 
upon the displacement of labelled ligand only from 
sites having high affinity in the context of the assay 
and as such can be subject to interference from 
‘non-specific’ binding with high affinity. Such 
interference could also affect assays for specific 
binding that depend upon displacement of radio- 
labelled ligand by a chemically different ligand (eg, 
by benzoquinonium or d-tubocurarine). In this case, 
however, the probability of competition between 
labelled and unlabelled ligand for the common ‘non­
specific’ site is much less, and, in general, the use of 
well-characterised, structurally distinct unlabelled 
ligands is to be preferred in the displacement of 
specific binding.^®
The concentration of ̂ ^^I-labelled a-bungarotoxin 
(15 nmol/I) recommended in the assay for AChR 
activity represents 5 nmol/1 in the incubation mixture, 
which is approximately 14 times the corresponding 
concentration of AChR obtained by using an average 
receptor preparation. Figure 1 shows that pre­
cipitation of AChR-toxin complex can continue to 
increase as the toxin: AChR molar ratio increases 
up to values of 6-10. In practice, it was found that 
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Fig. 1 Formation o f  toxin-AChR complex at varying 
molar ratios o f  ^^^I-labelled <x-bungarotoxin to AChR. 
Each o f  two samples o f  AChR extract (100 [lI) was 
separately incubated with increasing concentrations o f  
^^^I-labelled a-bungarotoxin in extraction buffer (50 \lI) 
for 15 minutes at 22°C. (AŒTOsS'Oa was then added to 40%  
saturation, and the mixture was further incubated fo r 24 
hours at 4°C. The precipitates were collected on glass 
fibre filters, washed with 40% saturated (N H i)iSO i 
solution, and counted. Specifically-bound a-toxin was 
determined by using benzoquinonium chloride in parallel 
incubations as described in the text.
a-bungarotoxin rarely led to non-linear response on 
dilution of AChR in the assay Isee the Methods 
section). The dissociation constant, Kd , for binding 
of 1251-iabelled a-bungarotoxin to AChR determined 
from the data of Fig. 1 had a value of 0 32 nmol/1, 
a value some 15 times lower than the concentration 
of a-toxin used in the assay.
In the assay for anti-AChR antibodies, incubation 
of labelled toxin-AChR complex with myasthenic 
serum for varying lengths of time at 4°C showed 
that apparent anti-AChR antibody titres increased 
up to approximately 16 hours, after which titres 
remained constant for incubation times up to a total 
of 48 hours. Identical titres were obtained for the 
same myasthenic serum samples when incubations 
were alternatively carried out for 2 hours at 22°C.
Incubation of labelled AChR-antibody complexes 
with goat anti-(human IgG) antisera at 4°C was 
found to lead to maximal anti-AChR antibody 
titres only after 24 hours. Titres fell slightly when 
longer incubation times, up to 60 hours, were 
employed. Results identical with those obtained by 
incubation for 24 hours at 4°C were obtained
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alternatively by incubation for 1, 2, or 4 hours at 
220C.
As described in the Methods section, serial 
dilutions of myasthenic sera were made routinely in 
order to ensure that the antibody assay was being 
done with sufficient molar excess of labelled AChR. 
An examination of the dependence of apparent 
antibody titres on the molar ratio of labelled AChR 
to specific antibodies showed that molar ratios of 
approximately 3:1 were sufficient to ensure maximal 
precipitation of anti-AChR antibodies in the 
myasthenic samples tested (Fig, 2). Maximal 
formation of AChR-anti-AChR antibody complexes 
requires not only a minimum AChR-antibody ratio 
but also a minimum concentration of AChR, which 
in turn depends upon the dissociation constants of 
the AChR-antibody complexes. A study of three 
myasthenic sera showed (Fig. 3) that minimal 
concentrations of AChR of 0*3-0*5 nmol/1, 
depending on the serum sample, were sufficient to 
effect maximum formation of complex. This range 
is just below the level 0*5 nmol/1 of AChR con­
centration suggested for use in the radioimmuno­
assay. Nevertheless the results indicate that the 
latter value may be close to a minimum acceptable 
figure for some myasthenic sera and that higher 
concentrations of receptor, if they can be obtained, 
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Fig. 2 Formation o f AChR-anti-AChR antibody com­
plexes at varying molar ratios o f  toxin-labelled AChR to 
antibody. A single appropriate dilution o f  serum was made 
from each o f  three different myasthenic patients. Samples 
(5 (x/) o f  each were incubated with increasing amounts o f a 
fixed concentration o f  toxin-labelled AChR, and labelled 
AChR-antibody complexes were precipitated and counted 
as described for the antibody assay procedure {see text). 
The molar concentrations o f antibody were, in each case, 
obtained from the maximum amount o f  AChR precipitated. 
Concentrations o f toxin-labelled AChR were e ,  1-02 
nmol j I, Â, 1-32 nmol 11, and 0 ,0 -3 2  nmol j I.
AChR (nm ol /1 )
Fig. 3 Formation o f  AChR-anti-AChR antibody com­
plexes by varying concentrations o f  toxin-labelled AChR. 
A single appropriate dilution o f serum was made from each 
o f three different myasthenic patients. Samples (5 y.1) o f  
each were incubated with a constant amount of toxin- 
labelled AChR at different concentrations so that a constant 
molar ratio o f toxin-labelled AChR: anti-AChR anti­
bodies was maintained. These ratios were e ,  3:1; A, 7:1; 
0 ,10:1 . Labelled AChR-antibody complexes were pre­
cipitated and counted as described for the antibody assay 
procedure {see text).
The procedure for radioimmunoassay of anti- 
AChR antibodies outlined in the Methods section 
allows the determination of relatively reproducible 
titres. Thus, repeat determinations on an individual 
serum sample using a single extract of acetylcholine 
receptor and a single freshly prepared sample 
of î ®I-labelled a-bungarotoxin gave values of 
2*99 ±  017 (±  SD, 15 assays) nmol/1 a-bungaro­
toxin binding sites. Repeat assays of the same serum 
using a single extract of acetylcholine receptor and 
four different preparations of ^^ Î-labelled a- 
bungarotoxin gave values of 3-23 ±  0*31 (±  SD) 
nmol/1 a-bungarotoxin binding sites (where the 
mean value for each toxin preparation resulted from 
15 separate assays). Repeat assays of a différent 
serum sample using a single preparation of 
labelled a-bungarotoxin and four different extracts 
of acetylcholine receptor gave values of 1 *80 ±  0*22 
(±  SD) nmol/1 a-bungarotoxin binding sites (where 
the mean value for each extract of acetylcholine 
receptor resulted from 10 separate assays).
It can be seen that rather more variability in these 
assays is usually found when different ^^ Î-labelled 
a-bungarotoxin and acetylcholine receptor prepara­
tions are used. Titres obtained for a given serum 
sample using a single extract of acetylcholine 
receptor and sample of labelled toxin change little 
over a period of less than three weeks. Thus repeat 
assays of a single serum sample using one extract of 
acetylcholine receptor made using freshly 
labelled a-bungarotoxin and the same toxin after'
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storage at 4°C for two and a half weeks gave values 
of 2*89 ±  0 10 (±  SD, 15 assays) and 2*99 ±  017 
(ib SD, 15 assays) nmol/1 a-bungarotoxin binding 
sites respectively. Storage of labelled toxin for 
periods of longer than three weeks was found to lead 
to much greater variation in antibody titres, and 
^^^I-toxin was not used beyond this point. We have 
found no evidence of systematic variation in anti­
body titres of given serum samples arising from 
changes in the extracts of acetylcholine receptor on 
storage at 4°C for up to three months.
In view of the somewhat greater consistency of 
assays obtained by using single ^^^I-labelled a-toxin 
and receptor preparations, there is some advantage 
to be gained by storing serial serum samples taken 
from an individual patient over a period of treatment 
in order to assess most accurately the effect of such 
treatment on anti-AChR antibody titres. Changes in 
titre induced by treatments such as immuno­
suppression and plasma-exchange® are, however, 
commonly much greater than the variations observed 
using several preparations of labelled toxin and 
receptor, and the precaution is usually not essential.
We have found that it is useful to store (at — 80°C) 
aliquoted standard samples of myasthenic serum 
which can be used to check the performance of each 
new acetylcholine receptor extract and the ^̂ ®I- 
labelled a-toxin preparation in the radioimmuno­
assay.
Apart from the use of the radioimmunoassay in 
monitoring a patient’s progress, the assay has, as 
already mentioned, a limited use in diagnosis and 
while not all clinically diagnosed myasthenic 
patients have anti-AChR antibody titres significantly 
above the normal range, most do. Assay of normal 
volunteers by the procedure discussed here gave 
values of 0*024 ±  0*033 (±  SD, duplicate assays on 
20 individuals) nmol/1 a-bungarotoxin binding sites, 
while anti-AChR antibody titres in clinically 
diagnosed myasthenic patients ranged from 0 to 
139*14 nmol/1 a-bungarotoxin binding sites with a 
mean value of 7 • 55 nmol/I sites.
Perhaps the most troublesome aspect of the assay 
procedure is the requirement for a minimum con­
centration of acetylcholine receptor in the extracts 
of human muscle, by no means all of which are 
directly usable in the radioimmunoassay. It is 
possible to increase the concentration of receptor 
extracts by vacuum dialysis which, although it gave 
increased non-specific binding of a-bungarotoxin 
and corresponding loss of sensitivity in the assay, 
did not obviously affect the titres obtained. As has 
been discussed, it is difficult to predict which samples 
of amputated muscle will have high receptor 
activity, and the more readily obtained postmortem 
muscle usually gives very low activity extracts. It has
been reported^^ that the use of AChR purified from 
rat muscle as antigen in the radioimmunoassay for 
anti-AChR antibodies in human sera gave the same 
titres as were obtained when purified human muscle 
AChR was used as antigen. In our experience, 
however, the use of rat receptor leads to very much 
lower titres compared with human AChR and 
consequently to a less sensitive system. Moreover, 
we found that correlation of disease severity with 
anti-AChR antibody titre was not improved by the 
use of rat antigen.^® These results do not encourage 
the use of experimental animals as an alternative 
source of muscle receptor, and this conclusion is 
supported by the finding that the use of rabbit 
muscle AChR also leads to relatively low anti- 
AChR antibody titres in the radioimmunoassay.^^ 
The temperatures and times of a number of the 
incubation steps in the overall procedures outlined 
here can be modified, as described, to fit the working 
convenience of laboratories engaged in the assay. 
Provided that the assay is performed within the 
limits discussed above, we have found the method 
to be reasonably convenient to apply and readily 
operated successfully by workers new to the 
determination.
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Summary
Acetylcholine receptors were partially purified from foetal and adult human 
muscle and their binding to myasthenic serum was compared. No significant 
differences between the binding characteristics of the two receptor types were 
detected; indicating the absence, at least in 14-22-week-old foetuses of antigenic 
sites unique to foetal receptor and recognised by myasthenic sera.
Key words: Acetylcholine receptors -  Adult muscle -  Foetal muscle -  Myasthenia 
gravis
Introduction
Sera from some 90% of myasthenic patients show the presence of anti-acetylcho­
line receptor (AChR) antibodies (Harrison and Behan 1983) as assayed by the 
commonly-used radioimmunoassay procedure (Lindstrom et al. 1976) using adult 
human AChR as antigen. If rat AChR is used as antigen in this assay then titres are 
generally smaller and are shown by a lower percentage of myasthenic patients 
(Savage-Marengo et al. 1979; McAdams and Roses 1980). Titres obtained by using 
extrajunctional AChR from denervated rats as antigen are usually found to be
This work was supported financially by the Muscular Dystrophy Group of Great Britain. 
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higher than by similar use of normal junctional rat AChR (Weinberg and Hall 1979; 
Savage-Marengo et al, 1980; Harrison et al. 1981), a fact which led Weinberg and 
Hall (1979) to suggest that embryonic AChR, in many ways similar to the extrajunc­
tional adult receptor, might constitute the auto-immunogen in myasthenia gravis. In 
view of the fact that the use of rat AChR in this way can only give information 
about a limited, cross-reacting proportion of the total anti-human AChR antibody 
population, we have made a direct comparison of antibody titres in myasthenic 
patients by using, as antigen, adult human AChR on the one hand and foetal human 
AChR on the other.
Materials
Serum samples from myasthenic patients and normal human controls were 
quickly frozen and stored at -20°C. Adult human muscle was obtained from lower 
limbs amputated from patients with severe vascular disease and in 1 case from an 
otherwise healthy individual following a road traffic accident. Within 15 min of 
amputation, the calf muscles were crudely dissected free from fat, tendon and skin, 
transported in ice or solid carbon dioxide and stored at -80°C. Human foetuses 
were obtained from prostaglandin-induced terminations (foetal age 14-22 weeks); 
limb, back and intercostal muscles were dissected prior to use.
Goat anti-(human IgG) antisera were raised by repeated intramuscular injections 
of purified human IgG.
a-Bungarotoxin was obtained from the Boehringer Corporation (Lewes, Sussex, 
U.K.). Naja naja siamensis venom was from the Miami Serpentarium (Miami, FL, 
U.S.A.). Carrier-free Na *̂ Î in dilute NaOH solution (100 mCi/ml) was from the 
Radiochemical Centre, Amersham, Bucks, U.K. and benzoquinonium chloride was a 
generous gift from Stirling Winthrop Inc., Rensselaer, NY,/U.S.A. Gel filtration 
reagents were supplied by Pharmacia Ltd., Hounslow, U.K. All other materials were 
from Sigma Chemical Co., Kingston-upon-Thames, U.K. or from B.D.H. Chemicals, 
Poole, Dorset, U.K.
Methods
'^^I-labelled a-bungarotoxin and purified human AChR were prepared and the 
latter was assayed as previously described (Stephenson et al. 1981).
Anti-AChR antibody levels were determined essentially as described by Carter et 
al. (1981). Purified AChR (0-1.7 nM a-bungarotoxin-binding sites) was incubated 
with a 10-fold molar excess of ['^^Ij-a-bungarotoxin for 45 min at 22°C. Parallel 
control incubations contained additionally 1 mM benzoquinonium chloride to block 
specific binding of a-bungarotoxin. Duplicate samples (100 /ul) of the resulting 
solutions were incubated with a fixed concentration of myasthenic serum or IgG 
(5 jal, appropriately diluted with normal human serum or IgG, respectively) for 2 h 
at 22°C (or 16 h at 4°C) and the labelled AChR-antibody complex was precipitated
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by the addition of goat anti-(human IgG) antiserum (65 j u l )  and storage for 16 h at 
4°C (or 2 h at 22°C). The resulting precipitate was separated by centrifugation at 
3000 X g for 10 min (4°C) and the pellet was washed twice with 10 mM potassium 
phosphate buffer, pH 7.4, containing 0.15 M sodium chloride, 1% (v/v) Triton 
X-100 and 0.1% (w/v) sodium azide and counted for radioactivity in an LKB 1280 
Ultrogamma counter. Precipitated specific a-bungarotoxin binding sites were de­
termined by subtraction of the counts obtained in the presence of benzoquinonium 
chloride. In each case excess of antigen was ensured by repeating the assay using 
serial 2-fold dilutions of serum or of IgG when a linear relationship should be 
obtained between the volume of undiluted serum and precipitated radioactivity.
Protein was determined by the method of Lowry et al. (1951) using BSA as 
standard.
Saturation curves of the form
were fitted to data points by the Maximum Likelihood Method (Silvey 1975). Here, 
a is yn̂ axi Y is a measure of how quickly y approaches ŷ ^̂ x x increases, and 
log(2 + )8)/log Y is the x-value at half maximal saturation. Normal errors of y-values 
were assumed, so that the fitting method was the same as least squares fitting; this 
was carried out using a standard computer package to minimize, iteratively, the sum 
of squared distances from the plotted points to the fitted curve. The identity of pairs 
of fitted curves was tested by means of the Asymptotic Likelihood Ratio Test (Silvey 
1975) in terms of the statistic where
2 / • r 1 J 1 ^ 1 / RSS p o o l e d  c u r v e
X  =  ( s i z e  o f  p o o l e d  s a m p l e ) X i o i ( . c u r y e  I + KSS 2 ^
and
RSS = residual sum of squares i.e. sum of squares of distances of points from 
fitted curve.
Significant difference at the 95% level between the two curves requires that > 7.8.
Results
Partially purified adult human AChR showed specific activities ranging from 0.3 
to 0.8 nmol a-bungarotoxin-binding sites/mg protein, the corresponding figure for 
foetal human AChR being 0.10 nmol/mg.
Serum from each of 3 myasthenic patients was assayed for anti-AChR antibodies 
by using both purified adult human AChR and purified foetal human AChR in the 
radioimmunoassay. In each case increasing concentrations of antigen were tested 
leading to a saturation curve from which antibody titre and affinity were de­
termined. Preliminary experiments showed that unpurified AChR extracts in which 
receptor concentrations were frequently below 0.5 pmol/ml, were less suitable for 
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complete saturation, led to a greater scatter of points. The experiments were 
repeated for 2 of the 3 myasthenic patients by using IgG purified from their serum 
instead of serum itself.
Parameters obtained from the various saturation curves are shown in Table 1 in 
which it can be seen that the values of anti-AChR antibody titre and Kd for a given 
serum sample are very similar irrespective of whether purified adult human AChR or
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Fig. 1. Representative saturation curves for the binding of purified AChR preparations with anti-(AChR) 
antibodies in myasthenic IgG from patient 3 (see Table I). An appropriate dilution of antisera was 
assayed with increasing concentrations of purified antigen, as described in the Materials and Methods 
sections. Antigens were: (a) foetal human AChR; (b) adult AChR from patients with SVD (severe 
vascular disease), and (c) adult AChR from RTA (road traffic accident) victim.
Each point is the mean of duplicate determinations. The values are taken from 2 independent assays 
using 2 different foetal AChR preparations (a)\ 3 independent assays using 3 different adult (SVD) 
AChR preparations (h); 1 assay using 1 adult (RTA) AChR preparation (c).
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purified foetal human AChR is used as the antigen. The similarity of pairs of fitted 
curves is reflected in the values which in no case exceed 4.10 (see Methods 
section).
As a check on the vahdity of using commonly amputated ischemic muscle as a 
source of normal junctional AChR, IgG from patient 3 was additionally assayed by 
using AChR purified from normal adult muscle (amputated followed a road traffic 
accident). No significant difference was found between the fitted saturation curve so 
obtained and that obtained with AChR from ischemic muscle.
Data for IgG from patient 3, representative of all the results in Table 1, are 
shown in Fig. 1.
Discussion
Preferential interaction of myasthenic IgG with denervated, as opposed to normal 
rat muscle AChR was first reported by Almon and Appel (1975) who demonstrated 
that such IgG inhibited binding of a-bungarotoxin to AChR from denervated but 
not normal muscle. These workers also used radioimmunoassay to show precipita­
tion of denervated rat muscle AChR by myasthenic IgG; normal muscle AChR was 
not so precipitated. Weinberg and Hall (1979) subsequently extended this latter 
approach by the radioimmunoassay of anti-AChR antibody titres in the sera of 10 
myasthenic patients by using, as antigen, either extrajunctional AChR from de­
nervated rat muscle or junctional AChR from normal rat muscle. Titres from a given 
serum sample were found to differ depending on the antigen; ratios of anti-ex- 
trajunctional AChR : anti-junctional AChR antibodies ranging from 1.0 to 2.4. 
These findings were interpreted in terms of the presence of antigenic sites unique to 
extrajunctional receptor and recognized by myasthenic sera and suggested that such 
sera might also preferentially interact with embryonic AChR; itself extrajunctional. 
Indeed this was investigated in the case of 1 myasthenic serum sample which showed 
the same antibody titre whether assayed by using, as antigen, either AChR from 
denervàted adult rat or that from 18-day-old rat embryos (Weinberg and Hall 1979).
Anti-rat AChR antibodies, whether anti-extrajunctional AChR or anti-normal 
AChR, usually comprise only a small proportion of the total anti-human AChR 
antibody population (Harrison et al. 1981) and the above results cannot necessarily 
be extrapolated to the corresponding human AChR types.
Vincent and Newsom-Davis (1979) compared myasthenic anti-AChR antibody 
titres obtained by using either “normal” or “denervated” adult human AChR as 
antigens and found essentially no differences between the two sets of titres. In these 
studies “normal” AChR and “denervated” AChR preparations were obtained from 
muscles of legs amputated from patients having respectively either arteriosclerotic 
ischemia or diabetes with ischemia and peripheral neuropathy. The same authors 
(1982) subsequently made further comparative studies in which “denervated” AChR 
was obtained as previously but “normal” AChR was derived post mortem from a 
patient dying of cerebral disease. In contrast to the earlier results, anti-“ normal” 
AChR antibody titres were found to be variable but generally slightly lower than
173
anti-“denervated” AChR antibody titres and the authors suggested that the previ­
ously observed equality of titres might result from partial denervation of the 
ischemic “ normal” muscle used in the earlier work. Lefvert (1981, 1982) has also 
similarly compared “denervated” AChR, again obtained from patients with diabetes 
mellitus and advanced neuropathy, with “ normal” AChR, prepared in this case from 
muscle amputated from patients with malignant tumours of the bone. Some 40% of 
the myasthenic sera did not react with “normal” AChR but for those that did, 
anti-AChR antibody titres were found to be approximately 50% lower than the 
corresponding anti-“ denervated” AChR antibody titres.
There is accordingly some evidence of a preferential interaction between 
myasthenic antibodies and extrajunctional, rather than junctional human AChR and 
the present work was designed to examine whether this preference extends to foetal 
human AChR. The results (Table 1) show no significant differences between anti­
body — “ normal” adult AChR and antibody — foetal AChR binding curves for 
any of the myasthenic sera studied, indicating identity not only of titre but also of 
affinity for antibodies directed against the two receptor types. Like those of Vincent 
and Newsom-Davis (1979) our comparisons were largely made by using “ normal” 
AChR obtained from muscle amputated from patients with severe vascular disease. 
However, a direct comparison of binding of antibodies to this AChR with that to 
AChR obtained from a healthy adult who had suffered a road traffic accident 
showed virtually identical saturation curves (Fig. 1). It appears therefore that while 
some ischemic muscle amputated from vascular disease patients may be partially 
denervated, that used in our experiments can be regarded as providing antigenically 
normal adult human AChR with regard to its interaction with myasthenic serum.
Our data therefore do not support the idea that foetal human AChR carries 
antigenic sites that are recognized by myasthenic sera and are not present on normal 
adult junctional AChR, although it is, of course, conceivable that such sites could 
have been differentially lost during the purification of foetal AChR or that the 
numbers of corresponding antibodies in the sera tested are very low. Vincent and 
Newsom-Davis (1982) comment, without data, that myasthenic sera reacted similarly 
with AChR from either denervated muscle or from cultured foetal human muscle; an 
observation which implies that anti-foetal AChR antibody titres are, like those 
against denervated AChR, higher than anti-normal AChR. This is in apparent 
contrast to our own findings although it is worth noting that the differences between 
anti-denervated AChR and anti-normal AChR antibody titres observed by Vincent 
and Newsom-Davis (1982) are not great and, moreover, that their foetal AChR is 
not directly comparable with ours. Our foetal AChR was obtained from prostaglan­
din-induced abortions, the foetuses being aged between 14 and 22 weeks, and it is 
certainly possible that AChR obtained from younger or older foetuses might be 
antigenically different.
Serum from different myasthenic patients vary in their specificities and, in 
particular, in their ability to distinguish between junctional and extrajunctional rat 
AChR (Harrison et al. 1981). However, sera from patients No. 1, 2 and 3 used in 
these studies had anti-junctional rat AChR: anti-extrajunctional rat AChR antibody 
titres of 0.29, 1.00 and 0.16, respectively, showing that differential interactions with
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rat antigens are not necessarily reflected in the case of human receptors. It appears 
therefore, that the idea of a foetal auto-immunogen in myasthenia gravis, conceived 
on the basis of experiments with rat AChR (Weinberg and Hall 1979), should be 
further tested with more extensive studies using more myasthenic sera, and if 
possible a wider range of foetal receptors.
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